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The endocervical mucosae of the female reproductive tract (FRT) not only serve as a 
physical barrier against microbial infection, but they also express a wide variety of 
immune mediators. The endocervical epithelial cells express a distinct profile of 
immune-regulators, which is higher than vaginal and ectocervical epithelial cells. 
Constant cytokine production would ensure rapid responses to infections and 
maintenance of the sterility of the upper genital tract. However, overproduction of 
cytokines could inhibit normal reproductive processes and stimulate excess growth and 
cell proliferation. The synthetic progestins medroxyprogesterone acetate (MPA) and 
norethisterone (NET) and its derivatives (norethisterone enanthate (NET-EN); 
norethisterone acetate (NET-A)) are synthetic steroidal hormones designed to elicit 
progestational effects similar to those of the endogenous hormone progesterone (P4). 
They are extensively used as contraceptives and in hormone replacement therapy 
(HRT). Numerous studies, however, have reported that synthetic progestins affect 
immune function, increase the risk of sexually transmitted infections (STIs) and also 
change the morphology of the cervicovaginal mucosa. Despite these findings little is 
known about the molecular mechanisms of action of MPA and NET, in particular their 
differential effects on gene expression. The first part of this thesis examined the 
regulation of three immune-regulator genes namely interleukin (IL)-6, IL-8, and 
regulated upon activation, normal T cell expressed and secreted (RANTES), by MPA 
and NET-A. Quantitative real-time PCR analysis showed that both MPA and NET-A 
significantly augmented tumour necrosis factor alpha (TNF-induced IL-8 and 
RANTES expression, in contrast to P4. While both MPA and NET-A upregulated the 
TNFresponse, they did so to different extents. Using siRNA technology, as well as a 
glucocorticoid receptor (GR) antagonist, it was found that the responses to P4, MPA 
and NET-A on the IL-6 gene are mediated predominantly via the GR. Towards further 
understanding the mechanisms of differential regulation via the progestins, different 
mitogen activated protein kinase (MAPK) pathways were shown to be involved in 
MPA and NET-A regulation of IL-6 mRNA levels. Both extracellular signal-regulated 
kinase (ERK1/2) and p38 MAPK pathways are involved in NET-A-induced IL-6 gene 
expression, whereas ERK1/2 and JNK (c-Jun N-terminal kinase) signalling pathways 




The second part of this thesis investigated a novel and unexpected mechanism of IL-6 
gene regulation involving the GR and TNF in the absence of GR ligand. GR silencing 
by siRNA, as well as the presence of the GR antagonist RU486, potentiated 
TNFinduced IL-6 gene expression. As shown by chromatin-immunoprecipitation 
(ChIP) analysis, TNF also recruited the GR to the IL-6 promoter in intact cells, to the 
same extent as dexamethasone (DEX), a potent GR agonist. This is the first study to 
report GR-recruitment to an endogenous cytokine gene promoter in response to TNF 
in the absence of GR ligand. Furthermore, it was shown that TNF selectively induces 
phosphorylation of the GR at Ser-226 and not Ser-211, consistent with a different 
mechanism of activation as compared to DEX, which results in phosphorylation at both 
these residues. Consistent with these results, biochemical fractionation revealed that 
partial nuclear translocation of the GR was also induced by TNF These results 
strongly suggest that TNF activates the GR in a ligand-independent manner. 
Moreover, ChIP as well as overexpression assays support a model in which the cofactor 
GR-interacting protein type 1 (GRIP-1) is recruited to the IL-6 promoter in response to 
TNFin the capacity of co-repressor. 
 
The results of this thesis provide insight into the immune response in the endocervix 
and the effect of synthetic progestins on the endocervix. Contrasting effects of P4 and 
progestins are clinically important as MPA and NET are widely used progestins in the 
regimen of HRT and contraceptives. Moreover, this thesis presents a novel mechanism 
of ligand-independent GR activation by TNF and subsequent modulation of IL-6 gene 
expression, which suggests a role for the unliganded GR in modulating immune 
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Mother Teresa's Anyway Poem  
People are often unreasonable, illogical and self centered; 
Forgive them anyway. 
If you are kind, people may accuse you of selfish, ulterior motives; 
Be kind anyway. 
If you are successful, you will win some false friends and some true 
enemies; 
Succeed anyway. 
If you are honest and frank, people may cheat you; 
Be honest and frank anyway. 
What you spend years building, someone could destroy overnight; 
Build anyway. 
If you find serenity and happiness, they may be jealous; 
Be happy anyway. 
The good you do today, people will often forget tomorrow; 
Do good anyway. 
Give the world the best you have, and it may never be enough; 
Give the world the best you've got anyway. 
You see, in the final analysis, it is between you and your God; 
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This thesis consists of five chapters. Chapters 3 and 4 are written up in manuscript 
format and will shortly be submitted for publication. The “Material and Methods” and 
“Reference” sections were excluded from Chapters 3 and 4 to prevent unnecessary 
repetition. A combined “Reference” section for all the chapters follows after the 
“Addendums”.  
 
Chapter 1: Literature review. This chapter gives a detailed overview of the relevant 
knowledge currently available in the literature, with a particular focus on the immune 
response pertaining to the lower female reproductive tract and the molecular 
mechanisms of action of medroxyprogesterone acetate (MPA) and norethisterone 
enanthate (NET-EN)/norethisterone acetate (NET-A). 
 
Chapter 2: Materials and Methods. This chapter gives details regarding the 
experimental protocols and materials used to obtain the results presented in chapters 3 
to 5. 
 
Chapter 3: Differential cytokine gene regulation by the synthetic progestins, 
medroxyprogesterone acetate (MPA) and norethisterone acetate (NET-A) in a 
human endocervical epithelial cell line. This chapter contains the results of a study 
investigating the mechanisms of regulation of endogenous cytokine genes by Prog, 
MPA and NET-A in the End1/E6E7 (human endocervical epithelial) cell line. All 
experiments were performed by the candidate and the manuscript is in preparation for 
submission to the journal “Contraception”. A brief introduction is included. 
 
Chapter 4: Ligand-independent GR-mediated repression of IL-6 in response to 
tumour necrosis factor-alpha (TNF) in an endocervical epithelial cell line. This 
chapter contains the results of a study investigating the ligand-independent activation of 
the GR by TNFin the End1/E6E7 cell line and the subsequent modulation of IL-6 
expression. All experiments were performed by the candidate and the manuscript is in 
preparation for submission to the journal “Molecular Endocrinology”. A brief 
introduction is included.  
 
Chapter 5: Conclusions and Future Perspectives. In this final chapter, the results of 
the overall study are discussed and conclusions drawn in the context of the larger 




The appendices include (A) optimisation of various experimental protocols and (B) 
data not shown, but referred to as supplementary material within Chapter 3. 
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Sexually transmitted infections (STIs) are a worldwide health problem (Brabin 2002). 
Pathogens such as Chlamydia trachomatis, Neisseria gonorrhoeae Candida albicans 
and Trichomona vaginalis as well as Human papillomavirus (HPV) are responsible for 
most sexually transmitted diseases, and these pathogens increase susceptibility to 
Human immunodeficiency virus (HIV) infection. HIV infection and Acquired immune 
deficiency syndrome (AIDS) are most prominent in sub-Saharan Africa, and present a 
serious burden to the health sector as well as the economy (Wira et al., 2005a). An 
understanding of the local immune response induced in the lower female reproductive 
tract (FRT) is therefore important, as this region is the first site of exposure to such 
pathogens in women. Epithelial cells of the FRT play a vital role in preventing infection 
and are influenced by hormonal treatment such as contraceptives and hormone 
replacement therapy (HRT). While a few reports regarding the immune response in the 
FRT are available, there still remain many unanswered questions, particularly regarding 
the molecular mechanisms involved.  
 
This chapter provides an overview of the human FRT, specifically the anatomical 
compartments which include the vagina, ectocervix and endocervix, as well as the role 
of epithelial cells in the immune response. A brief outline of innate and adaptive 
immune responses will be given, followed by signalling pathways required for the 
immune response.  
 
1.1. The female reproductive tract (FRT) 
Epithelial cells lining the FRT are the first line of defence against STI‟s and are 
generally considered to be the gatekeepers of the FRT. The epithelial surface of the 
FRT not only provides an uninterrupted physical barrier against infection, but is also 
capable of both innate and adaptive immune responses against invading pathogens 
(Wira et al., 2005a; Ochiel et al., 2008; Schaefer et al., 2005). The epithelial cells lining 
the FRT are capable of producing chemokines and cytokines that activate and recruit 
immune cells such as macrophages, natural killer (NK) cells, neutrophils and B-cells, 
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followed by the attraction and maturation of T-cells (Wira et al., 2005a; Ochiel et al., 
2008; Schaefer et al., 2005). In addition, epithelial cells are able to secrete anti-
microbial peptides, such as defensins, that provide protection against invading microbes 
(Wira et al., 2005a; Ochiel et al., 2008; Schaefer et al., 2005).  
 
The FRT comprises different anatomical compartments, namely the ovaries, fallopian 
tubes, uterus, cervix, and vagina. The lower FRT consists of three regions: the 
ectocervical, endocervical and vaginal mucosa (Figure 1.1). The mainly sterile 
endocervical mucosa is separated from the ectocervix by the transformation zone. The 
vaginal and ectocervical musoca are usually exposed to a wide variety of 
microorganisms, and is thus not as sterile as the endocervix.   
 
1.1.1 The lower female reproductive tract 
 
1.1.1.1 Vagina and ectocervix 
The vagina is the entry to the FRT and both the vaginal and ectocervical mucosae 
consist of aglandular, non-keratinised, stratified, squamous epithelial cells, which 
comprise multiple layers (Fichorova et al., 1997). The vagina is commonly infected by 
C. albicans and T. vaginalis (Quayle, 2002), while HPV generally infects the ectocervix 
or more commonly the transformation zone separating the ecto-and endocervix 
(Quayle, 2002). Commensal microorganisms such as the Lactobacillus and 
Enterococcus species are present in the vaginal- and ectocervical mucosae and assist in 
vaginal defence (Hillier et al., 1993; Reid et al., 2001). Lactobacilli do this by 
restricting the vaginal flora allowing only commensals that grow in the acidic 
environment. This species also produce hydrogen peroxide that has anti-microbial 
activity (Hillier et al., 1993; Reid et al., 2001). The ability of certain micro-organisms 
to lower the pH is particularly important in limiting the infection of the FRT by C. 
albicans as it cannot grow at low pH conditions (Mahmoud et al., 1995). The presence 
of commensal microorganisms in the vagina and ectocervix is probably due to the fact 
that both elicit a weak immune response. Consistent with this finding, immortalised 
vaginal and ectovaginal epithelial cell lines have been shown to have low basal and 
tumour necrosis factor-alpha (TNF and interleukin (IL)-1 stimulated immuno-




Figure 1.1: Schematic presentation of the lower female reproductive tract (Hladik 
& McElrath, 2008) 
 
1.1.1.2 Endocervix 
The epithelium of the endocervix consists of simple columnar epithelial cells with 
numerous glands, similar to that of the uterus and fallopian tubes (Fichorova et al., 
1997; Wira et al., 2005a), unlike the ectocervix and vagina. The endocervix separates 
the sterile uterus from the microbe-filled lower FRT. The sterility status of the 
endocervix is dependent on hormone levels influenced by the menstrual cycle (Quayle, 
2002). As the epithelium in this region consists of only a single layer of cells, the 
endocervix is more vulnerable to microbial infection and tissue injury than other 
regions of the FRT. N. gonorrhoeae and C. trichomatis are some of the main pathogens 
infecting the endocervix, with C. trichomatis being the most common cause of sexually 
transmitted diseases (Fenton et al., 2001). It has been reported that chlymadial infection 
is more prevalent in women using oral contraceptives than those using barrier methods 
or non-users of contraception (Shafer et al., 1984). In terms of HIV the exact site of 
infection remains unclear. However, it is believed to occur at epithelial cells of the 
lower female reproductive tract (al-Harthi & Landay, 2001), and indeed HIV has been 
isolated from the endocervix of HIV-infected women (Zhang et al., 1999; Kaul et al., 
2000; Mostad et al., 1997; Zorr et al., 1994).  
 
The endocervix, has been shown to have a higher constitutive and TNF and IL-
1induced immune-regulator profile than the vagina and ectocervix, as well as 
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distinctly different immunological mediators (Fichorova & Anderson 1999; Castrilli et 
al., 1997; Fahey et al., 2005). This means that cytokines are constantly produced, which 
would ensure rapid responses to infections and maintenance of the sterility of the upper 
reproductive tract.  
 
1.1.2 Immunity in the lower FRT 
Mucosal immunity in the lower FRT is very similar to that found in the respiratory tract 
and intestine (Wira et al., 2005a; Wira et al., 2005b; MasCasullo et al., 2005). The 
lower FRT lining, which consists mainly of mucus-secreting epithelial cells, forms a 
mucosal barrier protecting against invading pathogens. Tight junctions between 
columnar epithelial cells prevent transepithelial movement (Wira et al., 2005a). The 
lower FRT is capable of both innate and acquired immune responses that are under 
hormonal control (Grossman 1984; Beagley & Gockel 2003; Franklin & Kutteh 1999; 
Lü et al., 2002; Rakasz & Lynch 2002, Thongngarm et al., 2003). These responses 
ultimately regulate the levels of cytokines, the distribution of different cell populations 
and the transport of immunoglobulins (Wira et al., 2005a; Wira, et al., 2005b), allowing 
the acquired immunity in the FRT to act in concert with the innate immune response 
(Wira et al., 2005a; Wira et al., 2005b).  
 
Acquired immunity entails pathogen-specific defence responses, such as presentation 
of pathogenic antigens to T-cells by antigen-presenting cells, resulting in T-cell 
activation (indirect effect) (Wira et al., 2005a; Wira et al., 2005b). T-cell activation 
leads to cytokine production and subsequent antibody production and activation 
(Wira, et al., 2005a). Antibody production occurs via B-cell activation (humoral 
immunity). The immunoglobulin (Ig) G is the principal antibody secreted in the FRT 
(Wira et al., 2005a; Wira, et al., 2005). In addition, T-cells themselves are also 
capable of directly (cell mediated immunity) mediating an immune response against 
pathogens together with other immune cells e.g. macrophages, neutrophils etc.  
 
Innate immunity involves mostly macrophages, dendritic cells, neutrophils and 
epithelial cells and as it is not antigen specific it elicits a much quicker response than 
acquired immunity (Janeway & Medzhitov 2002; Medzhitov & Janeway 2000; Quayle 
2002). The epithelial cells of the FRT also release antimicrobials such as mucus, 
defensins, lactoferrin, and lysozyme that assist in the innate response. Secreted mucus 
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consists mainly of large mucin glycoproteins, which physically prevent microbial 
entrance and provide a medium for antibodies, peptides, proteins and organic molecules 
(Lamont, 1992). The presence of a wide variety of immune cells in the lower FRT has 
been identified. These include lymphocytes and antigen-presenting cells such as 
macrophages and dendritic cells (Wira et al., 2005a; Wira et al., 2005b). Additionally, 
Toll like receptors (TLRs), which are expressed mainly by macrophages and dendritic 
cells but also by vaginal, ectocervical and endocervical epithelial cells, are able to 
recognise pathogen proteins, or molecules such as lipoproteins, peptidoglycans, and 
repetitive protein structures (Fichorova et al., 2002). Furthermore, the epithelial cells of 
the lower FRT have been reported to present antigen to T cells, an immune response 
under strict control by hormones such as estrogen and progesterone (De Buysscher, 
1999; Prabhala & Wira, 1995). Both immortalised and primary vaginal, ectocervical 
and endocervical epithelial cells have also been shown to express a wide variety of 
cytokines and chemokines (Fahey et al., 2005; Fichorova & Anderson, 1999). 
Differential cytokine/chemokine expression was observed between the endocervical 
epithelial cell lines when compared to the ectocervical and vaginal epithelial cell lines 
(Fichorova & Anderson, 1999). These immuno-regulators play a vital role in the 
immune response, by protecting against invading pathogens. Taken together, it is clear 
that epithelial cells play an important role in both innate and acquired immune 
responses in the FRT as they express TLRs on their surface and produce microbiocides 
as well as secreting immunoglobulins and immuno-regulatory chemokines and 
cytokines (Wira et al., 2005b; De Buysscher, 1999).  
 
1.1.3 Cytokine and chemokine expression in the lower FRT 
Numerous cytokines and chemokines are constitutively expressed by the epithelial cells 
in the female reproductive tract e.g. interleukin (IL)-6, IL-8 and Regulated upon 
activation, normal T cell expressed and secreted (RANTES) (Fahey et al., 2005; 
Fichorova & Anderson, 1999). Constitutive expression ensures the presence and 
activity of immune cells immediately on antigen presentation. In addition, immune-
regulators produced by epithelial cells may also regulate the number and type of 
immune cells present in the FRT (Givan et al., 1997). Chemokines such as IL-8 and 
RANTES are mostly responsible for the attraction of immune cells (Baggiolini 1995; 
Kuna et al., 1992; Kameyoshi et al., 1992; Schall et al., 1990), while cytokines like IL-
6 are mainly involved in the activation and differentiation of T- and B-cells (Hodge et 
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al., 2005; Akira et al., 1990; Akira et al., 1992; Kishimoto, 2006). Some immune-
regulators also influence cell proliferation and apoptosis, which may assist in 
maintaining normal FRT structure and surroundings (Wira et al., 2005a; Wira et al., 
2005b). Cytokines and chemokines can also regulate each other by autocrine or 
paracrine mechanisms involving gene expression (Wira et al., 2005b; Legrand-poels et 
al., 2000; Shalaby et al., 1989). Moreover, sex hormones have been shown to control 
the expression of many immuno-regulators (Critchley et al., 2001). For example, 
progesterone (P4) withdrawal, as experienced during the follicular phase, has been 
implicated in the upregulation of IL-8 (Critchley et al., 2001). In the next sections, 
immune-regulators IL-6, IL-8, and RANTES will be discussed in more detail.  
 
1.1.3.1 Interleukin-6 
IL-6 is a multifunctional pleiotropic glycoprotein, the most significant role of which is 
that of a pro-inflammatory mediator (Kishimoto, 1989). Some of its pro-inflammatory 
roles include B-cell differentiation, leukocytosis and acute phase protein synthesis and 
T-cell lymphocyte activation (Kishimoto, 1989). Moreover, IL-6 has been shown to be 
anti-apoptotic and induce proliferation of numerous cell types including tumour cells, 
by both autocrine and paracrine mechanisms (Wei et al., 2001a; Wei et al., 2001b; 
Eustace et al., 1993; Kawano et al., 1988; Okamoto et al., 1997a; Okamoto et al., 
1997b; Iglesias et al., 1995). For example, IL-6 has been implicated in cervical cancer 
progression and pathogenesis (Tartour et al., 1994; Eustace et al., 1993; Scambia et al., 
1994; Wei et al., 2001a; Wei et al., 2001b; Wei et al., 2003; Tjiong et al., 1999) due to 
chronic inflammation during infection (Richter et al., 1999). In contrast, IL-6 has also 
been reported to inhibit cell proliferation of lung (Takizawa et al., 1993) and breast 
cancer cells (Danforth & Sgagias, 1993; Klein et al., 1995). IL-6 has been associated 
with many autoimmune and inflammatory diseases such as pelvic inflammatory disease 
(Richter et al., 1999) and rheumatoid arthritis (Okamoto et al., 1997b; Mihara et al., 
1995). Experimentally, IL-6 treatment induces collagen-induced arthritis (Alonzi et al., 
1998; Sasai et al., 1999) as well as antigen-induced arthritis (Ohshima et al., 1998) 
consistent with its pro-inflammatory effects. 
 
IL-6 signalling entails binding of IL-6 to the α-chain of the IL-6 receptor, thereby 
recruiting the receptor β-chain (gp130). This in turn initiates homodimerization of 
gp130, which activates cytoplasmic tyrosine kinases. Consequently, various signalling 
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cascades including Janus kinase-signal transducer and activator of transcription 
(Jak/STAT), phosphatidyl inositol-3 kinase (PI3K)/protein kinase B (Akt) and 
Ras/Mitogen activated pathways kinase (MAPK) pathways are activated (Hirano et al., 
1997).  
 
Regulation of IL-6 primarily occurs at the level of gene transcription and its 
expression is highly responsive to the early-response pro-inflammatory cytokines IL-
1β and TNFα, (Benveniste et al., 1990; Cromwell et al., 1992; Iglesias et al., 1995; 
Beyaert et al., 1996; Zhang et al., 1990). The promoter of IL-6 contains binding sites 
for several inducible transcription factors necessary for its induction by a variety of 
stimuli. These sites are situated in close proximity to each other as schematically 
represented in Figure 1.2A and include a nuclear factor-kappa (NFκB) binding 
element between positions –73 and –63, a CCAAT enhancer binding protein 
(C/EBP) binding site at position –173 and –145 and an activator protein-1 (AP-1) 
binding site located between –283 and –277, relative to the transcription start site 
(Ray et al., 1988; Georganas et al., 2000; Tanabe et al., 1988; Libermann & 
Baltimore, 1990). The NFκB binding site binds protein dimers of the Rel/NFκB 
family of transcription factors, the C/EBP binding site binds protein dimers of the 
C/EBP basic-leuzine zipper family, while the distal AP-1 site interacts with protein 
dimers of the Fos and Jun families (Lee et al., 1987). These cis-acting transcription 
factors all play a functional role in the regulation of the IL-6 promoter (Vanden 
Berghe et al., 1998). The transcription factor NFκB, the binding site of which is the 
most proximal of all the above-mentioned regulatory elements, plays a dominant role 
in IL-6 expression, and is responsible for basal IL-6 expression in various cell types 
(Vanden Berghe et al., 1998; Zhang et al., 1990; Shimizu et al., 1990). Studies using 
promoter mutations and deletion mutants showed that the NFB binding sequence is 
required for IL-6 promoter activity (Vanden Berghe et al., 1998), while AP-1 and 
C/EBP binding sites are only required for maximal IL-6 promoter activity (Vanden 
Berghe et al., 1998). In addition, the MAPKs, p38 and extracellular signal-regulated 
kinase (ERK1/2) have been implicated in the induction of IL-6 expression by TNFα 
and IL-1β (Blanque et al., 1997; Ridley et al., 1997; Miyazawa et al., 1998; Vanden 
Berghe et al., 1998; Wery-zennaro et al., 2000). In contrast, steroids acting via their 
cognate receptors have been shown to repress IL-6 expression in a wide variety of cell 
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types (Bellido et al., 1995; Kurebayashi et al., 1997; Waage et al., 1990; Koubovec et 
al., 2004). Repression by steroid receptors is mainly due to their direct protein-protein 
interactions with NFB and AP-1 transcription factors, which will be discussed later 
in this chapter. Interestingly, a negative feedback mechanism whereby IL-6 
overproduction is prevented has previously been reported (Kishimoto, 2006). In this 
feedback process, IL-6 acting via its cognate receptor activates the expression of 
STAT3, which in turn activates the suppressors of cytokine signalling (SOCS). The 
IL-6 receptor gp130  chain is subsequently inhibited by SOCS binding to the JAK 
tyrosine kinase (Kishimoto, 2006).  
 
1.1.3.2 Interleukin-8 and RANTES 
IL-8 and RANTES are both potent chemoattractant cytokines, although they belong to 
different chemokine families. IL-8 belongs to the CXC-chemokine family, while 
RANTES is a member of the CC chemokine family (Baggiolini, 2000; Song et al., 
2002). Similar to IL-6, both RANTES and IL-8 promoters contain a small region with 
similar cis-regulatory elements (Figure 1.2B & 1.2C). Both the RANTES- and IL-8 
promoters contain a proximal NFB binding site but unlike IL-8, RANTES contains 
two NFB binding sites situated next to each other (Moriuchi et al., 1997; Hiura et al., 
1999; Henriquet et al., 2007). Both chemokine genes contain the cis-regulator element 
for C/EBPβ (Song et al., 2000; Mukaida et al., 1994) and also AP-1 binding sites. 
However, the RANTES promoter contains two distal AP-1 binding sites, while the IL-8 
promoter contains only one (Moriuchi et al., 1997; Henriquet et al., 2007; Song et al., 
2000; Mukaida et al., 1994). Similarly, to the IL-6 gene, the NFB binding site plays a 
dominant role in both IL-8 and RANTES expression in a wide variety of cell types 
(Brasier et al., 1998; Hoffmann et al., 2002; Lebovic et al., 2001; Melchjorsen & 
Paludan, 2003; Moriuchi et al., 1997; Hiura et al., 1999), and has been shown in 
numerous studies to be strongly activated by TNF(Cromwell et al., 1992; Brasier et 
al., 1998)Brasier and colleagues demonstrated that NFB recruitment to the IL-8 
promoter in alveolar epithelial cells is required for IL-8 expression as it is the first 
transcription factor to associate with the IL-8 promoter on TNFstimulation (Brasier et 
al., 1998). C/EBP the binding site of which is situated in close proximity to the NFB 
binding site, has been proposed to form a dimer with NFB, and these two transcription 
factors thereby cooperatively affect transcription of IL-8 (Mukaida et al., 1990; Kunsch 
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& Rosen, 1993). Like IL-6 and most other immune-regulators, inhibition of IL-8 and 
RANTES expression can be influenced by steroid hormones. Glucocorticoids, acting 
via the glucocorticoid receptor (GR) are particularly potent inhibitors of IL-8 and 




Figure 1.2. Schematic representation of (A) IL-6, (B) IL-8, and (C) RANTES promoters.  
Abbreviations: AP-1; activating protein-1, C/EBP; CCAAT enhancer binding protein, NFB; nuclear 
factor kappa B; IL-6; interleukin-6, IL-8; interleukin-8, RANTES; Regulated upon activation, normal T 
cell expressed and secreted. 
 
 
RANTES and IL-8 have some similarity in their recruitment profiles of immune cells as 
both have been shown to recruit neutrophils (Larsen et al., 1989; Pan et al., 2000; 
Kunkel et al., 1991) eosinophils (Kameyoshi et al., 1992; Sehmi et al., 1993), T 
lymphocytes (Kameyoshi et al., 1992; Schall et al., 1990b), basophils (Bischoff et al., 
1993; Krieger et al., 1992), monocytes (Schall et al., 1990b; Hayashida et al., 2001), 
and macrophages (Holgate et al., 1997; Mitsuyama et al., 1994) to the site of infection. 
They are also activated by similar factors such as TNF, IL-1 and various pathogens, 
and similar regulatory factors are subsequently recruited to their respective promoters 
(Nakamura et al., 1991; Standiford et al., 1990; Fichorova & Anderson, 1999; 
Miyamoto et al., 2000; Andoh et al., 2002; Song et al., 2002; Matsukura et al., 1996; 
Ammit et al., 2002; Melchjorsen & Pedersen, 2002; Melchjorsen & Paludan, 2003). 
 
IL-8 and RANTES are expressed in a variety of cell types, such as T-lymphocytes 
(Ortiz et al., 1996; Song et al., 2002) and epithelial cells, including those of the cervix 






et al., 2005). IL-8 expression, like IL-6 expression, is significantly increased during 
cervical dilation during parturition, resembling the effect of inflammation (Kemp et al., 
2002). IL-8 stimulates granulocyte attraction, activation, and leukocyte degranulation. 
The subsequent release of a variety of proteinases such as matrix metalloproteinase-8 
and matrix metalloproteinase-9 from their granules can degrade extracellular matrix 
components leading to cervical ripening (Osmers et al., 1995). Moreover, in cervical 
and colonic epithelial cells, both IL-8 and IL-6 mRNA expression are significantly 
upregulated during chlamydial infection (Rasmussen et al., 1997). IL-8 has also been 
shown to increase HIV-1 infection in cervical explant tissue (Narimatsu et al., 2005) 
while RANTES expression inhibits HIV transfection as both RANTES and HIV 
compete for binding to the same receptor (Alfano & Poli 2005). RANTES expression in 
tumour cells has been demonstrated to stimulate tumour regression (Mulé et al., 1996; 
Kutubuddin et al., 1999). However, RANTES has been implicated in breast cancer 
progression indicating that the effect of RANTES on tumour growth is cell-type 
specific (Niwa et al., 2001; Azenshtein et al., 2002). IL-8 has also been implicated in 
tumour progression in a wide variety of cell types, including lung, prostate, bladder, 
breast and cervix (Chopra et al., 1998) with the exception of ovarian tissues where IL-8 
has been demonstrated to attenuate tumour growth (Lee et al., 2000). Therefore, like 
IL-6, both IL-8 and RANTES can affect cell growth and cancer progression, besides 
playing an important role in the immune response as chemoattactants.  
 
1.2 Important signalling pathways involved in immunity 
As discussed, cytokine gene promoters are predominately regulated by NFB and AP-1 
(Vanden Berghe et al., 2000; Kassel & Herrlich, 2007; Blackwell & Christman 1997; 
Liberman et al., 2007; Karin & Chang, 2001). TNF, a potent early response pro-
inflammatory cytokine, promotes the secretion of a large set of immune regulators by 
activating NFB and, to a lesser extent, AP-1 (Barbara et al., 1996; Vanden Berghe et 
al., 2000). In the following sections, the signalling pathways induced by TNF, NFB 
and AP-1 will be discussed.  
 
1.2.1 TNF alpha (TNF) signalling 
TNF is a pro-inflammatory cytokine responsible for the expression of a wide variety 
of other immunological mediators such as IL-6 and IL-8 (Vlahopoulos et al., 1999; 
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Vanden Berghe et al., 2000; Brasier et al., 1998) and is mainly expressed by activated 
macrophages, monocytes, lymphocytes, and keratinocytes (Baud & Karin, 2001). 
TNF is a 17 kDa cytokine consisting of 157 amino acids, which functions as a 
homotrimer. It is involved in a wide variety of cellular responses such as lymphocyte 
and leukocyte activation and migration, cell proliferation, cell differentiation, apoptosis, 
cytotoxicity, and immune regulation (Jones et al., 1989; Tracey & Cerami, 1993; 
Mohan et al., 2001). TNF belongs to family of trimeric cytokines, which include 
lymphotoxin-a, Fas ligand, receptor-activator of NFB ligand, CD40 ligand, and TNF 
related apoptosis-inducing ligand (Locksley et al., 2001). TNF acts primarily via its 
cognate receptor, a 415 amino acid polypeptide with a single membrane-spanning 
region (Barbara et al., 1996; Fessler et al., 2004). Binding of the trimeric TNF protein 
to its membrane-bound receptor, induces receptor trimerisation, which is required for 
receptor activation (Barbara et al., 1996; Fessler et al., 2004). TNF activates a cascade 
of signalling pathways such as protein kinase C (PKC) and the MAPKs, which leads to 
the expression of various immune-regulators such as IL-6, IL-8 and RANTES by 
activating transcription factors such as NFB and AP-1 in a wide variety of cell types 
(Fichorova & Anderson, 1999; Barnes & Karin, 1997; Karin et al., 1997; Rothe et al., 
1995; Hsu et al., 1996; Liu et al., 1996; Natoli et al., 1997). However, TNF can also 
activate the caspase cascade, resulting in apoptosis (Chang & Yang, 2000). The human 
TNF promoter itself contains both NFB and AP-1 binding sites and is therefore 
subjected to positive auto-regulation thereby ensuring a sustained inflammatory 
response (Barbara et al., 1996). TNF bound to its receptor, recruits TNFreceptor 1- 
associated death domain protein (TRADD), which serves as a platform recruiting other 
mediators including TNF receptor associated factor 2 (TRAF2). TRAF2 recruitment 
leads to the activation of IB kinase (IKK) and the activation MAPK pathways, 
including c-Jun N-terminal kinase (JNK) and p38 signalling pathways (Baud & Karin, 
2001; Liu et al., 1996; Song et al., 1997; Natoli et al., 1997). This subsequently leads to 
the activation of AP-1 and NFB, respectively (Rothe et al., 1995; Hsu et al., 1996b; 
Liu et al., 1996; Natoli et al., 1997). It is noteworthy that NFB is activated when the 
IB kinase (IKK) complex is activated, whereas AP-1 activity is regulated by multiple 




TRAF2 has been shown to be essential for TNFactivation of AP-1. TRAF2 interacts 
with the mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1 
(MEKK1), a member of the MAPK kinase kinase (MAPKKK) family. This interaction 
subsequently activates JNK, which is important for TNFinduced AP-1 activation 
(see Figure 1.3) (Minden et al., 1994). Lymphocytes expressing dominant negative 
TRAF2 protein were unable to activate JNK on TNF stimulation and subsequently 
AP-1, but not NFB, activation was affected (Lee et al., 1997), highlighting the 
importance of TRAF2 in TNFmediated activation of AP-1.  
 
Figure 1.3: Simple schematic presentation of TNF signalling via TNFR1, highlighting the two major 
activation pathways, IKK and MEKK1 which activate NFκB and AP-1, respectively. Trimeric TNFα 
binds to the TNFR1, which activates the association of TRADD, TRAF2, and RIP, which is required for 
the recruitment, and activation of IKK, which in turn phosphorylates IBleading to its ubiquitination 
and proteosomal degradation. NFB is then free to translocate to the nucleus. Association of TRADD 
and TRAF2 leads to the recruitment and activation of MEKK1 which triggers a cascade of pathways 
which finally activate JNK. JNK phosphorylates and activates c-Jun of the c-Jun/Fos heterodimer (AP-1) 
(adapted from Fessler et al., 2004). 
Abbreviations: TNFR1, Tumour necrosis factor receptor1; TRADD, TNF receptor 1- associated death 
domain protein; NFB, nuclear factor-kappaB; RIP, Receptor-interacting protein; IKK, inhibitory kappa 
kinase; IB, inhibitor kappaB; MEKK1; mitogen-activated protein kinase/extracellular signal-regulated 
kinase kinase 1; MKK, mitogen kinase kinase; JNK, c-JUN N-terminal kinase 
 
However, TNF treatment may also lead to the association of receptor-interacting 
protein 1 (RIP1) with TRAF2, which is involved in NFB activation (Hsu et al., 1996a; 
Fessler et al., 2004). RIP1 has also been shown to directly interact with TRADD 
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independent from TRAF2 (Hsu et al., 1996b; Devin et al., 2000). Similarly, TRAF5 has 
been shown to be recruited by TRADD directly and is involved in NFB activation 
only, distinct from AP-1 activation (Hsu et al., 1996a; Marsters et al., 1997; Hsu et al., 
1996b). TNF activation of NFB is a complex process involving numerous proteins 
and pathways, many of which could be bypassed without affecting NFB activation by 
TNF (Leitges et al., 2001; Ishida et al., 1996; Hsu, et al. 1996a; Marsters et al., 1997). 
This could also explain why in some cells TNF activates NFκB but not AP-1 (Vanden 
Berghe et al., 1999). These factors also highlight the very potent activation of NFB by 
TNF. To summarise, TNF initiates a cascade of events resulting in the proteolytic 
degradation of IB by the proteosome, thereby allowing NFB nuclear translocation. 
TNFα also causes activation of MEKK1 resulting in the activation of AP-1 (Figure 1.3), 
which will be further discussed in the following section. 
 
1.2.2 AP-1 signalling 
AP-1 is a transcriptional activator composed of a heterogeneous collection of Jun (v-
Jun, c-Jun, JunB, JunD), Fos (v-Fos, c-Fos, FosB, Fral, Fra2), and activating 
transcription factor (ATF2, ATF3/LRF1, B-ATF) families, all belonging to the basic-
leuzine zipper (bZIP) group of DNA binding proteins (Angel & Karin, 1991). They 
form a variety of homo- or heterodimers. Fos proteins are unable to form homodimers 
(Turner & Tjian, 1989), while Jun proteins are most commonly found as homodimers 
(Chiu et al., 1988; Ziff, 1990; Kouzarides & Ziff, 1989; Matsui et al., 1990; Hai & 
Curran 1991; Hsu et al., 1991; Dorsey et al., 1995). The Jun-Jun homodimers or Fos-
Jun heterodimers preferentially bind to the DNA binding site known as the TPA 
response element (TRE) (Lee et al., 1987), whereas Jun-ATF heterodimers and ATF 
homodimers bind to the cAMP-responsive element (CRE) (Hai & Curran 1991). Both 
promoter sequences (TPA and CRE) are palindromic and contain an AP-1 half-site. 
Other bZIP proteins have also been shown to bind to the TRE and CRE forming dimers 
with Jun and Fos (Kerppola & Curran, 1994). 
 
A wide variety of stimuli are able to activate AP-1, for example neurotransmitters, UV 
irradiation, growth factors, and cytokines, the latter including TNFas previously 
discussed (Caelles et al., 1997; De Bosscher et al., 2003). These stimuli activate various 
protein kinases including the MAPKs, which have been demonstrated to increase AP-1 
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activity. The JNK pathway phophorylates c-Jun at serine 63 and 73, thereby increasing 
its stability and transcriptional activity (Musti et al., 1997; Smeal et al., 1994; Davis, 
2000; Caelles et al., 1997). Phosphorylation of c-Jun results in the recruitment of 
cAMP responsive element binding protein (CBP) that aids in AP-1 transcriptional 
activity in fibroblast cells (Arias et al., 1994). Fos protein is extensively modulated by 
phosphorylation on several serine and threonine residues. Cyclic AMP-dependent 
protein kinase A (PKA) phosphorylates Fos at serine residue 362 (Tratner et al., 1992) 
thereby increasing its inhibitory effect on transcription. Similarly, protein kinase C 
(PKC) and 4α-phorbol 12-myristate 13-acetate (PMA) have been shown to induce 
phosphorylation of Fos (Abate et al., 1991; Barber & Verma, 1987). Interestingly, 
phosphorylation of Fos proteins obstructs dimerisation with Jun proteins. Thus Fos 
negatively regulates its own expression when phosphorylated, as a Fos binding site is 
present in the c-fos gene promoter (Ofir et al., 1990; Sassone-Corsi et al., 1988).  
 
1.2.3 NF-B signalling 
Ubiquitously expressed NF-B regulates the expression of numerous genes involved in 
inflammation, immunity, apoptosis, differentiation, cell growth and cell adhesion, 
including Il-6 and IL-8 (Vanden Berghe et al., 1998; De Bosscher et al., 2006; 
Rasmussen et al., 2008; Galien et al., 1996; Vanden Berghe et al., 1999; Brasier et al., 
1998). NFB is a dimeric transcription factor, which in its inactive state is bound to the 
inhibitory IB proteins, IB and IBin the cytoplasm, therebypreventing it from 
entering the nucleus (Vermeulen et al., 2002; Malek et al., 2001; Tam et al., 2001). A 
wide variety of stimuli, such as stress and cytokines, like TNF activate NF-B by the 
phosphorylation of IB, which is subsequently ubiquitinated and rapidly degraded. This 
results in the rapid nuclear translocation of the NF-B proteins (Vermeulen et al., 
2002), that are then further activated by several kinases including MAPK and PKC 
(Vermeulen et al., 2003; Anrather et al., 1999).  
 
The NF-B proteins are structurally related and are able to interact with each other and 
bind to DNA as dimers. Five different NF-B proteins have been described, NF-κB1 
(p50/p105) (Bours et al., 1990), NF-κB2 (p52/p100) (Neri et al., 1991), RelA(p65) 
(Nolan et al., 1991; Ruben et al., 1992), RelB (Ruben et al., 1992; Ryseck et al., 1992), 
and c-Rel (Galien & Garcia, 1997). Generally, the transcriptionally active NF-B 
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heterodimer consists of the p65 and p50 subunits (Barnes & Karin, 1997; Ahn & 
Aggarwal, 2005), which bind to NFB binding sites, positively regulating transcription. 
Similar to AP-1, NFB also interacts with co-factors thereby increasing transcription. 
The co-factors CBP and p300 have been shown to interact with p65 and augment its 
transactivational ability (Gerritsen et al., 1997; Perkins et al., 1997). Transfection 
studies showed that overexpression of CBP and p300 augmented p65 trancriptional 
activity on E-selectin and VCAM-1 promoter-reporter constructs. In addition, direct 
physical interactions of CBP and p300 with p65 were demonstrated by glutathione S-
transferase fusion protein binding, and co-immunoprecipitation studies (Gerritsen et al., 
1997). Interference with NFB signalling to diminish NFB regulated transcription, 
either through an increase in IB concentrations or direct interaction of other 
transcription factors with NFB, results in a reduced inflammatory response (Keller et 
al., 1996). Steroid-mediated repression of NFB-dependent transactivation is widely 
associated with the anti-inflammatory properties of steroids and their receptors. Most 
sex and adrenal steroid have been implicated in the repression of NFB gene activation 
(De Bosscher et al., 2006), but glucocorticoids exhibit the most powerful anti-
inflammatory activity. Similarly, androgens and progesterone have also been shown to 
suppress the immune response. In contrast, in some tissues, estrogen has both enhanced 
and suppressed immunity (reviewed by Grossman 1984 and Beagley & Gockel, 2003). 
Interestingly, synthetic progestin treatments have also been implicated in suppression of 
immune function (Wakatsuki et al., 2002; Koubovec et al., 2004; Bamberger et al., 
1999). In the next sections, these synthetic progestins become the focus of this chapter. 
 
1.3 Progesterone and the synthetic progestins Medroxyprogesterone 
acetate & Norethisterone enanthate/acetate 
 
1.3.1 The natural hormone-Progesterone 
Progesterone (P4), a derivative of cholesterol, is synthesised primarily by the corpus 
luteum in the ovaries of females, and the testis and adrenal cortex in males (Graham & 
Clarke 1997). It serves as a precursor for the synthesis of estrogens and androgens 
(Graham & Clarke 1997; Gellersen et al., 2009). P4 concentrations are generally higher 
in females than males, but during the follicular phase of the menstrual cycle P4 
concentrations in females decrease to concentrations similar to that found in males 
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(Kirschbaum et al., 1999). The functions of P4 include the regulation of the menstrual 
cycle, pregnancy support and antagonising the highly proliferative effect of estrogen 
(Gellersen et al., 2009). Mood changes, anxiety, depression, infertility, and 
miscarriages, are only a few of the medical conditions associated with low P4 
production in humans (Gellersen et al., 2009). As P4 has a very short half-life and 
limited bio-availability synthetic progestins were developed to mimic the physiological 
effects of P4 (Whitehead et al., 1980). These progestins are extensively used in 
hormone replacement therapy (HRT) to inhibit the proliferative effect of estrogen and 
as contraceptives to inhibit ovulation. 
 
1.3.2 Medroxyprogesterone acetate & Norethisterone enanthate/acetate: Synthetic 
progestins 
 
Synthetic progestins were primarily developed as contraceptive agents and have been 
used extensively for decades. The introduction of synthetic progestins as contraceptives 
in the 1960‟s radically revolutionised birth control, making it safer and far more 
convenient for women (Sitruk-ware, 2006). Steroidal contraceptive methods fall into 
two categories, combined (synthetic progestins and estrogen) oral contraceptives or 
progestins-only contraceptives (Sitruk-ware, 2004). Progestin-only contraceptives were 
primarily developed due to side-effects associated with estrogen sensitivity in combined 
oral contraceptive users (Mansour, 2005). These side-effects include some associated 
health risks, such as hypertension, headaches, breast tenderness, and the risk of venous 
thromboembolism or arterial disease (Sitruk-ware, 2003; Mansour, 2005; Spencer et al., 
2009). Progestin-only contraceptives are administered as implants, intrauterine systems, 
oral preparations, or by injection. Moreover, the dosages of the different progestins also 
differ. Progestin-only injectable contraceptives offer a convenient alternative for those 
women who forget to take the daily contraceptive pill. Moreover, for women who want 
or are forced to keep contraception a secret from their partners, injectable contraception 
offers a safe alternative. Thus, injectable long-acting contraception offers women 
convenient, safe, and reversible birth control.  
 
Generally, synthetic progestins are classified according to the steroid from which they 
are derived. This could be either from progesterone 17-hydroxy (OH) progesterone 
derivatives: pregnanes and norpregnanes or from testosterone 19-nortestosterone 
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derivatives: estranges and gonanes (Sitruk-ware, 2004). The two most commonly used 
progestin-only injectable contraceptives in sub-Saharan Africa are Depo-Provera® and 
Noristerate®, in which the active compounds are medroxyprogesterone acetate (MPA) 
and norethisterone enanthate (NET-EN), respectively. MPA, a 17-OH progesterone 
derivative and norethisterone (NET, the active metabolite of NET-EN) a 19-
nortestosterone derivative, are both highly effective reversible contraceptive agents and 
are both available at no cost to users at public health facilities in South Africa. MPA is 
also commonly referred to as depo-medroxyprogesterone acetate (DMPA) (Mansour, 
2005). Additionally, MPA and NET-A (the acetate form of NET-EN) are also 
extensively used in hormone replacement therapy (HRT) and cancer treatment 
(Stahlberg et al., 2004). The structures of MPA and NET-EN, as well as P4 are 
depicted in Figure 1.4. 
 
MPA is administered in an aqueous solution at a dosage of 150 mg every 12 weeks or 
91 days while NET-EN (Noristerat®) is administered at 200 mg every two months in 
an oily solution. Although both MPA and NET-EN are effective in preventing 
pregnancy, there are some side-effects associated with their use. The side-effect profile 
of both these progestins includes irregular bleeding, breast tenderness, acne, 
amenorrhea, weight gain, headaches, and vaginal discharge (Kaunitz 2000; Greydanus 
et al., 2001; Westhoff, 2003; Haider & Darney, 2007; Spencer et al., 2009).  
 
 
Figure 1.4: The chemical structures of (a) progesterone (P4), (b) medroxyprogesterone 
acetate (MPA),and (c) norethistherone (NET) (R=OH), norethisterone acetate (NET-A) 





1.3.2.1 Mode of contraceptive action 
DMPA and NET-EN inhibit ovulation, largely by inhibiting the release of the pituitary 
gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), by 
decreasing the pulse frequency of gonadotropin-releasing hormone (GnRH) release 
(Mishell, 1996; Kaunitz 2000; Greydanus et al., 2001). This results in the prevention of 
follicular maturation and ovulation, which consequently prevents increased estradiol 
levels (Mishell, 1996; Kaunitz, 2000; Greydanus et al., 2001). Secondary effects 
include preventing implantation of fertilised eggs, increasing the thickness of the 
cervical mucus thereby obstructing sperm mobility and atrophy, as well as the thinning 
of the endometrium (Mishell, 1996; Greydanus et al., 2001).  
 
1.3.2.2 HRT and other applications 
Both MPA and NET are also commonly used in the treatment of a range of 
physiological conditions. MPA and NET-A are commonly used in HRT in combination 
with estrogen (Sitruk-ware, 2003; Nath & Sitruk-Ware, 2009; Warren 2004). Moreover, 
high dosages of MPA and NET are regularly used for the treatment of gynaecological 
cancers including breast cancer and endometriosis (Maltoni et al., 2001; Cavalli et al., 
1984; Muss et al., 1990; Telimaa et al., 1987). These applications of synthetic 
progestins will be briefly discussed. 
 
1.3.2.2.1 MPA and NET in HRT 
Synthetic progestins are included in hormone replacement therapy (HRT) primarily to 
alleviate menopausal symptoms, such as hot flushes, urogenital atrophy, bone loss and 
vaginal dryness, which are side-effects associated with decreased estrogen levels 
(Hickey et al., 2005; Greendale et al., 1999). Two forms of HRT are prescribed, 
estrogen only or combined estrogen and progestin. The latter is given to women with an 
intact uterus, so as to counteract the stimulatory effect of estrogens on endometrial 
hyperplasia and carcinoma (Gambrell Jr et al., 1980; Taitel & Kafrissen, 1995; Brunelli 
et al., 1996). However, concern has been raised regarding the use of progestins in HRT. 
Two clinical studies, the Women‟s Health Initiative (WHI) study (Rossouw et al., 
2002; Anderson et al., 2003) and the Women‟s International Study of Long Duration 
Oestrogen after the Menopause (WISDOM) (Vickers et al., 2007), both which 
investigated post-menopausal women using combined HRT (MPA and conjugated 
equine estrogens (CEE)) were prematurely terminated due to adverse side-effects. 
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These side-effects included increased risk of breast cancer, coronary heart disease, 
venous thromboembolism, stroke and dementia (Rossouw et al., 2002). In a follow-up 
study to the WHI study, an increased risk of ovarian cancer was also shown (Anderson 
et al., 2003). Consistent with the observed side-effect of breast cancer, the „Million 
Women Study‟ found that both MPA and NET substantially increased the risk of breast 
cancer in long-term HRT users (Beral et al., 2003). A trial with estrogen alone, 
however, found no increase risk of breast cancer indicating that MPA is responsible for 
this adverse effect although this trial itself was also prematurely terminated due to the 
increase risk of strokes (Anderson et al., 2004). Further investigation at the clinical and 
experimental level is thus needed to determine the exact role of MPA and NET in the 
side-effects experienced by HRT users. At this stage however, the current approach 
when using MPA and NET in therapy is that the benefits outweigh the risks.  
 
1.3.2.2.2 High dosage progestin therapy 
In addition to HRT and contraception, progestins at high dosages are commonly used 
for the treatment of metasized endometrial-, breast-, and ovarian cancer. MPA and 
megestrol acetate are two of the most commonly used progestins in the treatment of 
cancer (Muss et al., 1990; Schindler et al., 2003). MPA has also successfully been used 
in the treatment of endometriosis for decades, significantly relieving pelvic pain with 
only breakthrough bleeding reported as a side-effect (Telimaa et al., 1987).  
 
1.4 Effect of synthetic progestins on immunity 
In addition to the side-effects already mentioned, various epidemiological studies have 
reported that synthetic progestins can modulate immunity (Majumder et al., 1987; 
Brunelli et al., 1996; Malarkey et al., 1997). However, very little research has been 
conducted regarding the role of synthetic progestins in immunity at the molecular level. 
NET has been shown to modestly inhibit an immune response in mice (Hulka et al., 
1965) while the immunosuppressive effect of MPA in mice has been shown to be 
similar to that of cortisol, the endogenous glucocorticoid (Hulka et al., 1965). Similar 
anti-inflammatory effects of MPA have been reported in other animal models (Turcotte 
et al., 1968; Gomez et al., 1998; Wakatsuki et al., 2002). In post-menopausal women 
using combined CEE plus MPA for HRT, a decrease in pro-inflammatory mediators 
was observed (Wakatsuki et al., 2002; Stopińska-Głuszak et al., 2006). While CEE had 
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little if any effect on cell adhesion molecule expression, MPA significantly inhibited its 
expression in human endometrial biopsies (Wakatsuki et al., 2002). Similarly, the very 
high doses of MPA used in the treatment of breast cancer caused a decrease in the 
number of immune regulatory cells such as T-helper cells and other T-lymphocyte 
subsets (Mallmann et al., 1990; Scambia et al., 1988; Kurebayashi et al., 1999; Naglieri 
et al., 2002). Furthermore, fewer T-lymphocyte subsets were observed in 
postmenopausal women using high-dose MPA in the treatment of breast cancer 
(Mallmann et al., 1990; Scambia et al., 1988).  
 
Numerous in vitro studies have also reported suppressive effects of MPA on immune 
regulators, which are summarised in Table 1.1 (Mantovani et al., 1997; Lan et al., 
1999; Bamberger et al., 1999; Kelly et al., 1994). Briefly, MPA was reported to 
suppress phytohemaglutinin-induced IL-6, IL-1, and TNF expression in peripheral 
blood mononuclear cells (Mantovani et al., 1997). Similarly, Lan and colleagues 
showed that IL-1 expression is significantly repressed by MPA in primary cultures of 
rat uterine smooth muscle cells (Lan et al., 1999). Consistent with these studies, another 
study demonstrated that both IL-1 and IL-6 expression are significantly suppressed by 
MPA in normal human lymphocytes (Bamberger et al., 1999). Dexamethasone (DEX), 
a strong GR agonist, and MPA significantly inhibited lipopolysaccharide (LPS)-
induced IL-8 production in the endometrium and chorio-decidual primary cells, while 
P4 had no effect on IL-8 production (Kelly et al., 1994). In one of the very few 
comparative studies of the two progestins, MPA and NET-A, MPA was shown to 
extensively repress TNF induced IL-8 promoter activity in the human embryonic 
kidney HEK293 cell line, while NET-A only elicited a slight decrease in IL-8 promoter 
activity (Koubovec et al., 2005). The effect of MPA on immunity has also been shown 
not only to be cellular but also systemic (Parr et al., 1994; Kaushic et al., 2003; 
Gillgrass et al., 2003).  
 
MPA is extensively used in mice as an immune compromising agent to investigate STIs 
(Parr et al., 1994). Consistent with this, MPA treatment of mice was found to increase 
their susceptibility to genital herpes simplex virus type 2 (HSV-2) infection (Kaushic et 
al., 2003). Interestingly, longer treatment (15 days) with MPA failed to protect mice 
from subsequent HSV-2 challenge due to a decrease in both innate and adaptive 
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immune responses (Gillgrass et al., 2003). Vaginal thinning and subsequent simian 
immunodeficiency virus infection in macaque monkeys as a result of progesterone 
implants used as a contraceptive have also been reported (Marx et al., 1996). Another 
study conducted with macaque monkeys demonstrated that MPA at injectable 
contraceptive dosage repressed antiviral immune responses and increased susceptibility 
to SIV infection (Trunova et al., 2006) suggesting that MPA may have deleterious 
effect on sexually transmitted diseases (STDs) and also suggesting that MPA‟s effect 
on SIV infection is immune based rather than transmission based. Such an association 
has been made in a prospective study with 819 women. Morrison and colleagues 
reported that injectable MPA treatment increased the acquisition of cervical chlamydia 
and gonococcal infections (Morrison et al., 2004). Moreover, an increase in both HIV 
and HSV cervical shedding has been shown in women using MPA as contraception 
(Mostad et al., 1997; Mostad et al., 2000; Wang et al., 2004). In agreement with these 
studies, another study reported that HIV-positive women using MPA as a contraceptive 
have increased viral loads as well as a higher number of viral variants compared to non-
users (Lavreys et al., 2004). Similarly, increased HIV-1 infection rates have been 
reported amongst Kenyan sex workers using hormonal contraceptives, compared to 
non-users (Martin et al., 1998). However, caution should be exercised in interpreting 
these findings, as women on contraceptives might be less likely to use condoms, which 
may be the reason for the increase in STIs, rather than a physiological effect of MPA. 
However, an alternative explanation proposed by Ildgruben et al. (2003) suggests that 
hyperplasia of vaginal epithelium and changes of immune cell milieu induced by MPA 
could account for the increased risk of STIs in MPA-users compared to non-users 
(Ildgruben et al., 2003). In contrast to the studies showing an increased risk of HIV 
acquisition, a few studies have suggested that MPA has no effect on HIV acquisition 
(Myer et al., 2007; Kleinschmidt et al., 2007; Morrison et al., 2007). Nonetheless, the 
use of MPA has also been associated with cervical ectopy (Mauck et al., 1999; 
Morrison et al., 2004), which in turn is linked to higher HIV-1 shedding in women 
(Moss et al., 1991; Kreiss et al., 1994; Royce et al., 1997). A recent study also shows 
an association between MPA and an increased risk of cervical infection with chlamydia 
and gonorrhea (Pettifor et al., 2009).  
 
In summary, results from clinical studies are conflicting regarding the role of synthetic 
progestins, especially MPA, on immune function. However, in vitro evidence from 
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studies in mice and primates would strongly suggest that progestins do have an effect 
on the immune response. Synthetic progestins are used by millions of women 
worldwide, either as contraceptive or in HRT. It is therefore imperative that the 
molecular mechanism of action of these compounds be fully understood.  
 
Table 1.1: Immune cells and regulators inhibited by MPA  
Immune cells or-regulators Cell type Reference 
cell-adhesion molecule Endometrial biopsies  Wakatsuki et al.,, 2002 
NK cells, IL-2, & IFN PBMC Stopinska-Głuszak et al.,, 2006 
T-helper cells PBMC Mallmann et al.,, 1990 
Monoclonal antibodies PBMC Scabia et al.,, 1988 
IL-6  KPL-4 human breast cancer Kurebayashi et al.,, 1999,  
IL-2, IL-6, & IL-1 Normal human lymphocytes Bamberger et al.,, 1999 
IL-1 myometrial smooth muscle cells Lan et al.,, 1999 
IL-6, IL-1, & TNF  PBMC Mantovani et al.,, 1997 
IL-8 promoter activity human embryonic kidney HEK293 Koubovec et al.,, 2005 
IL-8 
endometrium and chorio-decidual 
cells 
Kelly et al.,, 1994 
 
1.5 Molecular mechanism of progestin signalling 
Like the natural hormone P4, the synthetic progestins MPA and NET-A both have a 
very high binding affinity for the progesterone receptor (PR) (Bray et al., 2005). In 
addition both progestins have been shown to interact with other steroid receptors such 
as the androgen receptor (AR), mineralocorticoid receptor (MR), glucocorticoid 
receptor (GR), and although not yet well defined also the estrogen receptor (ER) 
(Philibert et al., 1999; Bentel et al., 1999; Koubovec et al., 2005; Africander PhD 
thesis, 2010). The molecular mechanism of action of these two progestins via different 
steroid receptors will be discussed with particular emphasis on their effects on the 
immune response.  
 
1.5.1 Steroid receptor signalling 
The PR is a steroid receptor belonging to the steroid hormone receptor sub-family, 
which forms part of the nuclear receptor superfamily. Steroid receptors consist of 
distinct domains as illustrated in Figure 1.5. The amino-terminus primarily contains the 
highly variable transcriptional activation function 1 domain (AF1). Situated next to the 
AF1 domain is the highly conserved zinc finger DNA-binding domain (DBD). This 
domain plays an important role in receptor dimerization, DNA-binding specificity, and 
interaction with co-factors (Griekspoor et al., 2007). The ligand-binding domain (LBD) 
is situated at the COOH-terminus and is a moderately conserved region, which is 
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involved in protein-protein interactions with chaperones or co-regulators (Beato et al., 
1995; Gronemeyer & Moras, 1995; McEwan et al., 1997; Moras & Gronemeyer, 1998). 
Furthermore, the nuclear localisation signal is embedded in both the DBD and LBD 
(Tang et al., 1998).  
 
 
Figure 1.5: Functional domains of the steroid receptor. The highly variable amino terminus contains the 
transcriptional activation funtion 1 (AF-1), while the ligand binding domain (LBD) and ligand-dependent 
activation function 2 (AF-2) are present in the carboxy-terminus. The highly conserved DNA-binding 
domain (DBD) is situated in the centre of the protein. The domains concerned with receptor dimerization, 
co-factor binding, and nuclear localisation are mainly present in the carboxy-terminal end of the steroid 
receptor protein. H refers to the hinge region. (Diagram adapted from Zhou & Cidlowski, 2005). 
 
In the absence of ligand, the AR, GR and MR are predominantly present in the 
cytoplasm whereas the ER and PR are predominately present in the nucleus 
(Griekspoor et al., 2007) in an inactive state in a protein complex with heat shock 
proteins (hsp)-90 and hsp70, immunophillins, and other factors (Pratt & Toft, 1997). 
Hsp90 acts as a molecular chaperone, and prevents unliganded steroid receptor from 
translocating to the nucleus. The liphophilic steroids passively diffuse across the plasma 
membrane where they bind to the ligand-binding domain of the steroid receptor 
(Hammes & Levin, 2007). On ligand binding, a conformational change of the steroid 
receptor occurs, followed by rapid nuclear translocation (Griekspoor et al., 2007; Zhou 
& Cidlowski, 2005). Furthermore, steroid receptors are hyper-phosphorylated upon 
ligand binding, which is generally associated with a transcriptionally active steroid 
receptor. In the nucleus, the ligand-bound steroid receptor binds to specific palindromic 
DNA sequences known as steroid responsive elements (SREs), thereby positively 
regulating transcription (Griekspoor et al., 2007). In contrast, steroid receptors can 
negatively regulate transcription by either directly or indirectly interfering with other 
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DNA-bound transcription factors such as NFB, AP-1, and C/EBP (Kassel & Herrlich 
2007; De Bosscher & Haegeman, 2009; Revollo & Cidlowski, 2009). The direct 
protein-protein interaction also referred to as the tethering mechanism, is often 
associated with the repression of immune-regulator genes such as IL-6 and IL-8 
(Barnes & Adcock 1993; Scheinman et al., 1995; van der Saag et al., 1996; De 
Bosscher et al., 1997; De Bosscher et al., 2000; Adcock & Caramori, 2001; Reichardt 
et al., 2001; De Bosscher et al., 2006; Jonat et al., 1990; Nissen & Yamamoto, 2000). 
Although steroid receptor signalling is essentially similar for all steroid receptors, they 
regulate the transcription of different genes in different tissues in response to their 
specific ligands (Griekspoor et al., 2007).  
 
Steroid receptors can also regulate transcription in the absence of ligand when activated 
by various stimuli such as peptide growth factors, neurotransmitters, and cyclins 
(Bunone et al., 1996; El-tanani & Green 1997; Pierson-Mullany & Lange 2004; Tanaka 
et al., 1996; Eickelberg et al., 1999; Kotitschke et al., 2009; Cenni & Picard 1999). The 
ER, AR, PR, and GR have all been shown to be activated in the absence of ligand, with 
most studies identifying phosphorylation of the specific receptor as a marker of 
activation (Bunone et al., 1996; El-tanani & Green, 1997; Power et al., 1991; 
Trowbridge et al., 1997; Zwijsen et al., 1998; Chauchereau et al., 1994; Nazareth & 
Weigel, 1996; Kotitschke et al., 2009). Ser-118 of transiently transfected ER has shown 
to be hyper-phosphorylated at least 3-fold in response to epidermal growth factor 
(EGF), a similar level to that induced by 17--estradiol in SK-Br-3 cells (Bunone et al., 
1996). Similarly, Pierson-Mullany & Lange (2004) showed that in breast cancer T47D 
whole cell extracts, hyper-phosphorylation occurs at Ser-400 of the PR in response to 
EGF, PMA, and insulin-like growth factor (IGF) (Pierson-Mullany & Lange, 2004). PR 
hyper-phosphorylation induced by these mitogens was similar to the extent of hyper-
phosphorylation induced by the PR-specific synthetic agonist R5020 (Pierson-Mullany 
& Lange, 2004). Consistent with that shown for the ER and PR, a recent study in the 
mouse pituitary cell line LT2 showed that endogenous GR is selectively 
phosphorylated in response to Gonadotropin releasing hormone (GnRH) at Ser-234 and 
not Ser-220 (equivalent to the human Ser-211 and Ser-226, respectively) (Kotitschke et 
al., 2009). In addition, phosphorylation of unliganded ER has also shown to facilitate 
co-factor binding, thereby increasing ligand-independent ER induced transcription in 
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response to EGF (Tremblay et al., 1999; Tremblay & Giguère, 2001; Dutertre & Smith, 
2003). 
 
1.5.2 Interaction of P4 and synthetic progestins with steroid receptors 
 
Even though MPA and NET have similar binding affinities and elicit similar biological 
responses via the PR (Bray et al., 2005; MacLaughlin & Richardson, 1979; Bergink et 
al., 1983) they have been shown to have differential interactions with other steroid 
receptors. Both MPA and NET have been shown to bind to endogenous AR with equal 
affinity in human breast cancer MCF-7 cells (Bergink et al., 1983). However, binding 
experiments with cytosolic fractions of the same cell line showed that MPA has a 
slightly higher binding affinity for the AR than NET (29% versus 17% of binding 
relative to the natural AR ligand, dihydrotestosterone (DHT) (Bergink et al., 1983). 
Although determined in different cell systems, the Kd of MPA for the AR in MFM-223 
human mammary cancer cells was found to be between 1.2 nM-3.6 nM (Hackenberg et 
al., 1993), which is 20 times less than the Kd of DHT as determined in the rat 
hypothalamus and pituitary (Pérez-Palacios et al., 1983). A recent study in transfected 
COS-1 monkey kidney fibroblast cells reported that the Kd of both MPA and NET-A 
for the AR were found to be similar, to each other and DHT (~20 nM) (Africander PhD 
thesis, 2010). Furthermore, using promoter reporter assays, both MPA and NET-A were 
shown to exhibit weak agonist activity for transactivation similar to that of DHT via the 
AR in transfected COS-1 cells on a promoter reporter construct, (Africander PhD thesis 
2010). It has been suggested that the androgenic effects of MPA may counteract the 
protective effects of endogenous androgen signalling in the breast (Birell et al., 2007), 
which might also apply to NET-A. Consistent with this idea, both MPA and NET-A 
were demonstrated to increase the risk of breast cancer in long term HRT (Beral, 2003). 
 
P4 has been shown to exhibit weak binding affinity for the AR and GR. In contrast, it 
has a high binding affinity for the MR, in both transfected COS-1 cells (Africander PhD 
thesis, 2010) and cytosols of adrenalectomized rat kidneys (Wambach & Higgins, 
1978) and exhibits potent antagonist and weak partial agonist activity for the MR 
(Wambach et al., 1979; Rafestin-Oblin et al., 1992; Quinkler et al., 2002; Quinkler et 
al., 2002; Africander PhD thesis, 2010). MPA and NET, however, both exhibit no 
agonist or antagonist activity via the MR (Winneker et al., 2003; Africander PhD thesis, 
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2010). The inability of synthetic progestins to mimic the effects of P4 via the MR could 
have negative consequences for women on HRT, as antagonism of aldosterone (Ald) 
activity by P4 prevents health risks such as high blood pressure and hypertension is a 
cardiovascular disease risk factor. Thus the choice of progestin used in HRT is 
especially crucial to protect women from cardiovascular disease. 
 
In terms of the interaction of MPA and NET with the ER, reports are contradictory. 
Both MPA and NET have been reported to weakly bind the ER both in vitro and in vivo 
(Di Carlo et al., 1983). The weak binding of NET and its metabolites to the ER is also 
supported by other studies (Markiewicz & Gurpide, 1994; Mendoza-Rodríguez et al., 
1999; Sasagawa et al., 2008). However, some reports have shown that NET does not 
bind to the ER (Schoonen et al., 2000; Bergink et al., 1983). These discrepancies could 
be due to the metabolism of NET in different cell systems, as it is the NET metabolites 
that appear to have estrogenic activity (Larrea et al., 2001). In contrast to the early 
study by Di Carlo and co-workers (1983) showing that MPA binds to the ER, several 
subsequent studies have shown that MPA has no binding affinity for endogenous or 
transfected ER in numerous cell types (Teulings et al., 1980; Bergink et al., 1983; 
Markiewicz & Gurpide, 1994; Sasagawa et al., 2008). Binding of synthetic progestins 
to the ER is therefore a controversial issue, and is most likely cell- and tissue type-
specific.  
 
Numerous studies have reported binding of MPA to the GR (Bojar et al., 1979; 
Teulings et al., 1980; Kontula et al., 1983; Winneker & Parsons, 1981; Bamberger et 
al., 1999; Simoncini et al., 2004; Koubovec et al., 2004; Koubovec et al., 2005; 
Ronacher et al., 2009). Kontula and colleagues (1983) demonstrated in leukocytes that 
although MPA did not interact with the GR as strongly as the potent synthetic 
glucocorticoid, DEX, it did have a higher binding affinity for the GR than cortisol, the 
endogenous hormone (Kontula et al., 1983). Similar results were shown in human renal 
carcinoma cells (Bojar et al., 1979) and human breast cancer cells (Teulings et al., 
1980). On the other hand, NET interacts only weakly with the GR (Koubovec et al., 
2005; Kontula et al., 1983; Schoonen et al., 1995; Ronacher et al., 2009). In fact, NET 
exhibited a similar binding affinity for the GR to P4, both 25 times less than that of 
MPA in the human alveolar epithelial carcinoma (A549) cell line (Koubovec et al., 
2005). Furthermore, MPA has also been shown to have dissociative glucocorticoid-like 
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properties (Bamberger et al., 1999). While MPA and DEX were equally capable of 
transrepressing an IL-2 promoter, transactivation of a glucocorticoid response element 
(GRE) in the same cell system was lower in the presence of MPA than DEX 
(Bamberger et al., 1999; Ronacher et al., 2009). The effects of MPA were reported to 
occur via the GR, as neither PR nor the AR are expressed in the lymphocyte cell line in 
which the experiments were conducted (Bamberger et al., 1999). In a human embryonic 
kidney (HEK293) cell line, MPA induced both GR-mediated transactivation of a GRE 
containing promoter reporter (EC50=7.2 nM) as well as GR-mediated transrepression of 
an IL-8 promoter (EC50=2.7 nM) (Koubovec et al., 2005). NET was unable to induce 
transactivation although it did elicit some transrepression (approximately 22% of that 
elicited by DEX) (Koubovec et al., 2005). Furthermore, in contrast to MPA, NET was 
shown to antagonise GR-mediated transactivation in transfected COS-1 cells 
(Africander PhD thesis 2010).  
 
Taken together, MPA and NET may exert biological effects via interaction with the 
GR, AR, MR, or ER. Furthermore, most of the effects by MPA regarding immune 
regulation are believed to be via the GR (Bamberger et al., 1999; Koubovec et al., 
2004) although anti-inflammatory effects could also be via the AR (Africander Phd 
thesis 2010; Wakatsuki et al., 2002) The mechanisms by which progestins such as 
MPA and NET may elicit anti-inflammatory responses via the GR are discussed below. 
 
1.6. Glucocorticoid receptor-mediated repression of immune-
regulators 
Inflammatory diseases such as asthma and rheumatoid arthritis are extensively treated 
with glucocorticoids, which inhibit the production of immune-regulators, promote 
apoptosis and inhibit cell proliferation of immune cells. Inflammation also triggers a 
negative feedback loop to the hypothalamic-pituitary-adrenal (HPA) axis, which 
stimulates the synthesis and secretion of glucocorticoids by the adrenal cortex. As 
previously stated, ligand-activated GR can either stimulate or inhibit gene transcription. 
Glucocorticoids are extensively used as anti-inflammatory agents and there are various 
mechanisms by which ligand-bound GR can inhibit expression of immune regulators. 
These mostly involve interference with transcription of pro-inflammatory genes, which 
have been extensively discussed by several groups (Kassel & Herrlich, 2007; De 
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Bosscher et al., 2003; Newton & Haegeman, 2009; Rogatsky & Ivashkiv, 2006; 
Liberman et al., 2007). The gene repression can occur in one of three ways. Firstly, the 
GR can directly interact with pro-inflammatory transcription factors such as NFB and 
AP-1 (Barnes & Adcock, 1993; Scheinman et al., 1995; van der Saag et al., 1996; De 
Bosscher et al., 1997; De Bosscher et al., 2000; Adcock & Caramori, 2001; Reichardt 
et al., 2001; Jonat et al., 1990; Nissen & Yamamoto, 2000; De Bosscher et al., 2006). 
Secondly, activated GR can compete with transcription factors for nuclear co-factors 
thereby limiting their transcriptional activity (Sheppard et al., 1998; Kamei et al., 
1996). Thirdly, the GR can indirectly influence immune-regulators either by interfering 
with upstream signalling proteins, responsible for the activation of pro-inflammatory 
transcription factors, or by the transcriptional up-regulation of anti-inflammatory genes 
(Caelles et al., 1997; Ayroldi et al., 2002; Alexander & Hilton 2004; Auphan et al., 
1995). These mechanisms, which are schematically represented in Figure 1.6, will be 
discussed in more detail with a focus on the mechanism by which glucocorticoids, 
MPA, and to a lesser extent NET-A, may exert their anti-inflammatory effects via the 
GR.  
 
1.6.1 Direct interaction of the GR with pro-inflammatory transcription factors  
The inhibitory activity of ligand-bound GR on immune-regulatory genes can be 
mediated by direct protein-protein interaction with pro-inflammatory transcription 
factors (Kassel & Herrlich, 2007; De Bosscher et al., 1997; Tuckermann et al., 1999; 
Ray & Prefontaine, 1994; De Bosscher et al., 2000; Kleinert et al., 1996). The 
interacting complex of the GR and other transcription factors is well established. 
Numerous studies in different cell types have shown by co-immunoprecipitation and/or 
glutathione S-transferase fusion binding protein (GST) pull down experiments, that the 
GR directly interacts with pro-inflammatory transcription factors such as NFB and 
AP-1 (Touray et al., 1991; Barnes & Adcock 1993; Scheinman et al., 1995; van der 
Saag et al., 1996; De Bosscher et al., 1997; De Bosscher et al., 2000; Jonat et al., 1990; 
Nissen & Yamamoto 2000). The interactions between the GR and the transcription 
factors NFB and AP-1 are the best studied, mainly because they are commonly 
associated with increased expression of a wide variety of inflammatory cytokines (e.g. 
IL-6, IL-8, RANTES, TNF IL-1 etc) (Barnes, 1998). The interaction of the GR with 
NFB and AP-1 requires the zinc finger region situated in the DNA-binding domain of 
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the GR as determined by deletion mutants and/or domain mapping in a wide variety of 
cell types (Stein & Yang, 1995; Liden et al., 1997; Wissink et al., 1997; Nissen & 
Yamamoto, 2000; Scheinman et al., 1995; Jonat et al., 1990; Yang-Yen et al., 1990; 
Ray et al., 1990). In addition, interactions between the GR and a number of other 
transcription factors have been demonstrated, such as signal transducer and activator of 
transcription (STAT)-5 (Stöcklin et al., 1996) and CREB (Imai et al., 1993).  
 
Early studies proposed that the direct interaction of the GR with other transcription 
factors prevents DNA binding of transcription factors NFB and AP-1 and 
consequently repression of target genes (Scheinman et al., 1995a; Scheinman et al., 
1995b; Ray & Prefontaine 1994; Mukaida et al., 1994; Schüle et al., 1990; Yang-Yen 
et al., 1990). These studies showed that DEX treatment diminished binding of AP-1 or 
NFB to DNA in electrophoretic mobility shift assays (EMSAs). However, other 
studies also using EMSAs, reported no reduction in DNA binding of AP-1 (Jonat et al., 
1990) or NFB (De Bosscher et al., 1997). Similarly, in vivo footprinting demonstrated 
that AP-1 binding to DNA remained unaltered in response to glucocorticoids (König et 
al., 1991). It could be argued that these differences are due to promoter- or cell 
specificity. However, the studies by Yang-Yen et al. (1990) and Jonat et al. (1990) both 
investigated the collagenase-1 promoter (Yang-Yen et al., 1990; Jonat et al., 1990) and 
a later study involving chromatin immunprecipitation (ChIP) confirmed that AP-1 
subunit levels at the collagenase-1 promoter do not change upon glucocorticoid 
treatment (Kassel et al., 2004). Similar findings were also reported for NFB recruited 
to the IL-8 promoter, which remained unchanged in response to DEX (Nissen & 
Yamamoto, 2000; Luecke & Yamamoto, 2005; Kassel et al., 2004; Garside et al., 
2004), in contrast to the earlier studies. Several other studies also show unaltered pro-
inflammatory transcription factor recruitment to various promoters, with DEX-
dependent GR recruitment (Rogatsky et al., 2001; Ogawa et al., 2005; Garside et al., 
2004). Taken together, these findings suggest a repression model in which the protein-
protein interaction between GR and pro-inflammatory transcription factors occurs while 
the latter are bound to DNA, at the promoter.  
 
Protein-protein interactions at the promoter DNA is also commonly referred to as 
tethering. Tethering of GR to pro-inflammatory transcription factors gives rise to 
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different molecular events that lead to transcriptional repression. These molecular 
events include the involvement of co-factors (McKay & Cidlowski, 2000; Rogatsky et 
al., 2001; Rogatsky et al., 2002; He & Simons, 2007; Ogawa et al., 2005) and 
destabilising of basal transcription machinery recruited to the promoter (Nissen & 
Yamamoto, 2000; De Bosscher et al., 2000; Luecke & Yamamoto, 2005).  
 
1.6.1.1 Co-factors involved in transrepression 
The involvement of co-factors in GR-mediated transcriptional repression via tethering 
is complex and several mechanisms have been proposed. Both CBP and GR interacting 
protein-1 (GRIP-1) are historically associated with transcriptional activation (Glass & 
Rosenfeld, 2000). However, these two co-activators have recently been shown to also 
be involved in GR-mediated repression. Overexpression of CBP, a histone acetyl 
transferase, has been shown to increase the physical interaction between NFB and GR, 
and augment GR-mediated repression of an NFB responsive reporter (McKay & 
Cidlowski, 2000). Similarly, overexpressed GRIP-1 augmented GR-mediated 
repression of the collagenase-3 promoter, which is AP-1 dependent (Rogatsky et al., 
2001). The authors demonstrated by ChIP analysis that GRIP-1 is recruited to the 
collagenase-3 promoter in response to DEX, and not in response to the pro-
inflammatory agent PMA, suggesting it is in the role as co-repressor (Rogatsky et al., 
2001). In addition, it has been established that GRIP-1 also functions as a co-repressor 
of liganded-GR on a synthetic NFB-responsive promoter reporter (Rogatsky et al., 
2002). The exact mechanism that determines how these two co-factors are involved in 
transcription inhibition needs to be elucidated. However one could postulate that they 
serve as bridging proteins that interact with other proteins with histone deacetylase 
activity needed for repression (Kassel & Herrlich, 2007; Ito et al., 2000). In fact, GRIP-
1 has been shown to interact with histone deacetylase 1 (HDAC1) by co-
immunoprecipitation (Liu et al., 2006).  
 
The GR can also block the recruitment of co-activators to transcription factors 
associated with pro-inflammatory genes. Two studies have shown that the GR disrupts 
the formation of NFB and interferon regulatory factor (IRF) complexes (Ogawa et al., 
2005; Reily et al., 2006). The NFB/IRF complex is required for TLR-4- or TLR-9-
dependent transcriptional activation of inflammatory genes (Ogawa et al., 2005) and 
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IRF3 is a co-activator for NFB responsive genes such as IL-6 and TNF (Ogawa et 
al., 2005). Co-factor involvement in transrepression mediated by the tethered GR is 
complex and may be co-factor-, as well as promoter-specific.  
 
1.6.1.2 The effect of tethered GR on basal transcription machinery 
The GR has also been shown to negatively affect the basal transcription machinery of 
various promoters via tethering (Nissen & Yamamoto, 2000; De Bosscher et al., 2000; 
Luecke & Yamamoto, 2005). Although the GR does not prevent the recruitment of 
RNA polymerase II (Pol II) to the NFB responsive IL-8 promoter (Luecke & 
Yamamoto 2005; Nissen & Yamamoto 2000), it has been shown to inhibit serine-2 
phosphorylation of the Pol II carboxy-terminal domain (CTD), which is essential for 
Pol II transcriptional activity (Nissen & Yamamoto, 2000). Prevention of Pol II 
phosphorylation is achieved by the GR competing for promoter binding with 
transcription elongation factor b (P-TEFb) (Luecke & Yamamoto, 2005), which is 
responsible for the phosphorylation of the CTD of Pol II (Barboric et al., 2001). Ligand 
activated GR has also been demonstrated to inhibit phosphorylation of H3 at serine-10 
(Hasegawa et al., 2005). Since this histone modification is linked to transcription of 
pro-inflammatory genes (Martenset et al., 2005; Karrasch et al., 2006; Chan et al., 
2005), this represents yet another mechanism by which the GR can decrease 
transcriptional activity.  
  
1.6.2 Co-factor competition model 
Besides the models discussed above, early studies proposed that GR-mediated 
repression is influenced by limited amounts of co-factors present in the cell (Kamei et 
al., 1996; Sheppard et al., 1998; Lee et al., 1998; Aarnisalo et al., 1998). CBP and 
steroid receptor co-activator (SRC)-1 act as co-factors for AP-1, NFB, and the GR 
(Arias et al., 1994; Perkins et al., 1997; Kamei et al., 1996; Lee et al., 1998; Na et al., 
1998) and it has been suggested that the GR and pro-inflammatory transcription factors 
compete for binding to these cofactors (Kamei et al., 1996; Sheppard et al., 1998; 
Aarnisalo et al., 1998). Consistent with this hypothesis, overexpressed CBP was shown 
to potentiate NFB and c-Jun activated gene transcription (Gerritsen et al., 1997; Arias 
et al., 1994) and was also subsequently shown to decrease GR-mediated repression 
(Kamei et al., 1996; Sheppard et al., 1998). A similar mechanism has been shown for 
32 
 
SRC-1 and AP-1, where overexpression of SRC-1 in CV1 cells induced AP-1-mediated 
promoter activity, while also attenuating DEX-mediated repression (Lee et al., 1998). 
However, overexpressing CBP in murine L929A fibrosarcoma cells showed that CBP 
did not affect DEX-mediated repression of an IL-6 promoter reporter construct (De 
Bosscher et al., 1997). DEX-mediated transactivation of a GRE-containing promoter 
construct was negatively affected by co-expression of CBP and p65, a result which does 
not support the hypothesis of transrepression through co-factor competition (De 
Bosscher et al., 1997). These authors also showed that increasing the co-factor protein 
does not affect GR repression of IL-6 promoter induced by staurosporine, a compound 
that selectively activates AP-1 but not NFB. A similar finding was demonstrated on an 
AP-1-driven promoter construct, suggesting that the lack of co-factor competition is not 
promoter specific. In contrast, using a GR mutant unable to bind to co-factors (Kassel et 
al., 2004), the GR was still able to mediate repression of an AP-1 driven promoter. 
Further studies are thus needed to address these disparities concerning the co-factor 
competition model of GR transrepression.  
  
1.6.3 Indirect repression by GR 
The above-mentioned mechanisms of GR-mediated repression (Section 1.6.1 & 1.6.2) 
all involve direct cross-talk between the GR and pro-inflammatory transcription factors. 
However, the GR can also interfere with upstream signal transduction involved in the 
activation of transcription factors, as well as increase of transcription of anti-
inflammatory genes.  
 
1.6.3.1 Cross-talk with signalling pathways 
Signalling pathways like the MAPKs and PKA have been shown to activate the pro-
inflammatory transcription factors AP-1 and NFB, thereby influencing transcription 
(Gonzalez et al., 2000; Stein et al., 1989; Devary et al., 1991; Radler-Pohl et al., 1993; 
Caelles et al., 1997; Zhong et al., 1997; Doucas et al., 2000). The GR has been 
demonstrated to negatively influence AP-1 and NFB activity indirectly by inhibiting 
the activity of the MAPKs, ERK, JNK, and p38 (Kassel et al., 2001; Imasato et al., 
2002; Lasa et al., 2002; Caelles et al., 1997; Gonzalez et al., 2000; Rider et al., 1996; 
Hulley et al., 1998). The main protein subunit of AP-1, c-Jun, is phosphorylated at 
serine residues 63 and 73 by JNK, which is required for its activity (Stein et al., 1989; 
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Devary et al., 1991; Radler-Pohl et al., 1993; Caelles et al., 1997). By quantitation of 
tryptic phosphopeptide maps of in vivo-labeled c-Jun in HeLa cells, Caelles and 
colleagues demonstrated that UV stimulation increased phosphorylation on Ser-63 and 
Ser-73 at least 2-fold whereas DEX abolished this increase without affecting total JNK 
protein levels (Caelles et al., 1997). Interestingly, although the GR antagonises AP-1 
transcriptional activity, both the GR and JNK were shown to be recruited to the c-jun 
promoter by means of ChIP analysis in HeLa cells (Bruna et al., 2003). Co-
immunprecipitation experiments showed a direct interaction between JNK and GR 
(Bruna et al., 2003).  
 
The PKA catalytic subunit phophorylates and physically interacts with NFB (Zhong et 
al., 1997; Doucas et al., 2000) thereby increasing NFB transcriptional activity, and the 
GR has been shown to interfere with the interaction between the PKA catalytic subunit 
and NFB (Doucas et al., 2000), thereby reducing NFκB activity. The GR can also 
associate with the PKA catalytic subunit, thus inhibiting activation of NFB. Doucas 
and colleagues showed by means of in vitro pull-down experiments that in vitro 
translated human GR interacts with GST-PKA. Subsequently, the same study 
demonstrated in human HEK293 cells, that transfected human GR co-
immunoprecipitated with PKA (Doucas et al., 2000). Overexpressed GR decreased 
p65/ PKA catalytic subunit interaction in a ligand-dependent manner as determined by 
co-immunoprecipitation (Doucas et al., 2000). The authors concluded that the GR 
competes with p65 for binding to the PKA subunit. However it could also weaken the 
association between p65 and PKA (Doucas et al., 2000). Ligand-activated GR has also 
been shown to decrease ERK and p38 activity (Kassel et al., 2001; Imasato et al., 2002; 
Lasa et al., 2002). However, this requires de novo protein synthesis, unlike inhibition of 
PKA and JNK (Kassel et al., 2001; Lasa et al., 2002). 
 
1.6.3.2 Increased transcription of anti-inflammatory genes 
Ligand-activated GR can also indirectly downregulate anti-inflammatory gene 
expression by the induction of numerous genes (summarised in Table 1.2) that are 
directly involved in the repression of the immune response. Besides direct interaction 
with signalling pathways, the GR can also indirectly influence MAPKs by increasing 
the expression of MAPK phosphatase-1 (MKP-1) (Kassel et al., 2001; Lasa et al., 
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2002; Jang et al., 2007; King et al., 2009). MKP-1 is a member of the dual specific 
(Thr/Tyr) phosphatase family (DUSPs) and is known for its negative regulation of 
immune processes, by dephophorylation of MAPKs (Camps et al., 2000). MKP-1 is 
induced by pro-inflammatory stimuli and mitogenic stress and therefore its attenuation 
of MAPK activation serves as a negative feedback mechanism (King et al., 2009). 
Endogenous GR increases MKP-1 expression at the promoter level in both RBL-2H3 
mouse bone marrow-derived mast cells and NIH-3T3 fibroblasts cells in a ligand-
dependent manner (Kassel et al., 2001). MKP-1 mRNA expression in mast cells and 
fibroblasts derived from mouse bone was shown to increase in response to 0.1 M DEX 
with maximal expression after one hour of treatment. GR-mediated activation of MKP-
1 has shown to occur via a tethering mechanism involving C/EBP in HEK293 cells 
stably transfected with human GR on the DUSP1 promoter (Johansson-Haque et al., 
2008). MKP-1 expression induced by DEX was shown to inhibit NFB-mediated 
transcription of IL-8 (King et al., 2009). Additionally, when activated by the 
endogenous ligand cortisol, liganded GR antagonises MKP-1 degradation in RBL-2H3 
mast cells compared to untreated cells (Kassel et al., 2001). Therefore, GR-mediated 
effects of DEX on MKP-1 are two-pronged: its expression is increased, while 
proteosomal degradation is decreased. The DEX-induced increase of MKP-1 is yet 
another mechanism by which glucocorticoids may elicit an anti-inflammatory response.  
 
Glucocorticoid-induced leucine zipper (GILZ) is another example of a GR-induced 
protein with a role in the anti-inflammatory response. Ligand-activated GR increases 
the expression of GILZ, a leuzine zipper protein that inhibits the expression of AP-1- 
and NFB-responsive genes (Mittelstadt & Ashwell, 2001; Ayroldi et al., 2001; 
Ayroldi et al., 2002; Riccardi et al., 2000; Riccardi & Cifone, 1999). Increased GILZ 
expression has been shown to be required for GR mediated repression of IL-2 mRNA in 
normal T-cells (Mittelstadt & Ashwell, 2001), as well as transrepression of AP-1- and 
NFB-responsive reporters in transfected Jurkat and human kidney epithelial 
carcinoma HEK293 cell line respectively (Mittelstadt & Ashwell, 2001; Ayroldi et al., 
2001). In addition, GILZ was shown to interact with AP-1 and NFB subunits by 
means of co-immunoprecipitation, and furthermore it prevents DNA binding of both 
transcription factors in vitro (Mittelstadt & Ashwell, 2001; Ayroldi et al., 2001). 
Overexpressed GILZ has been shown to inhibit ERK, MEK, and Raf-1 phosphorylation 
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by interacting with upstream Raf-Extracellular Signal-Regulated Kinase, which 
consequently impairs AP-1 activation (Ayroldi et al., 2002). Additionally, DEX-
induced GILZ expression has shown to significantly increase the expression of the anti-
inflammatory cytokine IL-10 in macrophages of non-lymphoid tissues from humans 
and mice (Berrebi et al., 2003). Suppressor of cytokine signalling-1 (SOCS-1) is 
another GR-induced protein that negatively influences the inflammatory response. 
SOCS inhibits the JAK/Stat pathway, through which cytokines such as IL-6 signal, by 
physically interacting with JAK and blocking STAT interaction, as well as increasing 
JAK degradation by recruiting E3 ubiquitin ligases (Alexander & Hilton, 2004). 
Ligand-mediated GR upregulates SOCS-1 mRNA expression in several cell types 
thereby increasing its inhibitory effect on the JAK/Stat pathway (Tonko et al., 2001; 
Yoshida et al., 2002). 
 
Lastly, the ligand-activated GR has been shown to induce IB expression, which 
directly inhibits NFB activation (Auphan et al., 1995; Crinelli et al., 2000; Quan et al., 
2000; Thiele et al., 1999; Scheinman et al., 1995). Ligand-activated GR was 
demonstrated to increase both IB mRNA and protein levels in Jurkat (Auphan et al., 
1995) and HeLa cells (Scheinman et al., 1995b). Additionally, NFB remained in the 
cytoplasm in response to DEX as determined by immunofluorescent microscopic 
analysis (Auphan et al., 1995) and subcellular biochemical fractionation (Scheinman et 
al., 1995b). Newly synthesised IB is proposed to sequester NFB thereby inhibiting 
NFB responsive genes (Auphan et al., 1995; Scheinman et al., 1995b). However, 
several studies have refuted the suggestion that glucocorticoids induce IB synthesis 
(Kleinert et al., 1996; Luecke & Yamamoto, 2005) and suggest that NFB inhibition by 
glucocorticoids is independent of IB synthesis (Heck et al.,, 1997; De Bosccher et al.,, 
1997). Glucocorticoid treatment neither activated nor suppressed TNF-induced IB 
mRNA expression in A549 (Luecke & Yamamoto, 2005) and L929sA (De Bosscher et 
al., 1997) cells, although the GR is recruited to the IB promoter (Luecke & 
Yamamoto, 2005). Taken together, these studies suggest that the indirect GR-mediated 








Table 1.2: Proteins upregulated by glucocorticoids that play a role in the inhibition of 
inflammation 
Protein Role in inflammatory inhibition Reference 
MKP-1 
Involved in the dephosphorylation of MAPK pathways 
including upstream kinases 
Caelles et al.,, 1997; Kassel et al.,, 
2001; Jang et al.,, 2007 
GILZ 
Inhibit phosphorylation of ERK, MEK and Raf-1 and 
the expression of immune-regulator genes such as IL-2 
Ayroldi et al.,, 2002; D‟Adamio et 
al.,, 1997; Riccardi et al.,, 1999;  
SOCS 
Inhibits Jak/Stat signalling pathway and promotes 
degradation of Jak 
Alexander & Hilton, 2004 
IB 
Inhibitor of NFB, which keeps it sequestered in the 
cytoplasm  
Auphan et al.,, 1995; Crinelli et al.,, 
2000; Quan et al.,, 2000 
 
The GR can therefore also indirectly influence the immune response as discussed above 
and summarised in Table 1.2 by inducing the expression of proteins i.e. de novo protein 
synthesis, responsible for the inhibition of signalling pathways involved in the 






Figure 1.6: Illustration of GR repression models as described in text by (A1) inhibition of 
DNA binding , (A2) tethering, (B) competing for co-factors, and (C) either directly or 
indirectly interfering with signalling pathways responsible for the activation of pro-
inflammatory transcription factors. Abbreviations: GR, glucocorticoid receptor; P, 
phosphorylation, IB, inhibitory B; NFB, nuclear factor B; AP-1, activation protein-1; c-Jun, 
cellular Jun; c-Fos, cellular Fos; TF, transcription factor; RE, response element; MKP-1, mitogen 




As summarised in Figure 1.5, there are numerous mechanisms by which the GR 
induces repression of immune regulators, and this is dependent on the promoter, local 
chromatin structure and the accessibility of interacting co-factors (Reily et al., 2006). 
The most extensively studied and discussed method of GR cross talk with immune 
signalling is that of tethering. However, GR induced repression may encompass more 
than one of the mechanisms mentioned. This may explain why glucocorticoids are so 
effective in anti-inflammatory treatment and it is a challenge to elucidate a single 
mechanism.  
 
1.7 Conclusion  
The FRT is a complex anatomical structure and the epithelial cells lining the FRT play 
an important role in the local immune response induced by pathogens or stress (Wira et 
al., 2005b). The epithelial cells of the FRT express a wide variety of both pro- and anti-
inflammatory cytokines and chemokines including IL-6, IL-8 and RANTES (Fichorova 
& Anderson, 1999; Fahey et al., 2005). Cytokines are under tight transcriptional 
regulation and hyper-expression is induced under conditions of stress or inflammation. 
The release of pro-inflammatory cytokines such as TNF and IL-1 triggers a cascade 
of signalling pathways leading to the activation of pro-inflammatory transcription 
factors such as AP-1 and NFB.  
 
STIs commonly occur at the FRT and numerous studies have implicated the use of 
contraceptives in the increased risk of various STIs as well as viral shedding in both 
humans and primates (Lavreys et al., 2004a; Lavreys et al., 2004b; Morrison et al., 
2004; MacLean 2005; Marx et al., 1996). MPA has also been shown induce thinning of 
the vaginal mucosa (Ildgruben et al., 2003), which is associated with increased HIV 
infection (Guimarães et al., 2007). Contraceptive use could directly influence 
susceptibility to various infections and diseases of the FRT. However, many 
unanswered questions remain regarding the molecular mechanism(s) of action of the 
synthetic progestins in the FRT. In addition, because MPA and NET-EN are used 
interchangeably as injectable contraceptives, and they are assumed to act similarly to 




MPA and NET-A were synthesised to mimic the actions of P4 but have been shown to 
differ from P4 and to each other in their actions (Koubovec et al., 2005; Stanczyk, 
2003; Hapgood et al., 2004). These differences are attributed to their different affinities 
for different steroid receptors and MPA‟s anti-inflammatory actions have been 
proposed to be mediated via the GR (Bamberger et al., 1999; Koubovec et al., 2004).  
 
Various mechanisms are responsible for the anti-inflammatory effects mediated via 
ligand activated GR as summarised in Figure 1.5. This and could explain why the 
immuno-compromising effects of the progestins on the FRT are not well understood 
and certainly need to be examined further.  
 
1.8 Aims of thesis 
Little is known about the molecular mechanism of action of MPA and NET-A with 
even less information on the molecular effects in the cervical mucosae. Synthetic 
progestins are generally considered anti-inflammatory and the effect of MPA and NET-
A on local endocervical epithelial immune function warrants investigation. Thus, in the 
present study the regulation of cytokines RANTES, IL-8, and IL-6 by synthetic 
progestins MPA, NET-A, and P4 was investigated in a cell model of the endocervix 
(End1/E6E7) (Chapter 3). It was hypothesised that cytokine gene regulation would 
occur and that, as suggested by the literature, MPA especially would be anti-
inflammatory. In addition it was hypothesized that MPA and NET-A would 
differentially regulate the expression of the cytokine genes. Possible differential gene 
regulation by the progestins is hypothesised to be due to different steroid receptors and 
MAPK pathways and was investigated. In studying the role of different steroid 
receptors in IL-6 gene regulation by progestins an interesting observation was made 
which lead to the second part of this thesis (Chapter 4). A novel mechanism of GR 






MATERIAL AND METHODS 
2.1 Cell culture  
End1/E6E7 (endocervical cells immortalized with the human papillomavirus 16/E6E7) 
were purchased from the American Type Culture Collection (ATCC), United States of 
America. Cells were grown 175 cm
2
 culture flasks (Greiner Bio-One International, 
Austria) in keratinocyte serum free (KSF) medium (Sigma-Aldrich, South-Africa) 
supplemented with CaCl2 (final concentration 0.4 mM), 100 IU/mL penicillin, 100 
g/mL streptomycin, the provided bovine pituitary extract (BPE) and 0.1 ng/mL 
recombinant epidermal growth factor (EGF).   
 
COS-1 (African green monkey kidney fibroblast) cells (ATCC, United States of 
America) and HeLa (human cervical carcinoma) cells were cultured in 175 cm
2
 culture 
flasks (Greiner Bio-One International, Austria) in Dulbecco‟s modified Eagle‟s medium 
(DMEM) from Sigma-Aldrich, South-Africa, supplemented with 10% (v/v) fetal calf 
serum (FCS) from Delta Bioproducts, South-Africa and a penicillin (100 IU/ml) and 
streptomycin (100 μl/ml) mixture (penicillin-streptomycin) from Gibco-BRL Life 
Technologies, United Kingdom. All cells were maintained at 37°C in a 5% CO2 
humidified incubator.  
 
Cell cultures were passaged twice weekly, except End1/E6E7 cells, which were sub-
cultured at 60% confluency. Cells were passaged with pre-warmed 0.25% trypsin / 
0.1% EDTA in calcium- and magnesium-free PBS (Highveld Biologicals, South 
Africa). For End1/E6E7 only, trypsinisation was terminated by adding 10 mL 
neutralisation medium (DMEM/F12 (1:1), 1% penicillin-streptomycin and 10% (v/v) 
fetal calf serum (Delta Bioproducts, South-Africa)). Cell were pelleted by 
centrifugation and resuspended in culture medium as described above.  
 
All cultures were regularly tested for mycoplasma infection by means of Hoechst 




2.2 Test compounds and antibodies 
4-pregnene-3, 20-dione (progesterone; P4), 6-methyl-17-hydroxy-progesterone 
acetate (medroxyprogesterone acetate; MPA), 17-ethynyl-19-nortestosterone 17-
acetate (norethindrone acetate; NET-A), 5-androstan-17-ol-3-one 
(dihydrotestosterone; DHT), 11-(4-dimethylamino)phenyl-17-hydroxy-17-(1-
propynyl)estra-4,9-dien-3-one (mifepristone; RU486), 11β,16α-9-fluoro-11,17,21-
trihydroxy-16-methylpregna-1,4-diene-3,20-dione (dexamethasone; DEX), 11,21-
dihydroxy-3,20-dioxo-4-pregnen-18-al (aldosterone; Ald), 17-β-estradiol (1, 3, 5(10)-
estratriene), and recombinant mouse TNF-α were obtained from Sigma-Aldrich, South 
Africa. NET-A, the acetate, was used as it is soluble in water compared with the 
insoluble ester of NET-EN. In vivo, both NET-EN and NET-A undergo hydrolysis and 
are converted to NET and its metabolites (Stanczyk & Roy, 1990). 17β-hydroxy-
7α,17α-dimethylestr-4-en-3-one (mibolerone; MIB), 17-17-hydroxy-17-methyl-estra-
4,9,11-trien-3-one (methyltrienolone; R1881) and promegestone (R5020) were 
purchased from (PerkinElmer Life and Analytical Science, South Africa).  
 
The JNK (SP600125)-, ERK (PD98059)- and p38 (SB230580) inhibitors were 
purchased from Merck Chemicals, South Africa. Hydroxyflutamide (OHFL) was 
obtained from Dr C. Tendler (Schering Plough Research Institute, USA). Tumour 
necrosis factor alpha (TNF) was kept at -80°C in aliquots at a stock concentration of 
0.1 g/mL in filter sterilized water. Working stock (20 mg/mL) was diluted in 
End1/E6E7 culture medium and kept at –20°C.  
  
Antibodies to glucocorticoid receptor (GR) (H-300, sc-8992), progesterone receptor 
(PR) (B-30, sc-811), androgen receptor (AR) (441, sc-7305), mineralocorticoid receptor 
(MR) (H-300, sc 11412), estrogen receptor alpha (ER (MC-20, sc-542) and GR 
interacting protein 1 (GRIP-1) (M-343, sc-8996) were obtained from Santa Cruz 
Biotechnology, USA. Antibodies to -actin (#4967) and GAPDH (#14C10) were 
purchased from Cell Signaling, South Africa. The anti-histone H3 antibody (ab1791) 
and anti-rabbit HRP conjugate (NA934VS) were purchased from Abcam, UK and AEC 






The human MR expression vector, pRShMR, was a kind gift from Ronald Evans 
(Howard Hughes Medical Institute, La Jolla, USA) and previously described (Arriza 
et al., 1987) while the human AR expression vector, pSVARo (Brinkmann et al., 
1999) was obtained from Frank Claessens (University of Leuven, Leuven, Belgium). 
The expression vector for the human PR isoform B, pSG5hPR-B (Kastner et al., 
1990), was obtained from Stoney Simons Jr (NIH, Bethesda, USA) and the wild type 
HA-tagged human GR (pCMV-HA-human GR) was a kind gift from Prof. M. J. 
Garabedian. The expression vector for the human ER, pSG5-hER (Denger, 2001) 
was a gift from F. Gannon (European Molecular Biology Laboratory, Germany) and 
the estrogen response element (ERE)-containing promoter reporter construct derived 
from the vitellogenin promoter, ERE.vit2-luc (Curtis & Korach, 1991) was a kind gift 
from K. Korach (National Institute of Environmental Health Science, USA). The 
reporter plasmid pTAT-GRE-E1b-luc (Sui et al.,, 1999), driven by the E1b promoter 
that contains two copies of the rat tyrosine aminotransferase containing glucocorticoid 
response element (TAT-GRE) was obtained from Dr G. Jenster at Erasmus University 
of Rotterdam, Netherlands. Reporter constructs for selective androgen response 
elements (AREs), 4xSC-ARE1.2 and 4xSLP-HRE2 (Schauwaers et al., 2007) were 
obtained from Prof. Frank Claessens (University of Leuven, Leuven, Belgium). The 
pGL2-basic empty vector and cytomegalovirus (CMV)-driven--galactosidase 
expression vector (pCMV--gal) were purchased from Promega, Madison, USA and 
Statagene, USA, respectively. HA-GRIP was a gift from M. R. Stallcup (University of 
Southern California, USA). 
 
2.4 Transient transfections 
End1/E6E7 cells were transiently transfected using the DEAE-Dextran transfection 
method (Sambrook et al., 1989). For reporter promoter reporter studies, End1/E6E7 
cell were plated in 24-well plates at a density of 1 x 10
5
 cells per well. Twenty-four 
hrs after plating cells were transiently transfected with 300 ng pTAT-GRE-E1b-luc 
plasmid or pGL2-basic empty vector (Promega Corp., USA) and 10 ng pCMV--
galactosidase (Stratagene, USA) and incubated for 24 hrs prior to treatment. After the 
24-hour induction period the medium was aspirated, 50 l of lysis buffer (Tropic Inc, 




For GRIP-1 co-factor over-expression studies, 12-well plates were used. End1/E6E7 
cell were plated at a density of 2 x 10
5
 cells per well and 24 hrs after seeding cells 
were transfected with 500 ng pHA-GRIP-1 or pGL2-Basic, empty vector. Briefly, the 
transfection mixture consisted of 500 ng plasmid DNA, 0.1 mM chloroquine, 0.1 
mg/ml DEAE-Dextran and KSF without supplements to a final volume of 500 L. 
Transfection medium was added to each well and cells were incubated at 37°C in a 
humidified incubator for 1 hr, followed by washing of cells with pre-warmed 10% 
DMSO/PBS. Finally transfected cells were incubated overnight in culture medium at 
37°C in a humidified incubator. Cells were treated 24 hrs after transfection and 
incubated for 24 hrs with various compounds, as described in figure legends. RNA 
was isolated as described in 2.7 
 
2.5 Promoter reporter luciferase assays 
Luciferase assay reagent (Promega Corp., USA) was used to quantify luciferase 
activity in accordance with the manufacturer‟s instructions. Briefly, 10 l cell lysate 
was allowed to react with 50 l luciferase assay reagent. The relative light units 
(RLU‟s) were measured using the Veritas luminometer (Turner Biosystems, Unites 
States of America). A further 5 l cell lysate for each sample was used to measure -
galactosidase activity with the -galactosidase chemiluminescent Galacto-Star™ 
reporter gene assay system for mammalian cells (Tropix Inc., USA). Luciferase 
RLU‟s were normalized to -galactosidase readings to control for differences in 
transfection efficiency between wells, and results were expressed as fold induction 
compared to vehicle EtOH control (0.1% EtOH) set as 1.  
 
2.6 Small interference RNA (siRNA) transfections 
End1/E6E7 cells plated at a density of 1 x 10
5
 cells/well in a 12-well culture plate 
were transfected with 10 nM validated GR HS_NR3C1_5 (cat# SI02654757) siRNA 
directed against the human GR, 10 nM validated AR Hs_AR_5 HP (cat# SI02757258 
siRNA directed against the human AR or validated non-silencing scrambled sequence 
control (NSC) siRNA (cat#1027310) (Qiagen, Germanstown, MD) using HiPerfect 
transfection reagent (Qiagen, Germanstown, MD) as per the manufacturers 
instructions. Briefly, specific or NSC siRNA was diluted in pre-warmed Optimem 
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medium with GlutaMAX 
TM
 (Gibco-BRL Life Technologies, UK) to which 3.5L 
transfection reagent was added. The transfection mixture was incubated at room 
temperature for 10 min and then added drop-wise to the cells to a final concentration 
of 10 nM. Cells were incubated for 24 hrs before being treated for 24 hrs with 
compounds. RNA was then harvested and IL-6 gene expression was analysed by 
quantitative real time PCR, as described below. Cells which were transfected in 
parallel were analysed by Western blotting as described below to verify the protein 
knockdown.  
 
2.7 RNA isolation and cDNA synthesis 
RNA was isolated from End1/E6E7 cells using TRI Reagent® (Sigma-Aldrich, South 
Africa). Briefly, End1/E6E7 cells were plated in 12-well culture plates (Nunc, 
Denmark) at a density of 1 x 10
5
 cells per well. At 70-80% confluency cells were 
treated with test compounds and incubated as described in figure legends. Induction 
medium was removed and 400 L TRI Reagent® was added to cells and incubated for 
5 min at room temperature to allow lysis. Lysates were transferred to clean 1.5mL 
microcentrifuge tubes and 80 L chloroform was then added. The mixture was then 
vortexed vigorously for 1 min followed by incubation at room temperature for 15 min. 
The mixture was centrifuged at 12 200 g (4°C) for 15 min. Equal amounts of the top 
aqueous phase were transferred to clean microcentrifuge tubes and 200 L isopropanol 
was added. Samples were then vortexed for 1 min and incubated for 10 min at room 
temperature, followed by centrifugation at 12 200 g (4°C) for 10 min to pellet the RNA. 
The RNA precipitate was sequentially washed twice with 75% EtOH diluted in DEPC 
(Sigma-Aldrich, South Africa) treated H2O and centrifuged for 5 min at 12 200g (4°C). 
The pellet was allowed to air dry for no more than 10 min. RNA was resuspended in 
15L DEPC-treated water and incubated for 5 min at 55°C to allow RNA to dissolve. 
RNA samples were stored at -20°C. 
 
RNA was quantified on a NanoDrop (ND-100 Spectrophotometer) and the 260 nm/280 
nm ratio was determined. The integrity of the 28S and 18S ribosomal bands was 
confirmed on denaturing formaldehyde agarose gels (Figure A1.1); (Sambrook et al., 
1989). Briefly, 5L of RNA sample buffer (12% DEPC-H2O, 5% bromophenol blue 
solution; 6.67% glycerol, 10% 10 x MOPS, 2 M formaldehyde, and 49% formamide) 
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was added to 0.5 ug (independent of volume) of each RNA sample and incubated at 
65°C for 10 min to allow for denaturation of secondary structures, followed by cooling 
on ice. Samples were then analysed on a 1% denaturing formaldehyde agarose gel in 1 
x MOPS buffer (40 mM MOPS; 10 mM sodium acetate; 1 mM EDTA, pH 8.00) at 
65V. A representative gel picture is shown in addendum A (Figure A1.1). 
 
RNA (0.5 g) was reverse transcribed using the Transcriptor First Strand cDNA 
synthesis kit (Roche, South Africa), primed with anchored 2.5 M oligo-dT(18) as per 
manufacturer‟s instructions in a total reaction volume of 10 L. Briefly, 0.5 ug RNA 
and 0.5 L, oligo-dT (50 M) was added to DEPC-treated water to a final volume of 
6.5 L. This mixture was incubated at 65°C for 10 min after which samples were 
placed immediately on ice. Next, 2 L Transcriptor Reverse Transcriptase reaction 
buffer, 0.25 L Protector RNase Inhibitor (40 U/L), 1 L dNTP (10 mM) mix (final 
concentration of 1 mM of each dNTP) and 0.25 L Transcriptor Reverse Transcriptase 
(20 U/l) were added to each sample, mixed carefully and incubated at 50°C for one 
hour. The reaction was terminated by placing the samples at 85°C for 5 min. 
Synthesised cDNA samples were kept at –20°C.  
 
2.8 Real time PCR 
Equal volumes of synthesised cDNA were used for semi-quantitative real time PCR 
using the SensiMix dT Kit (Quantace Ltd, UK) and the Corbett real-time PCR machine. 
Interleukin-6 (IL-6), interleukin-8 (IL-8), and RANTES gene expression were 
measured using the mRNA specific primer sets (Table 2.1) at a final concentration of 
0.3 M. GAPDH, which served as an internal control, was used at a final concentration 
of 0.2 M (Table 2.1). In short, 12.5 L SensiMix dT, 0.5L 50 x SYBR® Green I 
solution (Quantace Ltd, UK), 1 L cDNA, sense and anti-sense primers and PCR grade 
water, to a final reaction volume of 25 L, made up the real-time PCR reaction mix. 
PCR conditions for all primer sets were as follows; 95°C for 10 min followed by 40 
cycles of 95°C for 10 sec, 60°C for 10 sec and, 72°C for 10 sec. Melting curve analysis 
was performed to confirm amplification of a single product in each sample (See 
Addendum A, Figure A1.4.). Relative transcript levels were calculated using the 
method described by Pfaffl et al.,, 2001 (Pfaffl, 2001) and were normalised to the 




Table 2.1: Primer sequences of cytokine/chemokines genes investigated 
*Primer efficiency was determined as described in Addendum A 
 
2.9 Chromatin immunoprecipitation assay 
2.9.1 Treatment of End1/E6E7 cells 
To evaluate the association of the GR and the co-factor, GRIP-1, with the IL-6 
promoter, the protocol described by Ma and co-workers (2003) was followed (Ma, et 
al., 2003) with a few modifications. Briefly, End1/E6E7 cells were plated at a density 
of 5 x 10
6
 cells per 15 cm
2
 culture dish and allowed to reach 80% confluency after 
which culture medium was replaced with keratinocyte serum free medium not 
supplemented with BPE, EGF, CaCl2 and PenStrep, followed by incubation for 24 hrs. 
Cells were treated with steroid for 1 hr prior to the addition of 20 ng/L TNF, and 
then incubated at 37°C for a further 2 hrs. 
 
2.9.2 Formaldehyde crosslinking 
Formaldehyde (37%) was added directly to treatment medium to a final concentration 
of 1%, followed by incubation at 37°C for 10 min to allow for cross-linking of 
proteins and the chromatin. Thereafter, glycine (1.25 M) was added to a final 
concentration of 0.125 M and the mixture was incubated for 5 min at room 
temperature, while shaking on an orbital shaker. Cells were washed twice with ice-
cold 1 x PBS. Thereafter 4 ml PBS containing protease inhibitors tablet (1 x Complete 
Mini Protease Inhibitor Cocktail 1 tablet per 10 mL (Roche Applied Science, South 
Africa)) was then added to each dish and cells were harvested using a cell scraper, 
followed by centrifugation for 10 min at 1200 g. The pelleted cells were resuspended 
in 500 L nuclear lysis buffer (1% (w/v) SDS, 50 mM Tris-HCL, pH 8.0, 10 mM 
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EDTA plus 1 tablet 1 x Complete Mini Protease Inhibitor Cocktail per 10 mL). Cell 
lysates were placed on ice and sonicated to allow for fragmentation of DNA to 
fragments of between 150 and 500 bp‟s (see Addendum A, Figure A2.1). Cells were 
sonicated on Power 3, for 10 cycles at 20 sec per cycle, with 40 sec intervals between 
pulses, using the Misonix Sonicator® 3000 sonicator. Sonicated chromatin was 
centrifuged for 10 min at 15 000 g at 4°C to pellet cell debris and the supernatant was 
transferred to a clean microcentrifuge tube followed by spectrophotometry of the 
sonicated lysate to measure the amount of A260 units/l. Measuring the absorption at 
260 nm allows for normalisation of the amount of sonicated chromatin DNA for the 
immunoprecipitation step. Nuclear lysis buffer was used to dilute samples to equal 
chromatin concentration. Sonicated chromatin was either stored at –80°C or prepared 
immediately for immunoprecipitation. 30 g of diluted sonicated chromatin was made 
up to a volume of 30 L with nuclear lysis buffer, followed by dilution with 90 L IP 
dilution buffer (plus 1 x Complete Mini Protease Inhibitor Cocktail 1 tablet per 10 
mL). This mixture served as the input sample.  
 
2.9.3 Preparation of the sonicated cell lysate for immunoprecipitation 
A total of 100 g sonicated chromatin in 100 uL nuclear lysis buffer was diluted with 
900 L IP dilution buffer (0.01% (w/v) SDS, 20 mM Tris-HCL, pH 8.0, 1.1% (v/v) 
Triton X-100, 167 mM NaCl, 1.2 mM EDTA plus 1 x Complete Mini Protease 
Inhibitor Cocktail 1 tablet per 10 mL). Chromatin was pre-cleared with 20 μl 50:50 
(v/v) pre-blocked Protein A/G PLUS beads (sc-2003, Santa Cruz Biotechnology, USA) 
for 1 hr on a rotating wheel at 4ºC to reduce non-specific binding. Pre-blocked Protein 
A/G PLUS beads were prepared by incubating 500 µl of pure beads with 2 ml IP 
dilution buffer, salmon sperm DNA (final concentration 0.2 mg/ml) and BSA (final 
concentration 1 mg/ml) for 1 h on a rotating wheel at 4ºC. After centrifugation the 
beads were re-suspended as 50% slurry in IP dilution buffer. Pre-cleared chromatin was 
centrifuged at 15 000g for 10 min at 4ºC to pellet beads and the supernatant was 
transferred to a clean microcentrifuge tube followed by the addition of 2 g primary-
antibody (anti-GR, anti-GRIP-1 or anti-IgG antibody). This mixture was incubated 
overnight at 4ºC on a rotating wheel. The following day, 40 L pre-cleared protein A/G 
PLUS beads were added and the mixture was incubated for 6 hrs at 4 ºC on a rotating 
wheel to allow the capture of the immuno-sample complexes. The samples were then 
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centrifuged at 5000 g for 1 min at 4ºC and the pellet was washed sequentially with 1 
mL each of wash buffers I, II, and III (wash buffer I: (0.1 % (w/v) SDS, 1 % (v/v) 
Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.0 and 150 mM NaCl), wash buffer 
II: (0.1% (w/v) SDS, 1% (v/v) Triton X-100, 2 mM EDTA, 20 mM Tris-HCL pH 8.0 
and 500 mM NaCl) and wash buffer III: (1% (v/v) NP-40, 1% (w/v) sodium 
deoxycholate, 500 mM LiCl, 1 mM EDTA and 10 mM Tris pH 8.0) to remove DNA 
and proteins non-specifically associated with the protein A/G PLUS beads. This was 
followed by three washes with 1 ml TE (10 mM Tris-HCL pH 8.0 and 0.1 mM EDTA). 
The immunoprecipitated DNA–protein complexes were eluted from the Protein A/G 
PLUS beads twice with 150 L of elution buffer (1% (w/v) SDS and 100 mM 
NaHCO3) for 15 min on a rotating wheel. The mixture was then centrifuged at 5000 g 
for 1 min and the eluted complexes were transferred to a clean microcentrifuge tube. 
The eluates were pooled and DNA was purified as described below.  
 
2.9.4 Isolation and purification of DNA associated with the immunoprecipitated 
protein 
To reverse the cross-linking, the eluted DNA-protein complexes, as well as input 
samples, were incubated at 65°C overnight after the addition of 5M NaCl to a final 
concentration of 300 nM. This was followed by a further incubation at 45°C for 1 hr 
in the presence of 15 nM EDTA, 125 nM Tris-HCL and 60 ng/mL proteinase K 
(Roche Applied Science, South Africa) to digest the protein. Both 
immunoprecipitated- and input DNA were purified using the QIAquick® PCR 
Purification Kit (Qiagen, USA) according to the manufacturer‟s instructions.  
 
2.9.5 Analysis of DNA coupled with the immunoprecipitated protein 
Purified immunoprecipitated and input DNA were analysed by means of real-time PCR 
using primers specific for the IL-6 promoter (hIL-6 sense, 5‟-
GCGCTAGCCTCAATGACGACCTAAG-3‟ and hIL-6 antisense, 5‟-
GAGCCTCAGACATCTCCAGTCCTAT-3‟) (VanDen Berghe et al., 2006). 
Conditions for the real-time PCR reactions were as follows; 95°C for 10 min followed 
by 40 cycles of 95°C for 10 sec, 50°C for 10 sec and, 72°C for 10 sec. The volume of 
template DNA used was 2 L for input- or 4 L immunoprecipitated samples and 0.4 
M sense and antisense IL-6 primers. Both melting curve analysis and agarose gel 
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electrophoresis were performed to confirm specific product amplification in each 
sample. Relative protein recruitment was determined using real-time PCR and 
calculated by the method described by Pfaffl (2001) with slight modifications (Pfaffl 
2001) as the primer efficiency was assumed to be 2 and normalised relative to input, 
which was set as one.  
 
2.10 Subcellular nuclear fractionation assay 
End1/E6E7 cells, plated at a density of 2 x 10
5
 cells/well in a 6-well culture dish 
(Nunc, Denmark), were grown to 80% confluency after which culture medium was 
aspirated and replaced with KSF medium not supplemented with BPE, EGF, and 
CaCl2, followed by incubation for 24 hrs. Cells were pre-treated with steroid or 
vehicle (EtOH) for 1 hour before TNF stimulation (20 ng/L) and further incubated 
for 2 hrs, after which they were washed with ice-cold 1 x PBS. Buffer A (10 mM 
HEPES pH 7.9, 1.5 mM MgCl2 10 mM KCl, 0.5 mM DTT, 0.05% (v/v) NP40, 1 
proteinase minitablet (Roche, South-Africa)) was added to cells (100 L per well) and 
cell lysates were harvested by scraping. Lysates were placed in 1.5 mL 
micocentrifuge tubes and tubes were placed on ice for 10 min. Lysates were 
centrifuged for 5 min at 3000 rpm at 4°C (Eppendorf 5417R). The supernatant was 
transferred to a clean tube and represented the cytoplasmic fraction. The nuclear pellet 
was washed with 1 mL 1 x PBS and centrifuged at 3000 rpm for 5 min. The pellet was 
re-suspended in 80 L DNAse I buffer (40 mM Tris pH 7.9, 10 mM NaCl, 6 mM 
MgCl2, 10 mM CaCl2) and 5 L DNAse I enzyme was added, followed by incubation 
for 10 min at 37°C. To 80 L of both cytoplasmic and nuclear fractions, 20 L 5 x 
SDS-PAGE loading buffer (100 mM Tris-HCL pH 6.8, 5% (w/v) SDS, 20% (v/v) 
glycerol, 2% ß-mercaptoethanol and 0.1% (w/v) bromophenol blue) (Sambrook et al., 
1989) was added. For SDS-PAGE and Western blot analysis, samples were incubated 
at 100C for 10 min followed by SDS-PAGE as described below (see 2.11). For 
Western blotting, hybridisation was performed with antibodies raised against GR, 
GAPDH, and H3. GAPDH and H3 served, as controls for cytoplasmic and nuclear 




2.11 Western blot analysis 
For all Western blot analysis protein samples were separated by SDS polyacrylamide 
gel electrophoresis (PAGE) at 200 V in running buffer (25 mM Tris-HCl pH 6.8, 250 
mM glycine and, 0.1% SDS (Sambrook et al., 1989)) using a BioRad Mini Protean 
II electrophoresis cell. Proteins were electroblotted onto Hybond ECL 
nitrocellulose membrane (AEC Amersham Biosciences, South Africa) for 90 min at 
180 mA with BioRad Mini Trans-blot cell in ice-cold transfer buffer (25 mM Tris, 
200 mM glycine, 10% (v/v) methanol). Membranes were blocked in 10% (w/v) fat-
free milk powder in Tris buffered saline (50 mM Tris, 150 mM NaCl) (TBS) 
containing 0.1% (v/v) Tween (TBS-T), unless otherwise stated, for one hr at room 
temperature, followed by incubation with primary antibody overnight at 4C. After 
incubation with primary antibody the membranes were washed for 15 min and 2 x 5 
min in TBS-T at room temperature and incubated with the appropriate secondary HRP 
conjugated antibody at room temperature for one hr. The membranes were 
subsequently washed as before. For antibodies dilutions see Table 2.2 below.  
 
Table 2.1: Antibody concentrations used in Western blot analysis 
Antibody Dilution Dilutant 
GR-H300 1:4000 5% non-fat milk powder in 0.1% TBST* 
AR (441) 1:4000 5% non-fat milk powder in 0.1% TBST 
MCR (C-19) 1:1500 0.1% TBST 
PR (B-30) 1:500 0.1% TBST 
ER (MC-20) 1:1000 5% non-fat milk powder in 0.1% TBST 
-actin 1:1000 5% non-fat milk powder in 0.1% TBST 
phospho-GR Ser-221 1:10 000 5% non-fat milk powder in 0.1% TBST 
phospho-GR Ser- 226 1:10 000 5% non-fat milk powder in 0.1% TBST 
GAPDH 1:1000 5% non-fat milk powder in 0.1% TBST 
H3 1:1000 5% non-fat milk powder in 0.1% TBST 
*TBST: Tris buffered saline (50 mM Tris, 150 mM NaCl) (TBS) containing 0.1% (v/v) Tween 
 
Autoradiography and ECL visualisation were performed with AEC Amersham 
Hyperfilm MP high performance autoradiography film (AEC Amersham, South 
Africa). Autoradiograms were scanned and densometric analysis was performed using 




2.12 Data and statistical analysis 
GraphPad Prism® version 5.00 for Windows (GraphPad Software, USA) was used 
for graphical representations and statistical analysis. One-way ANOVA was 
performed with Dunnett‟s multiple comparison's test as post-test (when comparing 
treatment conditions to control (EtOH) only) or Tukey‟s post-test (when comparing 
all values to each other). For grouped analysis, i.e. how the response is affected by 
two factors, two-way ANOVA was used for statistical analysis with Bonferroni as 
post-test. P values for comparison of two samples were obtained by using the paired t-
test. P-values are represented as follows: p < 0.05 by *, p < 0.01 by **, and p < 0.001 
by ***. Where all values were compared to each other, different lower-case letters 
indicate statistically significant difference; therefore conditions with the same letter 
are not statistically significantly different from each other (p > 0.05), while those 
having different letters are statistically significantly different from each other (p < 
0.05). For all experiments, unless otherwise indicated, the error bars represent the 





RESULTS & DISCUSSION 
 
Differential cytokine gene regulation by the synthetic 
progestins, medroxyprogesterone acetate (MPA) and 
norethisterone acetate (NET-A) in a human endocervical 
epithelial cell line  
 
Abstract 
Norethisterone (NET) and its derivatives, and medroxyprogesterone acetate (MPA) 
are widely used as injectable contraceptives and in hormone replacement therapy, 
although little is known about their molecular mechanisms of action. While MPA has 
been shown to increase HIV (Mostad et al., 1997) and HSV cervical shedding in HIV-
infected women (Mostad et al., 2000), the effects of MPA and NET-A on gene 
expression in the female genital tract are not well understood. In this study, regulation 
of TNF-stimulated cytokine/chemokine genes for interleukin (IL)-6, IL-8, and 
regulated upon activation, normal T cell expressed and secreted (RANTES) by MPA 
and NET-A, as compared to the endogenous hormone P4, was investigated by real 
time PCR in an in vitro cell culture model for the female endocervical mucosa, 
namely the immortalised human endocervical epithelial cell line End1/E6E7. 
Interestingly, the synthetic progestins were shown to have pro-inflammatory effects, 
increasing expression of the cytokine/chemokine genes investigated. Both MPA and 
NET-A significantly upregulated IL-8 and RANTES gene expression, unlike P4, 
which did not elicit a significant response. IL-6 mRNA levels were differentially 
upregulated by P4, MPA, and NET-A, showing progestin-specific effects on the same 
gene. For the first time it was shown that proteins for the glucocorticoid receptor 
(GR), estrogen receptor (ER, androgen receptor (AR), and mineralocorticoid 
receptor (MR) are expressed in the End1/E6E7 cell line, although only the GR and 
ER are transcriptionally active. Using both GR siRNA and a GR antagonist, it was 
shown that P4, MPA, and NET-A induce IL-6 gene expression predominantly via the 
GR, in contrast to DEX, a potent GR agonist, which repressed IL-6 gene expression 
via the GR. The involvement of the PR-A and the ER could not be excluded. 
Different MAPK signalling pathways appear to be responsible for the differential IL-6 
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gene regulation by the compounds. Using MAPK inhibitors, both ERK1/2 and p38 
signalling pathways were shown to be involved in NET-A-mediated IL-6 gene 
regulation whereas only p38 is required for P4-induced IL-6 mRNA expression. In 
contrast ERK1/2 and JNK appear to inhibit MPA-induced IL-6 gene expression, 
although significance could not be established. These different kinase pathways may 
play a role in the differential effects of the progestins in promoter-specific gene 
expression. Differential gene regulation by the synthetic progestins compared to P4 




Epithelial cells lining the female reproductive tract (FRT) not only serve as a physical 
barrier against microbial infection but they also express a wide variety of immune 
mediators such as cytokines and chemokines, aiding in both innate and adaptive 
immunity (Wira et al., 2005a; Wira et al., 2005b). Interleukin (IL)-6 and the 
chemotactic cytokines or chemokines, IL-8 and Regulated-upon-activation-normal-T-
cell-expressed-and-secreted (RANTES), are expressed in vaginal and cervical epithelial 
cells, both primary and immortalised (Fichorova & Anderson 1999; Woodworth & 
Simpson, 1993; Barclay et al., 1993). IL-6 gene expression can be induced by viral 
infection (Malejczyk et al., 1991; Partridge et al., 1991) and exposure to the pro-
inflammatory cytokines IL-1 and tumour necrosis factor-alpha (TNF) (Yoshizaki et 
al., 1990; Zhang et al., 1990). IL-6 activates T-cells, causing them to differentiate, 
regulates biosynthesis of acute phase proteins in hepatocytes and plays a role in cervical 
dilation and tumour angiogenesis (Hirano et al., 1990; Jones et al., 2005). IL-8 recruits 
neutrophils, eosinophils and macrophages (Huber et al., 1991; Kelly et al., 1994; 
Hoffmann et al., 2002) and RANTES attracts T lymphocytes, eosinophils and 
monocytes (Schall et al., 1990) to the site of infection.  
 
Numerous pathogens such as herpes simplex virus (HSV), human papillomavirus 
(HPV), and human immunodeficiency virus (HIV) have been shown to infect epithelial 
cells of the lower FRT, and the process is affected by treatment with hormones such as 
progesterone (P4) (Brabin, 2002). The effects of steroidal hormones are variable and 
include increased susceptibility to infection, disease progression, as well as increased 
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risk of re-infection. These effects are also subject to variability with varying hormone 
levels (Sonnex, 1998; Forrest, 1991).  
 
Progestin treatment of animals (mice and non-human primates) and humans has been 
reported to increase susceptibility to viral and bacterial infection (Kaushic et al., 
2003; Gillgrass et al., 2003; MacLean 2005; Marx et al., 1996; Trunova et al., 2006; 
Morrison et al., 2004). Rhesus macaques treated with injectable medroxyprogesterone 
acetate (MPA) five weeks prior to exposure to simian HIV were more susceptible to 
infection than MPA-naïve macaques irrespective of inoculum dose (Trunova et al., 
2006). The immunosuppressive effect of MPA was also reported to be associated with 
an increase in viral diversity in rhesus macaques due to acceleration in viral 
replication (Trunova et al., 2006). This study also identified the effects of MPA on 
immunity to be immune based (i.e. involving immune regulators), rather than 
transmission based. Additionally, MPA treatment in mice increases susceptibility to 
HSV infection by decreasing immune responses (Kaushic et al., 2003; Gillgrass et al., 
2003). A prospective cohort study, which included 819 women, reported that 
injectable contraceptive users were more susceptible to both chlamydia and 
gonococcal infections than oral contraceptive users (Morrison et al., 2004). 
Additionally, increases in both HIV and HSV shedding have been reported in women 
using injectable contraceptives (Mostad et al., 1997; Mostad et al., 2000; Wang et al., 
2004) as well as the presence of more viral variants and higher viral loads in MPA 
users infected with HIV than non-users (Lavreys et al., 2004). In contrast there are 
studies that have reported no correlation between hormonal contraception and an 
increase HIV infection or viral shedding (Myer et al., 2007; Kleinschmidt et al., 2007; 
Morrison et al., 2007; McClelland et al., 2002). A South African prospective study 
with 4200 women participants, showed no correlation between HIV acquisition and 
usage of injectable contraceptives norethisterone-enathate (NET-EN) or MPA (Myer 
et al., 2007). In similar studies no evidence of an association between HIV infection 
and injectable contraceptives (MPA & NET-EN) was shown (Kleinschmidt et al., 
2007; Morrison et al., 2007). Another prospective cross-sectional study reported that 
hormonal contraceptive usage did not detectably increase cervical HSV shedding 
(McClelland et al., 2002). Nevertheless, the majority of evidence would suggest some 
adverse effects associated with synthetic progestins including cervical ectopy (Mauck 
et al., 1999; Morrison et al., 2004; Critchlow et al., 1995), which in turn has been 
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shown to be linked to higher HIV-1 shedding in women (Morrison et al., 2004; Moss 
et al., 1991; Kreiss et al., 1994; Royce et al., 1997). MPA has also been reported to 
induce hyperplasia of vaginal epithelium in women (Ildgruben et al., 2003) and it is 
regularly used as an immuno-compromising agent to induce viral infectability in mice 
(Parr et al., 1994). In vitro studies have reported that MPA has anti-inflammatory 
properties as it decreased IL-6 and IL-8 protein and gene expression in mouse 
fibroblast cells (Koubovec et al., 2004) and IL-2, IL-1, and IL-6 protein expression in 
normal human lymphocytes, via the glucocorticoid receptor (GR) (Bamberger et al., 
1999). These studies suggest that progestins have an effect on the immune response 
and play an important role in female reproductive health.  
 
The above studies have prompted a more detailed investigation into the role of 
synthetic progestins in cytokine gene regulation in the endocervix, a key physiological 
component of the lower FRT, which is vulnerable to infections. MPA and NET-EN are 
extensively used as progestin-only injectable contraceptives especially in sub-Saharan 
Africa, where infections such as HIV are rife. In addition MPA and norethisterone 
acetate (NET-A) are used in hormone replacement therapy (HRT) and in the treatment 
of endometriosis and cancer (Sitruk-ware 2003; Cavalli et al., 1984; Schindler et al., 
2003). Both NET-EN and NET-A are metabolised to the active molecule NET, as well 
as other metabolites, unlike MPA, which is itself the active compound (Stanczyk & 
Roy, 1990). The synthetic progestins MPA and NET are steroidal synthetic hormones 
designed to mimic the biological effects of the endogenous hormone P4 (Bray et al., 
2005). The progestational effects of P4 are mainly attributed to acting via its cognate 
receptor, the progesterone receptor (PR) (Sitruk-ware, 2004). Indeed both MPA and 
NET bind with similar affinities as P4 to the PR (Bray et al., 2005). However, studies 
have shown that both MPA and NET can bind to other steroid receptors such as the GR, 
androgen receptor (AR), mineralocorticoid receptor (MR) and estrogen receptor (ER) 
(Philibert et al., 1999; Bentel et al., 1999; Hapgood et al., 2004; Koubovec et al., 2005; 
Africander PhD thesis, 2010).  
 
While MPA, NET, and P4 bind with a high affinity to the AR, only MPA and NET, but 
not P4, are strong agonists of the AR (Africander PhD thesis 2010; Bentel et al., 1999; 
Hoppen & Hammann, 1987). Furthermore, P4 binds with high affinity to the MR, 
unlike MPA and NET (Winneker et al., 2003; Palacios et al., 2006; Africander PhD 
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thesis 2010). MPA has a relatively strong binding affinity for the GR as compared to 
NET (Kontula et al., 1983; Koubovec et al., 2005). In addition, while MPA is an 
agonist of the GR, NET is an antagonist (Africander PhD thesis 2010). Moreover, NET-
EN metabolites were shown to bind to the ER, albeit very weakly (Markiewicz & 
Gurpide 1994; Mendoza-Rodríguez et al., 1999). Although MPA and NET elicit similar 
progestational effects to P4 (Sitruk-ware 2004; Bray et al., 2005), differences in 
biological effects mediated via steroid receptors others than the PR could be expected 
(Hapgood et al., 2004). Women using progestins either in HRT or as contraception may 
become more susceptible to viral and bacterial reproductive tract infections as these 
hormonal contraceptives could modulate the immune function of the cervical mucosae 
(Morrison et al., 2004b). Unfortunately, very few studies have directly compared the 
molecular mechanism of action of MPA and NET and no study has ever investigated 
the effect of these progestins on cytokine gene regulation in endocervical epithelial 
cells. The effect of these compounds on immune responses in the endocervix, a site 
vulnerable to infection, has not been determined. Using a human immortalised 
endocervical (End1/E6E7) epithelial cell line (Fichorova et al., 1997) as a model for the 
mucosal surface of the endocervix, the molecular mechanisms involved in the 
regulation of endogenous IL-6, IL-8, and RANTES gene expression in response to 
MPA, NET-A, and P4, were investigated.  
 
Results 
MPA and NET-A regulate the expression of pro-inflammatory cytokine genes 
Before experimental treatments with the synthetic progestins and P4 commenced, 
optimisation of cDNA and quantitative real-time PCR (qPCR), including primer 
efficiency determination, was performed as discussed in Addendum A. The human 
End1/E6E7 cell line was treated with 20 ng/L TNF and 1 M P4, MPA, or NET-A 
for 24 hrs. Treatment in the presence of TNF mimics infection, which upregulates 
the expression of pro-inflammatory cytokine genes. Total RNA was isolated and 
expression of IL-6, IL-8, and RANTES was measured by quantitative real-time PCR 
(qPCR) using specific primers for the relevant genes. The target gene expression was 
normalised to the housekeeping GAPDH gene and results are depicted in Figure 3.1. 
Both MPA and NET-A induced IL-8 gene expression (greater than 2-fold), which was 
significantly different to that of P4 (p < 0.05), which had no effect on IL-8 gene 
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expression (Figure 3.1A). Similarly, MPA and NET-A, but not P4, significantly (p < 
0.05) increased RANTES mRNA expression by about 2-fold (Figure 3.1B). 
Interestingly, IL-6 gene expression was differentially regulated by MPA and NET-A 
(p < 0.05). NET-A induced an approximately 2.5-fold increase in IL-6 expression, 
while MPA showed a 1.5-fold increase, (p=0.08) when compared to vehicle control 
(Figure 3.1C). The finding that the synthetic progestins differentially regulate IL-6 
mRNA expression in the presence of TNF suggests that these two progestins act via 
different mechanisms. The effects of these progestins on IL-6 gene expression were 




(legend to follow on next page) 
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Figure 3.1: Effects of P4, MPA and NET-A on the TNFα-induced expression of (A) IL-8, 
(B) RANTES, and (C) IL-6 in a human endocervical cell line. End1/E6E7 cells were 
treated for 24 hrs with 20 ng/L TNF in the presence of 0.1% ethanol (EtOH, vehicle), 1 
M P4, 1 µM MPA or 1 µM NET-A. Total RNA was isolated and 500 ng RNA was reverse-
transcribed. Relative IL-6, IL-8 and RANTES gene expression was measured by qPCR and 
normalised to GAPDH mRNA expression, which served as internal control. Relative 
cytokine/chemokine gene expression of treated samples was calculated relative to vehicle 
control, which was set as 1. Graphs represent pooled results of at least three independent 
experiments. For statistical analysis one-way ANOVA was used and Tukey‟s multiple 
comparison post-test. Different letters indicate statistically significant differences (p < 0.05); 
while the same letter indicates no statistically significant difference (p > 0.05). Using 
Dunnett‟s multiple comparisons post-test MPA is significantly different from vehicle control 
(p < 0.05) in C. 
 
 
TNF is a potent activator of IL-6 as it increased IL-6 mRNA expression 
approximately 22-fold (Figure 3.2A). Interestingly, it was found that P4, MPA, and 
NET-A also upregulated IL-6 expression in the absence of TNF in the endocervical 
cell line (Figure 3.2B). NET-A and MPA induced IL-6 mRNA expression in the 
absence of TNFapproximately 4.5- and 2.5-fold respectively, while P4 increased 
IL-6 gene expression approximately 3.5-fold (Figure 3.2B). Induction of IL-6 by these 
progestins shows a similar trend in the absence (Figure 3.2B) and presence (Figure 
3.1C) of TNFα i.e. NET-A ≥ P4 > MPA. Statistical differences could not be 
established due to variability between individual experiments for P4, and MPA, 
however, NET-A does significantly upregulate IL-6 mRNA expression in the absence 
of TNFp = 0.043, compared to vehicle. The results suggest a similar mechanism of 




Figure 3.2: (A) TNF induces IL-6 expression in the End1/E6E7 cell line and (B) P4, 
MPA and NET-A increase IL-6 expression in the absence of TNFstimulation in a 
human endocervical cell line. End1/E6E7 cells were treated with (A) vehicle or 20 ng/L 
TNF or (B) with vehicle (0.1% EtOH) or 1 µM P4, MPA or NET-A for 24 hrs. Total RNA 
was isolated, cDNA synthesized and expression levels of IL-6 mRNA relative to GAPDH 
mRNA were determined by qPCR. Relative target gene expression of treated samples was 
calculated relative to vehicle control, which was set as 1. Results shown (ratio of the specific 
target gene/GAPDH gene) are the averages (±SEM) of at least three independent experiments. 
For statistical analysis paired t-test (***; p < 0.001) in A was used and one-way ANOVA was 




The AR, MR, ERα, and GR are expressed in the End1/E6E7 cell line 
As both MPA and NET-A have been shown to bind to and elicit a biological response 
via the GR, AR and MR (Koubovec et al., 2005; Africander PhD thesis 2010; 
Philibert et al., 1999) it was hypothesized that the differential regulation of the IL-6 
gene by P4, MPA and NET-A may be due to their actions via different steroid 
receptors. To this end, the steroid receptor content of the End1/E6E7 cells was 
investigated. Whole cell lysates of untreated End1/E6E7 cell lines were prepared and 
subjected to Western blot analysis and protein expression of the PR-B, GR, AR, MR, 
and ER (Figure 3.3A-E) was determined. Positive controls consisted either of COS-
1 cells transiently transfected with the receptor of interest (GR, PR-B, MR and AR), 
or whole cell lysate of the HeLa cervical carcinoma cell line for the ER. ER was 
shown to be expressed in End1/E6E7, corresponding in size to the positive control, as 
detected by Western blot analysis (Figure 3.3A). Similarly, the GR and MR are 
expressed in the End1/E6E7 cells as shown in figures 3.3B and 3.3D, corresponding 
in size to the positive control (Figures 3.3B and 3.3D). Although a strong band was 
detected in COS-1 cell lysates transiently transfected with hPR-B, no detectable PR-B 
protein was observed in End1/E6E7 cells (Figure 3.3C). Since immunohistochemical 
investigations have previously reported the expression of both PR isoforms (PR-A 
and PR-B) in primary cervical tissue (Nair et al., 2005; Remoue et al., 2003), it was 
surprising that Western blotting did not detect PR-B in the End1/E6E7 cells. 
However, several studies have reported the expression of the PR to be dependent on 
the menstrual cycle (Stjernholm-Vladic et al., 2004; Konishi et al., 1991). The present 
result cannot be ascribed to an inefficient antibody, as the positive control was clearly 
detected. As there are two functional isoforms of the PR, PR-A and PR-B (Kastner et 
al., 1990; Kraus & Katzenellenbogen 1993), it may be that the PR-A isoform, which 
is less transcriptionally active than PR-B (Vegeto et al., 1993), is expressed in this cell 
line. Optimization of the commercial antibody detecting the PR-A isoform was 
unsuccessful and thus the expression of the PR-A isoform in the End1/E6E7 cell line 
could not be confirmed. Finally, Western blot analysis also detected the MR 
expressed in End1/E6E7 cells corresponding in size to the overexpressed MR in COS-
1 cells (Figure 3.3D).  
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Figure 3.3: GR, AR, MR, and ER, but not PR-B are expressed in End1/E6E7 cells. 
Whole cell lysates were prepared from the human End1/E6E7 cell line. Untransfected COS-1 
cells served as negative control (-ve). COS-1 cells transiently transfected with steroid receptor 
expression vectors (pSG5hPR-B, pCMV-HA-hGR, pSVhARo, and pRShMR) served as 
positive controls (+ve). For ERthe HeLa carcinoma cervical cell line endogenously 
expressing ER, served as positive control (+ve). Equal volumes of lysate were analysed by 
Western blotting with antibodies against (A) hPR-B, (B) hGR, (C) hAR, (D) hMR, (E) hERα, 
and actin was used as a loading control. It should be noted that proteins on the SDS-gel of 
(B) migrated slightly skew in the last lane resulting in the -actin band to be slightly above 
the position of the previous lane. It should be noted that proteins on the SDS-gel in (B) 
migrated slightly skew in the last lane resulting in the -actin band migrating slightly above 
the position in the previous lane.  
 
 
Only the GR and ERα are transcriptionally active in the End1/E6E7 cell line 
To determine whether the endogenously expressed receptors are transcriptionally 
active, promoter-reporter assays were performed to measure transactivation activity in 
the presence of receptor-specific agonists. The results show that only the GR and ERα 
are transcriptionally active in the End1/E6E7 cell line (Figure 3.4A and 3.4B). For the 
GR, an ~8-fold induction was observed in the presence of the GR-specific agonist, 
dexamethasone (DEX), while for ERα, an ~4.5-fold increase was observed in the 
presence of the ER-specific ligand, 17--estradiol (E2). Consistent with the absence 
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of PR expression observed by Western blotting (Figure 3.3A), no transcriptional 
response was observed in the presence of the potent PR-specific ligand, R5020, in the 
End1/E6E7 cells (Figure 3.4A). Although Western blotting showed expression of the 
MR in the End1/E6E7 cell line (Figure 3.3D), the endogenously expressed MR was 
transcriptionally inactive, as aldosterone (Ald) the MR agonist, was unable to induce 
transactivation. Similarly, although Western blot analysis also showed the expression 
of the AR in the endocervical cells (Figure 3.3C), the AR-specific ligand, mibolerone 
(MIB), did not increase transcription from either of two AR-responsive promoters 
(Figure 3.4E). This lack of AR transcriptional activity could not be attributed to an 
inactive ligand as 1 M MIB induced transactivation of a GRE-containing reporter 
plasmid, as well as the 4xSC-ARE1.2 promoter reporter in the presence of transiently 
overexpressed hAR. The 4xSC-ARE1.2 promoter reporter contains two AR-specific 
AREs. These resemble a direct rather than a palindromic repeat of the 5‟-TGTTCT-3‟ 
hexamer. These AREs were previously shown to be AR-specific, as the AR but not 
GR is able to transactivate via these DNA motifs (Schauwaers et al., 2007).  
 
In summary, transactivation assays revealed that only the endogenous ER (Figure 
3.4A) and GR (Figure 3.4B) are transcriptionally competent. Although Western blot 
analysis did determine that endogenous MR and AR are expressed in the End1/E6E7 
cells, both receptors were transcriptionally inactive on promoter reporter assays. In fact 
the AR was unable to induce transcription of both GRE- and the AR specific ARE-




Figure 3.4: Transactivation of transiently transfected promoter-reporter constructs via 
endogenous or overexpressed steroid receptors. End1/E6E7 cells were transiently 
transfected with (A) 300 ng pSG5-ERE.vit2.luc promoter reporter construct, 30 ng pGL2-
basic empty vector controland 10 ng -galactosidase expression plasmid or (B) 300 ng 
pTAT-GRE-E1b-luc reporter construct, 30 ng pGL2-basic empty vector controland 10 ng -
galactosidase expression plasmid or (C) 300 ng pTAT-GRE-E1b-luc reporter construct, 30 ng 
pSG5hPR-B or pGL2-basic empty vector controland 10 ng -galactosidase expression 
plasmid (D) 300 ng pTAT-GRE-E1b-luc reporter construct, 30 ng pRShMR or pGL2-basic 
empty vector controland 10 ng -galactosidase expression plasmid or (E) 300 ng pTAT-
GRE-E1b-luc - or 4xSC-ARE1.2-luc reporter construct, 30 ng pSVARo or pGL2-basic empty 
vector controland 10 ng -galactosidase expression plasmid. Twenty-four hrs after 
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transfection, cells were treated with vehicle control (0.1 % EtOH) or (A) 1 M of the ER 
agonist, 17-estradiol (E2), (B) 1 M of the GR agonist, dexamethasone (DEX), (C) 1 M of 
the synthetic PR agonist, R5020, (D) 1 M of the MR agonist, aldosterone (Ald), or (E) 1 M 
of the AR agonist, mibolerone (MIB), for 24 hrs. Cells were lysed and both luciferase and -
galactosidase activities were measured. Luciferase activity in relative light units (RLU‟s) was 
normalised to -galactosidase activity in RLU‟s with EtOH in the absence of transfected 
receptor set as one. Results shown are pooled results of two independent experiments 
performed in triplicate.  
 
 
The role of the GR in the regulation of IL-6 by MPA and NET-A in the 
endocervical cell line 
As MPA and NET-A exhibited striking differences in IL-6 regulation, in-depth 
investigations into the molecular mechanism of differential IL-6 mRNA expression in 
End1/E6E7 cells by P4, MPA, and NET-A were performed. 
  
Having established that the GR protein is expressed and functional in the End1/E6E7 
cells (Figure 3.3B & 3.4B), it was next investigated whether the GR plays a role in IL-
6 gene expression in response to MPA and NET-A. MPA is known for its anti-
inflammatory effects, which are mainly attributed to its glucocorticoid activity 
(Koubovec et al., 2004; Bamberger et al., 1999), while NET-A has been reported to 
be an antagonist of the GR (Africander PhD thesis, 2010). Western blotting was used 
to determine whether P4, MPA, and NET, in the presence of TNF have an effect on 
GR protein levels. End1/E6E7 cells treated with the progestins in the presence of 
TNF for 24 hrs were analysed by means of Western blotting using a GR specific 
antibody and -actin as loading control. None of the progestins had any significant 
effect on GR expression following 24 hr treatment (Figure 3.5A & Figure 3.5B).  
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Figure 3.5: P4, MPA and NET-A do not affect GR protein levels after 24 hrs. End1/E6E7 
cells were treated with 1 M of each progestin, P4, MPA, or NET-A, in the presence of 20 
ng/L TNF for 24 hrs. (A) Cells were harvested and whole cell lysates were separated by 
8% SDS-PAGE and transferred to nitrocellulose membrane. A GR specific antibody was used 
for Western blotting analysis and a -actin specific antibody as loading control. (B) GR 
protein levels on Western blot were quantified and normalised to -actin levels. Graphs are 
representative of pooled results of two independent experiments with vehicle control (EtOH) 
set as one.  
 
 
To investigate the possible involvement of the GR in the IL-6 response to progestin 
treatment, the endocervical cells were treated with 1 M MPA or NET-A in the 
presence of TNF for 24 hrs in the absence or presence of 1 M of the GR antagonist, 
RU486. Total RNA was isolated, cDNA synthesised and IL-6 gene expression 
determined by qPCR. Interestingly, RU486 alone showed a significant upregulation of 
IL-6 gene expression (p < 0.001) (Figure 3.6) of approximately 3-fold. This result was 
unexpected, as it had previously been shown that 1 M RU486 in murine fibrosarcoma 
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L929 cells has no effect on IL-6 protein levels (Vanden Berghe et al., 1999). A slight 
decrease in of DEX-mediated repression by RU486 was observed, although this was 
not significant. RU486 had no effect on the response to either NET-A or P4, although a 
slight increase in the response was observed for MPA (Figure 3.6). When normalising 
for the induction seen with RU486 alone however, RU486 significantly antagonises P4, 
MPA, and NET-A- mediated IL-6 induction, suggesting the involvement of the GR 
(Addendum B, Figure B1).  
 
 
Figure 3.6: The role of the GR in IL-6 gene expression in response to P4 and the 
synthetic progestins MPA and NET-A in the endocervical cell line End1/E6E7. 
End1/E6E7 cells were treated with 20 ng/L TNFand 1 M P4, MPA, NET-A, or DEX in 
the absence or presence of 1 M RU486. Total RNA was isolated after 24 hrs and 500 ng 
mRNA was reverse-transcribed. Relative IL-6 mRNA expression was measured by 
quantitative real-time PCR and normalised to relative GAPDH gene expression, which served 
as internal control. Relative IL-6 gene expression of treated samples was calculated relative to 
vehicle control, which was set at 1. Graphs represent pooled results of at least three 
independent experiments. For statistical analysis two-way ANOVA was used with Bonferroni 
as post-test (***; p < 0.001).  
 
To confirm the results obtained with the GR antagonist, the GR protein expression was 
reduced, by transfecting End1/E6E7 cells with GR specific siRNA oligonucleotides (oligos). As 
a control, cells were transfected in parallel with validated non-silencing RNA oligos (NSC). 
Transfected cells were analysed by Western blotting to confirm GR knockdown (Figure 3.7). 




Figure 3.7: Reduction of GR protein by GR siRNA (A) For verification of GR knockdown, 
End1/E6E7 cells were transfected with 10 nM non-silencing control (NSC) or GR siRNA 
oligos. Forty-eight hrs after transfection, cells were harvested and whole cell lysates were 
separated by 8% SDS-PAGE and transferred to nitrocellulose membrane. A GR-specific 
antibody was used for Western blotting analysis and -actin-specific antibody as loading 
control was used. A representative blot is shown. (B) Western blots of at least four 
independent experiments were quantified to determine the percentage GR protein knockdown. 
For statistical analysis student t-test was used. p value represents p < 0.001; ***.  
 
 
As expected, DEX-induced repression of IL-6 expression was significantly reduced by the 
decrease in GR expression (Figure 3.8). NET-A-induced IL-6 mRNA expression was 
potentiated by the decrease in GR expression, suggesting a role for the GR in NET-A mediated 
induction of IL-6 mRNA transcripts (Figure 3.8A). For both P4 and MPA a slight increase in 
IL-6 gene expression was observed (p = 0.226 and p = 0.062, respectively). Interestingly, the 
response to RU486 was unaffected by the decrease in GR protein expression (Figure 3.8A). To 
normalise for the induction seen with GR siRNA alone, the results were also normalised to the 
vehicle control of each transfection condition (NSC vs GR siRNA) as shown in Figure 3.8B. As 
expected, DEX-mediated repression of IL-6 was abrogated by GR knockdown (p = 0.08) 
(Figure 3.8B). Furthermore, reduction in GR protein levels significantly (p < 0.05) reduced P4, 
NET-A and RU486 induced IL-6 mRNA expression (Figure 3.8B). In addition, a decrease in 






Figure 3.8: Effect of reduction of GR levels by siRNA on IL-6 gene expression in 
response to P4 and the synthetic progestins MPA and NET-A in the endocervical cell line 
End1/E6E7. End1/E6E7 cells were transfected with 10 nM NSC or GR siRNA and then 
treated with 1 M P4, MPA, NET-A, RU486, or DEX for 24 hrs in the presence of 20 ng/L 
TNF. Total RNA was isolated after 24 hrs and 500 ng RNA was reverse-transcribed. 
Relative IL-6 mRNA expression was measured by quantitative real-time PCR and normalised 
to relative GAPDH gene expression, which served as an internal control. Relative IL-6 gene 
expression of treated samples was calculated relative to vehicle control. Graphs presented are 
differently normalised. Results in (A) were normalised to EtOH of NSC transfection, which 
was set as 1 and in (B) each different transfection condition was normalised to its own EtOH, 
which was set as 1 (i.e. all the black bars were normalized to NSC EtOH and all the checked 
bars normalized to GR siRNA EtOH). Graphs represent pooled results of at least three 
independent experiments. For statistical analysis two-way ANOVA was used with Bonferroni 




Taken together, the results suggest that the GR is required for the upregulation of IL-6 
gene expression by RU486, P4, and the synthetic progestins MPA and NET-A and for 
the repression by DEX (Figure 3.8B).  
 
Different MAPK pathways are involved in P4-, MPA-, and NET-A-induced IL-6 
gene expression  
Both P4 and MPA are reported to activate ERK1/2 in hippocampal neurons, although 
only P4 induced ERK1/2 nuclear translocation in these cells (Nilsen & Brinton 2003). 
To the best of the author‟s knowledge no studies have investigated whether NET-A 
can activate the mitogen activated pathway kinases (MAPKs). Thus the involvement 
of members of the MAPK family of kinases i.e. extracellular signal-regulated kinase 
(ERK1/2), c-Jun N-terminal kinase (JNK1/2), and p38 kinase pathway was next 
investigated, to determine whether they play a role in TNF-induced IL-6 gene 
expression in response to P4, MPA, and NET-A (Figure 3.9).  
 
MAPK inhibitors were used to determine the involvement of MAPKs in IL-6 gene 
expression in response to the progestins. Inhibitors of both the ERK1/2 and p38 
pathways were found to abolish NET-A induced IL-6 mRNA expression (p < 0.05) 
(Figures 3.9A & 3.9B), while only the p38 MAPK inhibitor significantly repressed P4-
induced IL-6 mRNA expression (Figure 3.9B). Neither the ERK nor the JNK pathway 
inhibitor showed any effect on P4-induced IL-6 expression (Figures 3.9A & 3.9C). 
Minor, non-significant differences were seen in the presence of all the MAPK inhibitors 
in co-treatment with MPA (Figure 3.9A-C). A slight reduction in IL-6 mRNA 
expression was observed in response to MPA in the presence of the ERK pathway- and 
JNK inhibitors (Figures 3.9A & 3.9C), opposite to the effect seen with NET-A. As 
observed for NET-A, the p38 inhibitor decreased the small induction of IL-6 mRNA 
expression in response to MPA treatment (Figure 3.9B). In summary, ERK1/2, p38, and 
JNK1/2 pathways appear to differentially regulate P4-, MPA- and NET-A-induced IL-6 




Figure 3.9: Effects of MAPK inhibitors on IL-6 gene expression in response to the 
synthetic progestins, MPA and NET-A. End1/E6E7 cells were treated with 20 ng/L 
TNFand 1 M P4, MPA, or NET-A in the absence (no inhibitor) or presence of 10 M 
MAPK inhibitors, (A) ERK1/2 inhibitor (PD 98059), (B) p38 inhibitor (SB 203580), or (C) 
JNK inhibitor (SP 600125). Total RNA was isolated after 24 hrs of treatment and 500 ng 
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RNA was reverse-transcribed. Relative IL-6 mRNA expression was measured by quantitative 
real-time PCR and normalised to relative GAPDH gene expression, which served as internal 
control. IL-6 gene expression of treated samples was calculated relative to vehicle control 
without inhibitor, which was set as 1. The graphs represent pooled results of at least three (A) 
& (B) or two (C) independent experiments. For statistical analysis Two-way ANOVA was 
used with Bonferroni‟s post-test. P-values are represented as follows: p < 0.01 by ** and p < 
0.001 by ***. 
  
Discussion 
Differential cytokine gene regulation by P4, MPA, and NET-A  
Epithelial cells at mucosal surfaces such as at the female reproductive tract are 
important role players in the early immune response induced by pathogens or stress 
(Wira et al., 2005b). The simple columnar epithelial cells of the endocervix express a 
wide variety of both pro- and anti-inflammatory cytokines and chemokines 
(Fichorova & Anderson, 1999; Fahey et al., 2005) including IL-6, IL-8, and 
RANTES. These cytokines are constitutively expressed at low levels and upregulated 
in response to TNF (Fichorova & Anderson, 1999). The endocervix is a site of 
infection by HIV and other sexually transmitted diseases. Susceptibility may be 
influenced by factors affecting local immunity such as hormonal contraception. Little 
is known about the effects of MPA and NET-A, as compared to P4, in the 
endocervical mucosa, and whether or not they interfere with the local epithelial 
immune function. 
 
This novel study investigated the effect of P4 and the commonly used progestins, 
MPA and NET-A on pro-inflammatory cytokine/chemokine expression in the 
endocervical environment. In the present study, End1/E6E7 cells were used as a 
model cell system for the endocervical epithelium. These cells are immortalised by 
expression of E6 and E7 genes of the human papillomavirus type 16 and closely 
resemble primary cultures both morphologically and in their immunocytochemical 
expression profile (Fichorova et al., 1997; Fichorova & Anderson 1999; Fichorova et 
al., 2001).  
 
The effects of P4, MPA, and NET-A on TNF-induced expression of endogenous IL-
6, IL-8, and RANTES genes were investigated. These specific cytokines/chemokines 
were chosen because they have been shown to be repressed by MPA in other cell 
types (Koubovec et al., 2004; Zhao et al., 2002). These immune-regulators have also 
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been reported to play a role in HIV pathogenesis (Fichorova et al., 2004). 
Surprisingly, none of the compounds repressed the cytokine/chemokine genes 
investigated, in the presence or absence of TNF (Figures 3.1 & 3.2). MPA slightly 
increased TNF-induced IL-6 gene expression but statistical significance could not be 
established (p > 0.05) (Figure 3.1C). In contrast NET-A (p < 0.001) and P4 (p < 0.05) 
significantly induced IL-6 mRNA expression in the presence of TNF. Furthermore, 
all progestins increased IL-6 expression in the absence of TNFeven though 
statistical significance could not be established for P4 and MPA (Figure 3.2B). This 
may be attributed to the fact that IL-6 is expressed at very low levels in the absence of 
TNFand variability between experiments was thus high relative to the response. A 
higher fold induction was also observed by the progestins in the absence of TNF 
(Figure 3.2B). This is probably due to the very high fold increase induced by 
TNFalone (Figure 3.2A), which could mask any further IL-6 gene induction by the 
progestins. Most studies in other cell types have reported that MPA and NET-A 
decrease IL-6 expression, for example in peripheral blood mononuclear cells 
(Mantovani et al., 1997), mouse L929 fibroblast cells (Vanden Berghe et al., 1999), 
and a thyroid cancer cell line, KTC-2 (Kurebayashi et al., 2003). To the best of the 
author‟s knowledge, there are no other reports of an increase in IL-6 expression in 
response to MPA except a recent study in an ectocervical cell line, which showed a 
slight increase of IL-6 mRNA expression (Africander PhD thesis, 2010). Taken 
together, these results for MPA suggest that the upregulation observed in the 
End1/E6E7 cells and the ectocervical cell line is specific to the cervicovaginal milieu. 
NET-A has been shown to both up- and downregulate IL-6 expression (Zitzmann et 
al., 2005; Kriek MSc thesis 2005). IL-6 protein expression was shown to be repressed 
in activated monocytes from combined gender groups (Kriek MSc thesis 2005), while 
males administered NET-EN showed a significant increase in IL-6 levels (Zitzmann et 
al., 2005). In the present study, P4 upregulated TNF-induced IL-6 expression in the 
End1/E6E7 cell line (Figure 3.1). The level of endogenous P4 in women reaches its 
highest levels during pregnancy. These high concentrations inhibit the expression of 
IL-6 in trophoblast cells from placentae obtained from women with uncomplicated 
pregnancies (Das et al., 2002) and have also been shown to reduce IL-6 expression in 
rat corpus luteum tissue (Telleria et al., 1998). In contrast, P4 has been shown not to 
change IL-6 mRNA expression in normal human osteoblasts and human bone marrow 
74 
 
stromal cells (Rifas et al., 1995). Taken together, the regulation of IL-6 by P4, MPA, 
and NET-A appears to be cell specific. Moreover, the effects of MPA and NET-A on 
IL-6 gene regulation are different, indicating progestin-specific effects.  
 
Both MPA and NET-A increased TNF-induced IL-8 mRNA expression to the same 
extent (Figure 3.1A), while P4 had no effect (Figure 1A). Consistent with this result, 
1 M MPA was also reported to increase IL-8 mRNA expression in primary human 
endometrial stromal cells (Arici et al., 1996). In contrast to this result, IL-8 inhibition 
has been reported to occur in response to MPA in human embryonic kidney HEK293, 
as well as endometrial and chorio-decidual cells (Kelly et al., 1994; Koubovec et al., 
2005). In contrast, NET-A has been shown not to repress IL-8 promoter activity in 
HEK293 cells (Koubovec et al., 2005). To the best of the present author‟s knowledge, 
no other reports exist showing an increase in IL-8 expression in response to NET-A. 
Furthermore, the results showing a significant increase in IL-8 expression in response 
to P4 is contrary to other reports in the literature. In rabbit uterine fibroblasts cells, P4 
significantly repressed IL-1 induced IL-8 mRNA expression (Ito et al., 1994), 
whereas an increase in IL-8 expression was reported in human endometrial stromal 
cells in response to P4 (Arici et al., 1996). Taken together, IL-8 regulation by 
progestins, like that of IL-6, appears to be cell specific. Moreover, in the End1/E6E7 
cells, the effect of MPA and NET-A on IL-8 gene regulation are similar to each other, 
but dissimilar to the endogenous hormone, P4, indicating progestin-specific effects. 
 
Similar to the effects of MPA and NET-A on IL-8 expression, both progestins 
significantly enhanced TNFinduced RANTES expression (Figure 3.1B) while P4 
elicited only a small, non-significant induction of the RANTES gene. Consistent with 
these results, MPA has previously been shown to significantly enhance RANTES 
mRNA expression in human endometrial tissue obtained from women following 
short-term treatment with MPA for endometriosis (Deng et al., 2007). In contrast, 
another study reported a decrease in RANTES protein expression in response to MPA 
in human endometrial stromal cells from women following long-term MPA treatment 
(Zhao et al., 2002) suggesting that time of exposure to progestins influences their 
effect on RANTES expression. Previous studies have also shown contradictory results 
for P4 on RANTES gene expression. P4 significantly inhibited RANTES expression 
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in human CD8+ T lymphocyte cells, while RANTES expression was unaffected by P4 
treatment in CD4+ T lymphocyte cells (Vassiliadou et al., 1999). As observed for IL-
6 and IL-8, RANTES gene regulation thus appears to be cell and tissue specific. 
However, unlike the progestin-specific regulation of IL-6 and IL-8 genes, all the 
progestins tested elicited a similar response on the RANTES gene (Figure 3.1B). 
 
Due to the low bioavailability of P4 and short half-life, synthetic progestins were 
synthesised to act similarly to each other as well as to the natural hormone P4. This 
study clearly shows that the synthetic progestins MPA and NET-A are not always 
similar to each other, or the natural hormone P4 in their effects on gene expression of 
some cytokine genes in endocervical epithelial cells.  
 
This is the first study to show that both MPA and NET-A elicit pro-inflammatory 
responses in the End1/E6E7 cells. Both synthetic progestins significantly induced the 
mRNA expression of IL-8 and RANTES (Figure 3.1) and induction of IL-8 gene 
expression by MPA and NET-A is significantly different from that elicited by the 
natural progestin, P4. The physiological implications of the pro-inflammatory effects of 
the synthetic progestins could be two-pronged. Firstly, one could postulate that these 
progestins may increase the local immune response in the endocervical epithelial cells 
to protect against bacterial and viral infections, thereby decreasing the infection rate. 
Secondly, however, increased levels of these immuno-regulators could lead to chronic 
inflammation of the cervix, which could increase cervical cancer progression and HIV 
and HSV pathogenesis. IL-8 and IL-6 are implicated in cervical cancer progression and 
all three immuno-mediators are involved in the increase of HIV and HSV shedding and 
transmission (Tjiong et al., 1999; Das et al., 2000; Brabin, 2002; Wira et al., 2005a; 
Wei et al., 2001; Wei et al., 2003; Tartour et al., 1994). Long-term usage of oral 
contraceptives has for example been correlated to cervical cancer progression (Brinton 
et al., 1986; Moreno et al., 2002; Brabin, 2002; Ursin et al., 1994; La Vecchia et al., 
1986). Furthermore, both MPA and NET-EN used as long-term injectable 
contraceptives have been implicated in increasing the risk of invasive cervical cancer 
(Herrero et al., 1990). Thus the results of the present study suggest that the progestins 
could both positively and negatively influence infections of the endocervical mucosa by 
altering the local immune response. In addition, progestins could lead to chronic 
inflammation of the endocervix. This certainly needs to be investigated further to 
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ascertain the exact effects that synthetic progestins have on the lower FRT and how 
they affect the local epithelial immune response. It would be of interest to investigate 
the expression of these immune-regulators in endocervical swabs from healthy-, and 
HIV-1 infected- women using MPA and NET as injectable contraception, as compared 
to women not using these contraceptives. In the present study the molecular 
mechanisms of progestin regulation of the IL-6 gene were further investigated, since 
this gene exhibits differential regulation by the synthetic progestins MPA and NET 
(Figure 3.1C).  
 
Steroid receptors expressed in the End1/E6E7 cell line  
As progestins primarily act via steroid receptors, the steroid receptor content of the 
End1/E6E7 cell line was characterised using Western blotting and receptor-specific 
promoter-reporter analysis. Results showed that the GR, AR, MR and ER are 
expressed in the End1/E6E7 cells (Figure 3.3). Unexpectedly, the PR-B was found not 
to be expressed at detectable levels in these cells. Immunohistochemical analysis, 
Western blotting and RT-PCR of primary human endocervical cells have identified the 
expression of both PR isoforms (PR-A and PR-B) in the endocervix (Al-Hendy, et al., 
2006) although PR expression is dependent on the menstrual cycle. Decreased P4 
concentrations are associated with decreased PR-B levels (Stjernholm-Vladic et al., 
2004; Konishi et al., 1991). The End1/E6E7 cells might have been established during 
the follicular phase of the menstrual cycle, which could explain the lack of PR-B 
protein present, given that these cells were not maintained in the presence of P4. 
Similarly, the AR was shown to be present in the human ectocervix (Ruizeveld de 
Winter et al., 1991; van der Kwast et al., 1994) but not detectable in the endocervix 
(Ruizeveld de Winter et al., 1991), in contrast to the findings of the present study. 
Consistent with the current results however, immunohistochemical analyses of primary 
human endocervical cells have also shown the ER to be expressed in the endocervix 
(Hodgins et al., 1998, Snijders et al., 1992; Remoue et al., 2003; Al-Hendy et al., 
2006). Also consistent with the present study, the GR has been reported to be expressed 
in the HeLa cervical carcinoma cell line (Burnstein et al., 1991; Wallace & Cidlowski 
2001) and immunohistochemical analysis of cervical biopsies also showed GR 
expression (Vladic-Stjernholm et al., 2009). To summarise, this is the first study to 
show the expression of the ER, GR, AR, and MR in the End1/E6E7 cell line. P4, 
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MPA, and NET-A are able to bind to the GR, AR, and MR (Philibert et al., 1999; 
Koubovec et al., 2005; Africander Phd thesis, 2010) and the potential exists for the 
progestins to mediate a biological response via any or all of these steroid receptor in the 
End1/E6E7 cell line. However, on further investigation only the ER and GR were 
shown to be transcriptionally competent on an exogenous promoter reporter (Figure 
3.4). Contradictory, to the results of the Western blotting showing the presence of the 
AR, in the End1/E6E7 cells, MIB only induced a strong transcriptional response in the 
presence of transiently overexpressed AR, but showed no activity in mock-transfected 
End1/E6E7 cells. This result would suggest that the AR found to be expressed in the 
End1/E6E7 cell lysate is transcriptionally inactive or that the levels of endogenously 
expressed AR are too low to elicit a transcriptional response. Interestingly, similar 
findings were reported in U2OS cells (Hadley PhD thesis 2010) and in ectocervical 
(Ect1/E6E7) and vaginal (Vk2/E6E7) epithelial cells (Africander PhD thesis 2010) for 
the AR. Likewise, a band similar in size to the positive control was detected with the 
anti-MR antibody (Figure 3.3D) although the MR also was transcriptionally 
incompetent in upregulation via the GRE reporter (Figure 3.4D). This could be 
attributed to a faulty MR-antibody as the MR is detected in the negative control and it 
has previously been shown not to be expressed in the COS-1 cells (Han et al., 2005). In 
addition, because the loading of the positive control is slightly higher the possibility 
exists that the MR is not overexpressed in the End1/E6E7 cells. This hypothesis is 
supported by the low fold-induction induced by Ald in transiently overexpressed MR in 
End1/E6E7 cells. It is possible that this low induction could also be via the GR because 
Ald also acts via the GR (Ronacher et al., 2009).  
 
The role of the GR in IL-6 gene regulation by the progestins 
Having established that the GR is expressed and transcriptionally competent in the 
End1/E6E7 cells, the role of the GR in the regulation of IL-6 mRNA expression in 
response to P4, MPA, and NET-A was further investigated. To investigate the role of 
the GR in IL-6 gene regulation by the compounds, two approaches were used: GR 
antagonism by RU486, and GR knockdown using siRNA. Unexpectedly, treatment 
with RU486 and reduction of GR expression both augmented TNFinduced IL-6 gene 
expression in the absence of DEX (Figures 3.6 & 3.8A), suggesting that the unliganded 
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GR inhibits TNFinduced IL-6 gene expression. In the next chapter (Chapter 4) this 
response was further investigated.  
 
RU486 was unable to significantly (p > 0.05) antagonise DEX-mediated IL-6 mRNA 
repression in End1/E6E7 cells as only a slight lift in DEX-mediated repression was 
observed with DEX in the presence of RU486 (Figure 3.6). In the present study 
equimolar concentrations of DEX and RU486 were used and this might suggest that the 
concentration of RU486 is insufficient to significantly antagonise the DEX-mediated 
repression. However, the binding affinity of RU486 is approximately 10 times greater 
than that of DEX with Kd values equal to 0.68 nM (Wagner et al., 1999) and 9.4 nM 
(Charmandan et al., 2005) respectively. The fractional occupancy of the GR for RU486 
as calculated by the equation [ligand]/[ligand]+Ki would therefore suggest that 
approximately 90% of the total GR should be bound by RU486. An alternative 
explanation for the lack of significant antagonism by RU486 might be the steroid 
receptor density in the End1/E6E7 cells. Zhao and colleagues suggested that GR 
density plays a role in RU486 antagonism of a DEX response (Zhao et al., 2003). These 
authors showed that at low GR density, RU486 could antagonise DEX- mediated 
repression of a NFB promoter in COS-7 cells, whereas RU486 was unable to inhibit 
DEX-mediated repression at high GR levels (Zhao et al., 2003). Thus high endogenous 
GR levels in the End1/E6E7 cells may be responsible for the inability of RU486 to 
significantly antagonise DEX-mediated IL-6 mRNA repression. It would be interesting 
to compare GR expression levels of the End1/E6E7 cells to a cell line such as L929 
where RU486 has been shown to successfully antagonise DEX mediated repression, to 
test this theory (Vanden Berghe et al., 1999). Nonetheless, the results are difficult to 
interpret due to the observed induction of IL-6 mRNA expression with RU486 alone. 
Furthermore, although Western blotting analysis showed that the PR-B isoform is not 
expressed, the expression of endogenous PR-A has not been excluded and RU486 is 
also a well-known PR antagonist. Therefore GR siRNA was also used to determine GR 
involvement in IL-6 gene regulation and corroborate the RU486 results.  
 
Unlike RU486, GR siRNA significantly lifted DEX-mediated repression of IL-6 
(Figure 3.8A) and normalising to each treatment condition‟s vehicle control, DEX-
mediated repression is abrogated by GR knockdown (p = 0.09) (Figure 3.8B). The GR 
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knockdown results confirm the involvement of the GR in the DEX-mediated IL-6 
response and that it is an effective experimental approach to establish the involvement 
of the GR in the effects of P4, MPA, NET-A on IL-6 gene regulation.  
 
Interestingly, although P4, MPA and NET-A differentially regulate IL-6 gene 
expression (Figure 3.1C), several lines of evidence would suggest they all act via the 
GR (Figure 3.8B & Addendum B, Figure B1) as depicted in Figure 3.10. Decrease in 
GR protein levels attenuated IL-6 gene expression in response to P4, MPA, and NET-A 
(Figure 3.8B) and further support is provided by the observation that RU486 
significantly antagonised P4, MPA, and NET-A-induced IL-6 expression (Addendum 
B, Figure B1) when normalised for the induction of RU486 alone. A similar trend, 
although less pronounced, is also seen with the GR antagonist (RU486) experiments 
when compared to GR knockdown results for P4, MPA, and DEX, although a slight 
decrease is observed for NET-A in the presence of RU486, which is difficult to 
interpret (Figure 3.6 vs Figure 3.8A).  
 
All three compounds have previously shown to bind to overexpressed GR in COS-1 
cells (Koubovec et al., 2005; Ronacher et al., 2009) with the rank order for binding 
affinity being MPA > P4 > NET-A. MPA was shown to display much greater 
glucocorticoid agonist potency than P4 for both transactivation and transrepression on a 
(GRE)-driven reporter- and an IL-8 promoter-reporter constructs, respectively, in the 
human embryonic kidney (HEK293) cell line stably transfected with a rat GR 
expression vector (Koubovec et al., 2005). In contrast to MPA, NET-A did not 
transactivate the GRE-driven promoter, even at 10 μM, and only marginally (22%) 
transrepressed the IL-8 reporter at this concentration (Koubovec et al., 2005). Similar 
results in a COS-1 cell system, transiently transfected with hGR and a GRE-driven 
reporter construct (for transactivation) or an AP-1 or NFB promoter–reporter construct 
(for transrepression) were also reported (Ronacher et al., 2009). However, in 
End1/E6E7 cells, despite showing that P4, MPA, and NET-A appear to act 
predominantly via the GR in IL-6 regulation, these responses were not agonist 
responses as obtained for the potent synthetic GR agonist, DEX (Figure 3.8B). This is 
very interesting and should be examined further. It is plausible that these differences are 
a result of differences in the type or relative amount of co-factors recruited by the GR 
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when bound to P4, MPA, and NET-A versus DEX. Different signalling pathways could 
also be activated by P4 and the synthetic progestins MPA and NET-A, which could 
modulate different downstream transcription factors compared to DEX. Unfortunately 
when examining the role of the MAPK signalling pathways DEX was not included. It 
would be interesting to examine what role these signalling pathways play on the DEX-
mediated response compared to that observed for the progestins. Another possibility, 
although not shown in the model presented in Figure 3.10, is that the GR bound to the 
progestins is unable to tether to any of the transcription factors associated with IL-6 
promoter activity. It would thus be interesting to investigate in future the GR 
recruitment to the IL-6 promoter in response to P4, MPA, and NET-A. In addition, 
another explanation might be that the opposite effects seen with the progestins 
compared to DEX might be due to differential non-genomic effects by the progestins as 
compared to DEX. The observation that MPA mediates a biological response opposite 
to DEX is difficult to explain, especially as MPA has previously been shown to be a 
partial agonist (Koubovec et al., 2004). However, NET-A has been reported to be a GR 
antagonist under certain conditions (Africander PhD thesis, 2010), and hence may 
induce a different conformation of the GR as compared to DEX.  
 
Role of other steroid receptors 
Steroid receptors other than the GR might also play a role in progestin-mediated IL-6 
regulation. The ER might mediate some of the effects of NET-A on IL-6 gene 
expression, since NET-A and its metabolites have been shown to have estrogenic 
activity (Markiewicz & Gurpide, 1994; Mendoza-Rodríguez et al., 1999), although the 
evidence of the estrogenicity of NET is controversial (Schoonen et al., 2000; Bergink et 
al., 1983). However, preliminary results indicate that the endogenous ER is not 
responsible for the NET-A-mediated induction of IL-6 gene expression. Overexpression 
of ER resulted in the transrepression of IL-6 mRNA expression in response to NET-
A, in contrast to the increase in NET-A mediated IL-6 gene expression when the GR is 
overexpressed (Addendum B, Figure B2).  
 
Although PR-B protein was not detected by Western blot analysis and no 
transactivationally competent PR was identified, this does not exclude the possibility 
that the trancriptionally less active PR-A is expressed in the End1/E6E7 cells. This 
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could affect both MPA and NET-A induced IL-6 gene expression, although GR 
knockdown studies (Figure 3.8B) suggest that the GR is the main steroid receptor 
involved in P4,- MPA- and NET-A-induced IL-6 expression. Interestingly, 
overexpression of PR-B resulted in NET-A induced IL-6 transrepression (Addendum B, 
Figure B2). The potent PR agonist R5020 strongly repressed IL-6 gene expression 
(Figure B2) in contrast to P4, MPA, and NET-A, and overexpression of PR-B lifted the 
repression induced by R5020 (Figure 3.1B). Because Western-blotting showed that the 
PR-B is not expressed in these cells it is very likely that the PR-A isoform is expressed 
in the End1/E6E7 cells and that this isoform is responsible for the R5020-induced 
repression of IL-6 mRNA. The PR-A isoform is a potent activator of transrepression 
and not transactivation (Kalkhoven et al., 1996) further supporting this hypothesis. The 
involvement of PR-A in the responses induced by MPA and NET-A certainly needs to 
be investigated further.  
 
Both MPA and NET-A are reported to have androgenic activity (Bentel et al., 1999; 
Teulings et al., 1980; Bamberger et al., 1999; Kemppainen et al., 1999; Pérez-Palacios 
et al., 1981; Pérez-Palacios et al., 1983; Bergink et al., 1983) and are able to bind to the 
MR (Philibert et al., 1999; Africander PhD thesis, 2010). However, both the MR and 
AR were shown to be biologically inactive in a transactivation assay on a GRE (Figure 
3.4).  
 
Collectively the results of the present study suggest that the GR is the primary steroid 
receptor involved in the increase in IL-6 gene expression mediated by P4 and the 
synthetic progestins MPA and NET-A. The only steroid receptor that caused an 
increase in NET-induced IL-6 mRNA expression when overexpresssed, was the GR 
(Addendum B, Figure B2). This is in agreement with the findings of the GR 
knockdown studies (Figure 3.8B) and RU486 antagonism studies (Addendum B, Figure 
B1).  
 
MAPK involvement in the differential IL-6 regulation by the progestins 
The initial hypothesis for this study was that the differential effects of MPA and NET-
A may be due to activation of different steroid receptors. However, this was shown 
not to be the case, as both MPA and NET-A were shown by protein knockdown to act 
via the GR. Another mechanism that might explain the differential regulation of IL-6 
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by the progestins was thus investigated. It is known that TNF as well as hormonal 
steroids are capable of activating various signalling pathways including the MAPKs 
(Aronica et al., 1994; Muslin et al., 1993; Di Domenico et al., 1996; Migliaccio et al., 
1998; Ballaré et al., 2003; Lange, 2004; Skildum et al., 2005; Boonyaratanakornkit et 
al., 2007) and the possible role of the MAPKs in the differential IL-6 gene regulation 
by MPA and NET-A was thus investigated.  
 
The results of the present study show that different MAPK pathways are involved in 
IL-6 mRNA expression induced by P4, MPA, and NET-A (Figure 3.8) as summarised 
in Figure 3.9. Both ERK1/2 and p38 pathways play a role in the induction of IL-6 by 
NET-A in the End1/E6E7 cell line. In contrast, only p38 is involved in P4-induced 
activity. Although no significance was established, both ERK1/2 and JNK pathways, 
but not p38, appear to inhibit MPA-induced IL-6 mRNA expression. This is the first 
study comparing P4, MPA, and NET-A showing a differential requirement of MAPK 
pathways in progestin-induced IL-6 gene expression. Both ERK and p38 were shown 
to be required for the activation of nuclear factor-B (NFB) by TNF and maximal 
IL-6 induction in the mouse fibrosarcoma L929 cell line (Vanden Berghe et al., 
1998), suggesting that the effects of NET-A on IL-6 gene expression may be due to 
activation of NFB by the GR when bound to NET-A or possibly by non-genomic 
effects. However, the results obtained in the present study in the presence of the p38 
MAPK inhibitor should be interpreted with caution as the specificity of this inhibitor 




Figure 3.10: Schematic model for the role of the GR and MAPK pathways in regulation 
of the IL-6 gene by (A) P4, (B) MPA, and (C) NET-A . 
Abbreviations: P4: progesterone, MPA: medroxyprogesterone acetate, NET-A: 
norethisterone acetate, IL-6: interleukin-6, ERK1/2: extracellular signal-regulated kinase, 
JNK: c-Jun N-terminal kinase, GR: glucocorticoid receptor, NFB: nuclear factor kappa B, 
AP-1: activating protein 1, C/EBP: CAAT enhancer binding protein. 
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To summarise, although IL-6 is differentially regulated by P4, MPA, and NET-A 
(Figure 3.1C), both MPA and NET-A appear to act via the GR. In addition, both MPA 
and NET-A also increase expression of IL-8 and RANTES, thus exhibiting different 
effects to the endogenous hormone P4. Interestingly, the responses induced by MPA 
and NET-A are opposite to those of the potent GR agonist, DEX. This fact is especially 
surprising for MPA, as it has been reported to have anti-inflammatory properties similar 
to DEX in various cell systems (Koubovec et al., 2004; Koubovec et al., 2005; 
Bamberger et al., 1999). Although both MPA and NET-A act via the GR, as 
schematically represented in Figure 3.10, different MAPK pathways are involved in the 
divergent extents of IL-6 gene induction by the progestins (Figure 3.10). Future studies 
could investigate the role of other transcription factors, which might be modulated by 
progestin activated GR such as AP-1, C/EBP, and NFB, all of which have been shown 
to tether to the GR (De Bosscher & Haegeman 2009) as presented in Figure 3.10. 
 
The results of the present study highlight the importance of further research into the 
molecular mechanisms of action of progestins, as well as the signalling pathways 
involved. This will allow physicians to better evaluate the risk and benefit ratio of 
particular progestins, and may even ultimately lead to the design of improved progestin 
therapies without these possible negative effects on immune function. Knowing the 
molecular mechanisms by which MPA and NET-A influence gene expression of pro-
inflammatory regulators in the endocervix compared to P4, is important for women‟s 
health and will give further insight at the molecular level into inflammatory responses 
during infection. Understanding the extent of gene regulation by MPA and NET 
compared to P4 is an important issue for women‟s health, since these progestins 
influence the levels of pro-inflammatory regulators in the endocervix. Furthermore, a 
better understanding of the molecular mechanisms of action of these compounds will 
provide insight into the immune responses of mucosal surfaces within the FRT, which 





RESULTS & DISCUSSION 
Ligand-independent GR-mediated repression of IL-6 in 
response to tumour necrosis factor-alpha (TNF) in an 
endocervical epithelial cell line 
 
Abstract 
Tumour necrosis factor-alpha (TNF), an early response pro-inflammatory cytokine, 
is a potent inducer of interleukin-6 (IL-6) gene expression, while ligand-activated 
glucocorticoid receptor (GR) has strong anti-inflammatory properties and is able to 
significantly antagonise TNF-induced IL-6 expression. In this study, the role of 
liganded and unliganded GR in IL-6 gene regulation was examined in response to 
TNF in an immortalised human endocervical epithelial cell line (End1/E6E7). Both 
decreased GR protein expression by means of GR siRNA, as well as incubation with 
the GR antagonist RU486, resulted in potentiation of the TNF-induced IL-6 mRNA 
expression, suggesting a role for the unliganded GR in modulation of TNF-induced 
IL-6 expression. TNF was subsequently shown to induce phosphorylation of the 
unliganded GR at Ser-226 but not Ser-211, unlike dexamethasone (DEX), which 
induced hyperphosphorylation at both serine residues. The GR was also shown to 
partially translocate to the nucleus in response to TNF. Furthermore, TNF induced 
recruitment of the unliganded GR to the IL-6 promoter to a similar extent as DEX, 
providing further evidence of TNF-induced activation of the GR. Unliganded GR 
appears to actively attenuate IL-6 gene expression in response to TNF. In addition, 
TNF also induced the recruitment of GRIP-1 to the IL-6 promoter and 
overexpression studies indicate that in this context GRIP-1 functions as a co-
repressor. These results identify a novel mechanism of ligand-independent GR 
activation by TNF that modulates IL-6 gene expression. These findings suggest the 
presence of an auto-regulatory mechanism that prevents overproduction of IL-6 in 






TNF is a pleiotropic regulatory pro-inflammatory cytokine, which mediates its 
inflammatory effects via binding to the membrane-bound TNF receptor. It is 
responsible for the induction of various cytokines including IL-6 (Vanden Berghe et 
al., 1999; Cromwell et al., 1992). IL-6 is a multifunctional cytokine with potent pro-
inflammatory properties. It is responsible for T-cell and lymphocyte activation, B-cell 
differentiation, leukocytosis and acute phase protein synthesis (Kishimoto 1989). IL-6 
plays an important role in the host defence against pathogen infections as well as in 
cell proliferation and cell differentiation (Iglesias et al., 1995). IL-6 has also been 
associated with various autoimmune diseases and the progression of cervical cancer in 
the cervix in response to pathogen infections (Rasmussen et al., 1997). The IL-6 
promoter contains numerous regulatory elements within the region 300 bp upstream 
of the transcriptional start site. These include a nuclear factor B (NFB) binding 
element between positions –73 and –63, CCAAT enhancer binding protein (C/EBP) 
binding sites at positions –173 and –145 and an activator protein-1 (AP-1) binding 
site located between –283 and –277 relative to the transcriptional start site (Vanden 
Berghe et al., 1998; Vanden Berghe et al., 1999). Bacterial and viral infections and 
other stress situations increase TNF expression and binding to its receptor, triggering 
a cascade of signalling events that leads to the activation of the transcription factors 
NFB and AP-1 (Rothe et al., 1995; Hsu et al., 1996; Liu et al., 1996; Natoli et al., 
1997; Lee et al., 1997). 
 
Like TNF, glucocorticoid levels are increased by inflammatory stress through the 
activation of the hypothalamic-pituitary-adrenal (HPA) axis (Newton, 2000). 
Lipophilic glucocorticoids elicit a biological response via binding to their cognate 
receptor, the glucocorticoid receptor (GR). The GR belongs to the steroid hormone 
receptor sub-family, part of the broader nuclear receptor superfamily. As an inducible 
transcription factor, it is found predominately in its inactive state in the cytoplasm of 
target cells (Picard et al., 1990). While in the cytoplasm the GR is bound to a protein 
complex, which consists of heat shock proteins (hsp)-90, hsp70, immunophillins and 
other factors (Pratt & Toft, 1997). Hsp90 acts as a molecular chaperone preventing 
unliganded GR from translocating to the nucleus (Pratt & Toft, 1997). The classical 
mechanism of glucocorticoid action entails binding of the ligand to the ligand-binding 
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domain of the GR resulting in a conformational change of the receptor followed by 
the dissociation of the GR from the chaperone protein complex (Griekspoor et al., 
2007). The ligand-bound GR translocates rapidly to the nucleus where it recognises 
specific palindromic DNA sequences known as glucocorticoid response elements 
(GREs) in the promoters of target genes to positively regulate transcription (Zhou & 
Cidlowski, 2005). Glucocorticoids can also negatively regulate gene expression of 
target genes via either direct GR binding to DNA, at so-called negative GRE 
sequences, or by interacting with other transcription factors (Scheinman et al., 1995; 
van der Saag et al., 1996; De Bosscher et al., 1997; De Bosscher et al., 2000; Adcock 
& Caramori, 2001; Reichardt et al., 2001; De Bosscher et al., 2006; Jonat et al., 1990; 
Nissen & Yamamoto, 2000). Ligand-activated GR has been shown to interact with 
NFB, AP-1 and C/EBP transcription factors, thereby repressing a variety of immune 
function genes (Scheinman et al., 1995; De Bosscher et al., 1997; Jonat et al., 1990; 
De Bosscher & Haegeman, 2009; Beck et al., 2009).   
 
In addition to activation by steroidal ligands, the GR has also been reported to be 
activated by various stimuli in the absence of ligand (Tanaka et al., 1996; Eickelberg 
et al., 1999; Kotitschke et al., 2009). Ursodeoxycholic acid and the beta-adrenergic 
receptor agonists, salmeterol and salbutamol, were shown to induce nuclear 
translocation of the GR and subsequent GR-dependent transcriptional activity (Tanaka 
et al., 1996; Eickelberg et al., 1999), although the mechanism of this activation and 
requirement for receptors other than the GR was not established. The recent study 
from the Hapgood laboratory showed that gonadotropin releasing hormone (GnRH)-
induced glucocorticoid-independent increase of GR phosphorylation and 
transcriptional activity on an endogenous promoter (Kotitschke et al., 2009). It was 
demonstrated that GnRH-induced activation of the GR is dependent on the 
membrane-bound GnRH receptor and involves mitogen activated phosphatase kinases 
(MAPKs) (Kotitschke et al., 2009). From the above-mentioned studies, it is clear that 
the unliganded GR can be activated by the GnRH receptor and possibly by other 
plasma membrane receptors. Whether the unliganded GR can be activated by TNF 
has not been previously investigated. The present study investigates the roles of 
liganded and unliganded GR in the response to TNFon the IL6 promoter, in the 




TNF is a potent inducer of IL-6 mRNA expression in End1/E6E7 cells 
To study the transcriptional regulation of IL-6 gene expression in the endocervical 
epithelium by TNF and DEX, End1/E6E7 cells were treated with 1 M DEX in the 
absence and presence of 20 ng/L TNF for 24 hrs, and IL-6 mRNA levels were 
measured by means of quantitative real-time PCR (qPCR), and normalised to GAPDH 
mRNA levels. As shown in Figure 4.1, IL-6 mRNA expression is significantly (p < 
0.001) increased in response to TNF, by approximately 22-fold compared to EtOH 
control. Additionally, 1 M DEX strongly attenuates TNF induction of IL-6 gene 
expression, while DEX alone showed a slight repression of basal IL-6 expression, 
although this was not significant (Figure 4.1).  
 
Figure 4.1: Treatment of the endocervical cell line End1/E6E7 with TNF results in a 
significant increase in IL-6 mRNA expression, which is significantly repressed by DEX. 
End1/E6E7 cells were treated with 0.1% EtOH as vehicle control or 1 M DEX in the absence or 
presence of 20 ng/l TNF Relative Interleukin-6 mRNA levels were normalised to GAPDH 
mRNA levels, which served as an internal control. Relative IL-6 mRNA expression was calculated 
relative to EtOH control, which was set as 1. The graph shows results of at least five independent 
experiments. For statistical analysis one-way ANOVA was used and Tukey‟s multiple comparison 
post-test. Different lower-case letters indicate statistically significant differences; therefore 
conditions with the same letter are not statistically significantly different from each other (p > 0.05), 





Decreased GR protein expression potentiates TNFinduced IL-6 gene expression 
It has previously been shown that the GR is expressed and is transcriptionally 
functional in the End1/E6E7 cells (Figure 3.3). In order to investigate the involvement 
of the GR in TNFinduced IL-6 mRNA expression, End1/E6E7 cells were transfected 
with 10 nM validated GR-specific small interfering RNA (siRNA) oligos or scrambled 
non-silencing control (NSC) siRNA. The efficiency of the GR siRNA was determined 
by Western blotting and GR protein expression was found to decrease by to about 42% 
as compared to the NSC (Figure 4.2B).  
 
The GR siRNA-transfected End1/E6E7 cells were stimulated with 20 ng/L TNF in 
the absence and presence of 1 M DEX for 24 hrs after which IL-6 gene expression 
was determined by qPCR. Reduced GR expression significantly (p < 0.001) reversed 
DEX-mediated repression of TNFinduced IL-6 gene expression, confirming a 
requirement of the GR in DEX-induced repression of IL-6 mRNA expression (Figure 
4.2C). Interestingly, qPCR analysis revealed that diminished GR protein levels resulted 
in an approximately 2.6-fold increase in TNFinduced IL-6 gene expression in the 
absence of GR ligand (Figure 4.2C). As expected, the liganded GR inhibits the TNF 
response in the presence of DEX, while the results suggest that the unliganded GR 
inhibits the TNF response in the absence of DEX on the endogenous IL-6 gene in 






Figure 4.2: Reduced GR protein expression results in increased TNFmediated induction of 
IL-6 mRNA expression in End1/E6E7 cells. (A) For verification of GR knockdown, End1/E6E7 
cells were transfected with 10 nM non-silencing control (NSC) or GR siRNA oligos. Forty-eight 
hrs after transfection cells were harvested and whole cell lysates were separated by 8% SDS-PAGE 
and transferred to nitrocellulose membrane. GR-specific antibody was used for Western blotting 
analysis and -actin-specific antibody as loading control. A representative blot is shown. (B) 
Western blots of at least four independent experiments were quantified to determine the percentage 
GR protein expression. For statistical analysis student t-test was used. p value represents p < 0.001; 
***. (C) In parallel, End1/E6E7 cells were transfected with either non-specific siRNA (NSC (black 
bars)) or with siRNA specific for the human GR (checked bars). Twenty-four hrs after transfection 
cell were treated with 20 ng/L TNF in the absence or presence of 1 M DEX. Total RNA was 
isolated 24 hrs after induction, reverse transcribed and relative levels expression of IL-6 mRNA 
was measured by quantitative qPCR and, normalised to relative GAPDH mRNA expression. 
Relative fold induction of IL-6 mRNA expression was normalised to EtOH/TNF, NSC. The graph 
shows pooled results of at least three independent experiments. For statistical analysis two-way 
ANOVA was used with Bonferroni‟s post-test. P-values are represented as follows: P < 0.01 by ** 





The GR antagonist RU486 augments TNFinduced IL-6 gene expression in 
End1/E6E7 cells 
RU486 is a well known GR antagonist with a high binding affinity for this steroid 
receptor (Cadepond & Ulmann, 1997). To further establish the involvement of the GR 
in the TNF mediated response on IL-6 expression, End1/E6E7 cells were treated 
with 20 ng/L TNF in the absence and presence of 1 M DEX or 1 M RU486. It 
was found that TNFinduced IL-6 mRNA expression was significantly increased 
approximately 2.5-fold in the presence of 10 M RU486 (Figure 4.3). This is 
consistent with the result seen in Figure 4.1, in the presence of GR siRNA. In contrast, 
the DEX-mediated repression of IL-6 expression remained unchanged in the presence 
of RU486.  
 
 
Figure 4.3: The GR antagonist RU486 potentiates IL-6 mRNA expression in the 
presence of TNF. End1/E6E7 cells were induced with 20 ng/L TNF in the absence or 
presence of 1 M DEX, and in the absence or presence of 1 M RU486. The graph represents 
pooled results of three independent experiments. For statistical analysis two-way ANOVA 
was used with Bonferroni‟s post-test. P-values are represented as follows: p < 0.001 by ***. 
Abbreviations; w/o: with out; n.s: not significant. 
 
TNF induces phosphorylation of unliganded GR at Ser-226 
Agonist-induced phosphorylation of the GR has been suggested to play an important 
role in GR-mediated cellular responses (Ismaili & Garabedian, 2004). A recent study 
also showed that ligand-induced phosphorylation is required for maximal GR 
activation of a GRE-containing promoter in COS-1 cells transfected with human GR, 
which facilitates GRIP-1 co-factor recruitment (Avenant et al., 2010). Thus, TNF-
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induced phosphorylation of the GR in the absence of ligand could be a mechanism 
whereby TNF activates the unliganded GR. End1/E6E7 cells were treated with 20 
ng/L TNF in the absence or presence 1 M DEX for 1 hr. The phosphorylation 
status of the endogenous GR was determined by Western blotting using specific anti-
P-Ser-211- and anti-P-Ser-226 GR antibodies (Figure 4.4). The results demonstrate 
relatively high basal phosphorylation levels of endogenously expressed GR at both 
Ser-211 and Ser-226 residues (Figures 4.4A & Figure 4.4C). Although significance 
could not be established DEX induced ligand-dependent phosphorylation at both Ser-
211 and Ser-226 of the endogenous GR in End1/E6E7 cells (Figures 4.4B & Figure 
4.4D). Furthermore, TNF in the absence of GR ligand, also induced GR 
phosphorylation at Ser-226 but not at Ser-211, showing that TNF selectively induces 









Figure 4.4: TNF induces phosphorylation of the GR at Ser-226 and not Ser-211. 
End1/E6E7 cell were treated with 1 M DEX in the absence and presence of 20 ng/L TNF 
for 1 hour. Cells were harvested and whole cell lysates were separated by 8% SDS-PAGE. 
Phopho-GR specific antibodies raised against (A) serine 211 and (B) serine 226 respectively 
were used for Western blotting. Phospho-GR protein levels were normalised to total GR 
expressed. Total GR protein levels were measured after membrane was stripped and re-
probed with an anti-GR specific antibody. Graphs are representative of pooled results from 
three independent experiments. The relative amounts of phosphorylation at the specific serine 
residues were quantified and expressed as amount phosphorylated GR relative to total GR 
with vehicle control (EtOH) set as one. For statistical analysis one-way ANOVA with 
Tukey‟s multiple comparison post-test was performed.   
 
 
The GR only partially translocates to the nucleus in response to TNF  
The unliganded GR is mostly found in the cytoplasm (Georget et al., 1997; Htun et 
al., 1996). Upon ligand-binding, the GR is activated and translocates to the nucleus 
(Griekspoor et al., 2007), where it regulates transcription either by direct interaction 
to specific DNA sequences (GREs) or directly through protein-protein interactions 
with other transcription factors (Nissen & Yamamoto 2000; Luecke & Yamamoto, 
2005; Stein & Yang, 1995; Liden et al., 1997; Zhou & Cidlowski, 2005; Wissink et 
al., 1997). Using subcellular biochemical fractionation, it was next investigated 
whether TNF could cause nuclear translocation of the GR. End1/E6E7 cells were 
treated with vehicle control (EtOH) or 1 M DEX in the absence or presence of 20 
ng/L TNF. Cells were pre-treated with EtOH or DEX for 1 hr before the addition 
of TNF after which cells were incubated for a further 2 hrs. Subsequently, 
cytoplasmic and nuclear fractions were prepared and separated via SDS-PAGE, 
followed by Western blotting with anti-GR, anti-GAPDH, and anti-histone H3 
antibodies. The cytoplasmic GAPDH and nuclear H3 Western blots served as controls 
to (i) illustrate that pure fractions were obtained and (ii) to normalise for equal loading 
(Figures 4.5A & 4.5C) 
 
As expected for DEX, decreased GR in the cytoplasmic fractions coincides with 
increased GR in the nuclear fractions (Figure 4.5), although some degradation of GR 
protein in the nuclear fractions was noted (Figure 4.5A). The results demonstrate that 
DEX treatment induced GR translocation into the nucleus by approximately 1.5-fold, 
with a corresponding 2-fold GR depletion from the cytoplasm as compared to EtOH 
control. (Figure 4.5B). Although not as pronounced as for DEX, TNF in the absence 
of GR ligand, also caused nuclear translocation of the GR (Figure 4.5B). In contrast to 
94 
 
DEX-induced translocation of the GR, TNF mediated depletion of GR from the 
cytosolic fraction was not visible (Figure 4.5C).  
  
 
Figure 4.5: TNF induces partial nuclear translocation of the GR in the absence of DEX. 
End1/E6E7 cells were pre-treated with EtOH or 1 M DEX for 1 hr before the addition of 20 
ng/LTNF after which cells were further incubated for 2 hrs. Subsequently, cytoplasmic and 
nuclear fractions were prepared and equal amounts of fractions were separated via SDS-PAGE 
followed by Western blotting with anti-GR, anti-GAPDH, and anti-histone (H3) antibodies. 
The cytoplasmic GAPDH and nuclear H3 Western blots illustrate that pure fractions were 
obtained (Figures 4.5A & Figure 4.5C). GR levels were quantified and normalised to H3 (A) 
or GAPDH (B) loading controls, and presented relative to vehicle control using Alphaease 
densitometry software. 
  
The GR is recruited to the IL-6 promoter in response to TNF in the absence of 
GR ligand 
Having established that a decrease in GR protein results in a significant (p < 0.001) 
increase of TNFinduced IL-6 mRNA expression and that TNF induces 
unliganded GR phosphorylation at serine residue 226 as well as nuclear translocation, 
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recruitment of the GR to the endogenous IL-6 promoter in the presence of TNF was 
next investigated in intact End1/E6E7 cells. This was done by chromatin-
immunoprecipitation (ChIP) assay, using an anti-GR antibody for 
immunoprecipitation, and primers spanning 296 bp of the IL-6 promoter 
encompassing the most important regulatory elements, which include NFB, C/EBP, 
and AP-1. Intact End1/E6E7 cells were treated with vehicle control (EtOH) or 1 M 
DEX in the absence or presence of 20 ng/L TNF. As shown in Figure 4.6B, DEX 
treatment resulted in significant recruitment of the GR to the endogenous IL-6 
promoter (p < 0.05). Similarly, DEX treatment in the presence of TNF also induced 
significant (p < 0.001) GR recruitment (Figure 4.6B). Surprisingly, in the absence of 
DEX, TNF caused recruitment of the endogenous GR to the IL6 promoter to a 
similar extent as that of DEX in the presence and absence of TNF (p < 0.01; Figure 
4.6B). Recruitment of GR to the IL6 promoter by TNF alone was not significantly 
different from that induced by TNF plus DEX. Figure 4.7 shows that an increase in 
GR protein expression is also not required for the response by DEX and TNF as GR 
levels remained unchanged when End1/E6E7 cells were stimulated with TNF or 
DEX for 3 hrs. The IgG negative control confirmed the specificity of the GR antibody 
and IL-6 primers (Figure 4.8A). Furthermore, agarose gel analysis showed that a 
single, specific product of the expected size is amplified by the PCR reaction, and that 






Figure 4.6: The GR is recruited to the IL-6 promoter in response to TNF in the absence and presence 
of DEX. End1/E6E7 cells were pre-treated with EtOH or 1 M DEX for 1 hr and subsequently treated with 20 
ng/LTNF for an additional 2 hrs, followed by ChIP. Immunoprecipitated GR protein bound to the 
endogenous IL-6 promoter, was detected using primers specific for the IL-6 promoter encompassing the NFB, 
C/EBP, and AP-1 regulatory elements. The co-immunoprecipitated DNA fragments and input DNA were 
analyzed by qPCR. (A) The qPCR products were analysed on a 2% agarose gel and a representative result is 
shown. (B) The graph is representative of pooled quantified results of at least 4 independent experiments and is 
shown normalized to input and expressed as the fold-response relative to EtOH control, which was set as 1. For 
statistical analysis one-way ANOVA was used and Tukey‟s multiple comparison post-test was performed. 
Different lower-case letters indicate statistically significant differences; therefore conditions with the same letter 
are not statistically significantly different from each other (P>0.05), while those having different letters are 
statistically significantly different from each other (P<0.05). P-values are represented as follows: P < 0.05 by *, 




Figure 4.7: GR protein levels remain unchanged in response to TNF in the absence 
and presence of DEX. End1/E6E7 cells were pre-treated with EtOH (vehicle control) or 1 
M DEX for 1 hr and subsequently treated with 20 ng/L TNF for an additional 2 hrs. 
Equal volume of whole cell extracts were separated via SDS-PAGE followed by Western 
blotting with anti-GR and anti--actin antibodies. The graph is representative of pooled 
results from three independent experiments with vehicle control (EtOH) set as one. For 
statistical analysis one-way ANOVA was used and Tukey‟s multiple comparison post-test. 




Increased GRIP-1 co-factor recruitment to the IL-6 promoter occurs in response 
to TNF in the presence and absence of DEX and not with Dex alone 
 
The finding that the GR is recruited to the endogenous IL-6 promoter to a similar 
extent in the presence of TNF, DEX or DEX plus TNFsuggests that a different 
factor is involved in the strong DEX-induced IL-6 gene repression in the presence of 
TNF(Figure 4.1). As the co-factor GR-interacting protein type 1 (GRIP-1) was 
recently shown to be involved in repression of both AP-1- and NFB-driven 
promoters in a GR ligand-dependent manner (Rogatsky et al., 2001; Rogatsky et al., 
2002) the involvement of GRIP-1 in GR mediated repression of IL-6 was investigated 
in the absence and presence of DEX and TNFα or in combination thereof. 
 
As shown in figure 4.8B, DEX treatment alone did not induce recruitment of GRIP-1 
to the endogenous IL-6 promoter (p > 0.05) (Figure 4.8B), while treatment with 
TNF significantly (p < 0.01) recruited GRIP-1 to the promoter. DEX in the presence 
of TNF caused the most significant recruitment of GRIP-1 to the IL-6 promoter (p < 
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0.001). These results suggest that GRIP-1 plays a role in the regulation of IL-6 
expression in response to TNF alone and to co-treatment with DEX plus TNF. 
Figure 4.8: The co-factor, GRIP-1 is recruited to the IL-6 promoter in response to both TNF and 
DEX/TNF. End1/E6E7 cells were pre-treated with EtOH or 1 M DEX for 1 hr before the addition of 
20 ng/ L TNF for 2 hrs. Immunoprecipitated GRIP-1 protein bound to the endogenous IL-6 promoter, 
was detected using primers specific for the IL-6 promoter. The co-immunoprecipitated DNA fragments and 
input DNA were analyzed by qPCR with (A) the PCR product analysed on an 2% agarose gel. (B) The 
graph is representative of pooled quantified results of at least 3 independent experiments and are shown 
normalized to input and expressed as fold-response relative to EtOH control. For statistical analysis one-
way ANOVA with Tukey‟s multiple comparison post-test was performed. Different lower-case letters 
indicate statistically significant difference; therefore conditions with the same letter are not statistically 
significantly different from each other (p > 0.05), while those having different letters are statistically 
significantly different from each other (p < 0.05). P-values are represented as follows: p < 0.01 by ** and p 




Overexpression of GRIP-1 protein in End1/E6E7 cells attenuates TNFinduced 
IL-6 mRNA expression  
 
As the previous results suggest that GRIP-1 is involved in the regulation of IL-6, the 
role of GRIP-1 in TNFinduced IL-6 gene expression in End1/E6E7 cells was 
further investigated. GRIP-1 protein is recruited to the IL-6 promoter in response to 
20 ng/L TNFowever more GRIP-1 was found to be present on the IL-6 
promoter following co-incubation with DEX and TNFa condition which causes the 
most repression of IL-6 gene expression. It was thus hypothesised that GRIP-1 
recruited to the IL-6 promoter in response to TNF alone in the absence and presence 
of DEX acts as a co-repressor. To further investigate the role of GRIP-1 as a repressor 
of the TNF-induced response, End1/E6E7 cells were transiently transfected with a 
GRIP-1 expression vector. Twenty-four hrs after transfection, cells were treated with 
1 M DEX in the absence and presence of 20 ng/L TNF for 24 hrs. Total RNA was 
isolated and IL-6 mRNA expression was measured by qPCR and was normalised to 
GAPDH mRNA levels.  
 
Overexpression of GRIP-1 had no effect on basal (vehicle control) IL-6 mRNA 
expression (Figure 4.9). Increased GRIP-1 protein levels were found to moderately 
increase DEX-mediated repression of TNFinduced IL-6 mRNA expression as 
shown in Figure 4.9, although significance was not established, which suggests that 
the IL-6 promoter may already be saturated with GRIP-1 protein. However, in the 
absence of DEX, TNFinduced IL-6 transcription was significantly (p < 0.01) 
reduced when GRIP-1 protein was overexpressed. This reduction of IL-6 gene 
expression in End1/E6E7 cells in the presence of GRIP-1 expression vector was 
approximately 54%. Taken together with the results in figures 4.6, 4.8 & 4.9 these 
results suggest that in the presence of TNF, GRIP-1 recruited to the IL-6-promoter 
modulates the levels of transcription of endogenous IL-6 in End1/E6E7 cells, via GR 
bound to the promoter, both in the absence and presence of DEX. In the absence of 
DEX, but in the presence of TNF, the unliganded GR occupies the promoter and 
recruits some GRIP-1 which functions in this context as a co-repressor to dampen the 
TNF response. In the presence of DEX and TNF, more GRIP-1 is recruited, where 




Figure 4.9: Overexpression of GRIP-1 attenuates TNF induction of IL-6 gene 
expression. Twenty-four hrs after transfection with 500 ng mock plasmid (black bars) or 500 
ng GRIP-1 plasmid DNA (chequered bars), End1/E6E7 cells were treated with vehicle control 
(EtOH) or 1 M DEX in the absence or presence of 20 ng/L TNFfor 24 hrsTotal RNA 
was isolated and 500 ng mRNA was reverse-transcribed. Relative IL-6 mRNA expression was 
measured by qPCR and normalised to relative GAPDH gene expression, which served as 
internal control. Relative IL-6 gene expression of treated samples was calculated relative to 
vehicle control. Graph represents pooled results of at least three independent experiments. For 
statistical analysis two-way ANOVA was used with Bonferroni as post-test. P-values are 
represented as follows: p < 0.01 by **. 
 
Discussion 
In the present study the role of the GR in transcriptional regulation of endogenous IL-6 
in response to TNF and DEX in End1/E6E7 cells was investigated. The results show a 
significant (p < 0.001) increase of IL-6 mRNA expression in response to TNF, while 
DEX was found to result in repression of TNFα-induced IL-6 gene expression by 
approximately 80% (Figure 4.1). Evidence is also provided by means of siRNA 
technology that the DEX-mediated repression of IL-6 gene expression is mediated via 
the GR. Interestingly, this study also provides evidence for the first time that the 
unliganded-GR is involved in dampening TNF-induced IL-6 mRNA regulation 
(Figure 4.2C) since RU486, the GR antagonist, decreased the TNF response in the 
absence of DEX (Figure 4.3). In addition, decreasing GR protein levels by GR 
knockdown was found to increase TNFα-induced IL-6 expression (Figure 4.2C). 
Consistent with this result, TNFinduced GR nuclear translocation, albeit not as 
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efficiently as DEX (Figure 4.5). TNFα also selectively induced hyper-phosphorylation 
of the GR at Ser-226 but not Ser-211, in contrast to DEX, which elicited GR hyper-
phosphorylation at both Ser-211 and Ser-226 (Figure 4.4). Moreover, the GR is 
recruited to the IL-6 promoter in response to TNF in both the absence and presence of 
DEX. Taken together, the results show for the first time that unliganded GR represses 
IL-6 gene expression induced by TNF.  
 
TNF is an early response pro-inflammatory cytokine released on bacterial and viral 
infection and is responsible for the induction of various cytokines including IL-6 
(Fichorova & Anderson, 1999; Rasmussen et al., 1997; De Bosscher et al., 1997). The 
finding that TNF dramatically increases IL-6 expression is consistent with previous 
reports in End1/E6E7 cells (Fichorova & Anderson, 1999). The repressive action of 
DEX on TNFinduced IL-6 expression is also in accordance with previous studies in 
murine endothelial heart-(TC10s) and mouse fibroblast (L929A) cells (De Bosscher et 
al., 1997; Koubovec et al., 2004). This is however the first study to show ligand-
independent IL-6 gene repression by the GR in response to TNF. For both treatment 
conditions (TNF alone and TNF in the presence of DEX), GR acts as a repressor 
indicating that while TNF dramatically induces IL-6 expression (~ 22-fold; Figure 
4.1), it concurrently recruits the GR to dampen gene expression, possibly thereby 
preventing overproduction of IL-6 mRNA. This is the first report demonstrating GR 
recruitment to a cytokine gene promoter in response to TNF (Figure 4.6), which 
occurs to the same extent as that of DEX in the presence and absence of TNF(Figure 
4.6). In contrast, although the ChIP and nuclear fractionation protocols both followed 
similar treatment conditions i.e incubation times and ligand concentrations, nuclear 
translocation in response to TNF only was not as pronounced as for DEX alone or in 
co-treatment with TNF (Figure 4.5). It is difficult to explain this apparent 
inconsistency. It is plausible that the amount of GR recruited to the nucleus by DEX is 
in huge excess over what is needed for binding to the IL-6 promoter and that binding of 
the GR to the IL-6 promoter could be a high affinity interaction. There is some GR 
present in the nuclear fractions under basal conditions (Figure 4.5), therefore a large 
increase in the concentration of nuclear GR may not be required for GR to elicit a 
nuclear response. Together this could possibly explain the similar levels of GR detected 
by ChIP on the IL-6 promoter, even when the extent of nuclear translocation differs 
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between conditions. Nevertheless, GR recruitment to the IL-6 promoter confirms GR 
nuclear import in response to TNFin the absence of ligand.  
 
Numerous studies have reported ligand-independent activation of steroid receptors 
including the estrogen receptor (ER) (Bunone et al., 1996; El-tanani & Green 1997), 
progesterone receptor (PR) (Pierson-Mullany & Lange, 2004), and androgen receptor 
(AR) (Ueda et al., 2002a; Ueda et al., 2002b). However, only a few studies have 
investigated ligand-independent activation of the GR (Tanaka et al., 1996; Eickelberg 
et al., 1999; Kotitschke et al., 2009). Results regarding nuclear translocation of the GR 
concur with other studies investigating unliganded GR activation (Tanaka et al., 1996; 
Eickelberg et al., 1999; Kotitschke et al., 2009). Both GnRH and 2-adrenergic 
receptor agonist have been reported to induce nuclear translocation of unliganded GR, 
and both compounds were found to be less effective than DEX in eliciting translocation 
of GR protein from the cytoplasm (Kotitschke et al., 2009; Eickelberg et al., 1999), as 
found in the present study for TNF. A 2-adrenergic receptor agonist induced GR 
translocation to the nucleus after 4 hrs stimulation as determined by means of nuclear 
fractionation (Eickelberg et al., 1999). Immunohistochemical analysis in mouse 
pituitary cells (LT2) demonstrated that after 1 hr treatment with GnRH, a peptide 
hormone binding to the GnRH-receptor in cellular membranes (Kotitschke, Sadie-Van 
Gijsen, Avenant, Fernandes, & Hapgood, 2009), the GR moves to the nucleus. 
Similarly, in Chinese hamster ovary cells, Tanaka and co-workers (1996) reported 
nuclear import of the GR in response to ursodeoxycholic acid (UDCA) after 2 hrs 
stimulation (Tanaka et al., 1996). All three studies investigating activation of the 
unliganded GR reported increased transactivation of glucocorticoid inducible promoters 
whereas the present study is the first to report ligand-independent transrepression by the 
GR of an endogenous target gene. Ligand-independent repression by nuclear receptors 
has been shown for the thyroid hormone receptor (TR) (Lin et al., 2002), retinoic acid 
receptor (RAR) (Chen & Evans, 1995), and the peroxisome proliferator-activated 
receptor  (PPAR) (Yu et al., 2005). However, the ligand-independent repression 
induced by the nuclear receptors is reversed in the presence of agonists, in contrast to 
the present study, which shows increased repression of IL-6 expression in the presence 
of ligand. The above-mentioned studies showed less co-repressors recruited in response 
to ligand, unlike the finding of the present study whereby increased GRIP-1 is recruited 
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in the presence of ligand, further supporting the hypothesis that GRIP-1 acts as a co-
repressors for the GR in this context. The ability of GRIP-1 to act as a GR co-repressor 
via a tethering mechanism is consistent with the literature (Rogatsky et al., 2001; 
Rogatsky et al., 2002).  
 
The GR contains a number of phosphorylation sites with Ser-203, 211 and 226 
conserved between species. These become hyper-phosphorylated on ligand binding 
(Weigel & Moore 2007; Ismaili & Garabedian 2004). Hyper-phosphorylation at one or 
more of these sites was shown to be required for promoter-specific increased 
transcriptional activation efficacy (Avenant et al., 2010). As shown in Figure 4.4, DEX 
induced phosphorylation of both serine residues, Ser-211 and Ser-226, in the absence 
and presence of TNF, while TNF selectively increases phosphorylation at Ser-226. 
Interestingly, basal phosphorylation of both serine residues investigated was high, 
which might suggest GR agonist present in the medium. However the selective 
phosphorylation induced by TNF argues against this phenomenon. A recent study by 
Kotitschke and co-workers (2009), investigating ligand-independent activation of the 
GR by GnRH also reported selective GR phosphorylation at Ser-226 and not Ser-211 in 
a mouse pituitary cell line (LT2) (Kotitschke et al., 2009). Taken together these results 
suggest that Ser-226 plays an important role in ligand-independent activation of the 
GR. In addition, other phosphorylation sites may also be involved in activation of the 
unliganded GR. Other serine residues of the GR have been shown to be phosphorylated, 
e.g. Ser-203 (Weigel & Moore, 2007) and Ser-404 (Galliher-Beckley & Cidlowski, 
2009), and may also undergo changes in phosphorylation status in response to non-
glucocorticoid stimuli. Differential GR phosphorylation may induce dissimilar GR 
conformational changes that could differentially influence GR interaction with other 
proteins such as co-factors, thereby causing differential affects on gene transcription. 
Furthermore the kinase pathways responsible for GR phosphorylation at Ser-226 in an 
unliganded manner still need further examination. Eickelberg and colleagues (1999) 
showed that an increase in cellular cAMP levels resulted in the activation of the GR in 
lung fibroblast cells (Eickelberg et al., 1999). This could explain GR phosphorylation at 
Ser-226 by TNF, as the PKC pathway is activated by TNF(Comalada et al., 2003). 
In support of this hypothesis, the PKC pathway in combination with the MAPK 
pathways, were reported to be involved in the GnRH-induced ligand-independent 
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phosphorylation of the GR in LT2 cells (Kotitschke et al., 2009). However, in the 
human derived breast carcinoma cell line, T47D cells, GR phoshorylation status did not 
change in cells treated with DEX plus PKA and PKC activators, compared to DEX only 
(Moyer et al., 1993), suggesting that the involvement of kinase pathways in GR 
phosphorylation is cell-specific. Activation of the JNK pathway has been shown to 
increase phosphorylation of the GR at Ser-226 specifically in transiently transfected 
COS-7 cells (Itoh et al., 2002). Direct interaction of the GR with JNK has also been 
shown without affecting JNK‟s interaction with c-Jun (Bruna et al., 2003). This may 
therefore represent a possible mechanism of TNFinduced GR phosphorylation at 
Ser-226, as TNF is able to activate the JNK pathway. However, Kotitschke and 
colleagues (2009) showed by using JNK inhibitor, that the GR was not phosphorylated 
by JNK in LT2 cells indicating that kinases involved may be cell-specific (Kotitschke 
et al., 2009). The present author has also shown, using MAPK pathway inhibitors in the 
End1/E6E7 cells, that the MAPK pathways ERK, JNK, and p38 do not effect TNF 
induced IL-6 mRNA expression in the absence of DEX (Chapter 3). This suggests that 
in the End1/E6E7 cells, the MAPKs are not involved in phosphorylation of unliganded 
GR at Ser-226. The exact signalling pathway by which TNF activates unliganded GR 
phosphorylation at Ser-226 and induces nuclear import still remains to be established. 
This and the fact that DEX induced GR recruitment to the IL-6 promoter to a similar 
extent (Figure 4.6) in the presence and absence of TNF lead to the investigation of the 
possible role GRIP-1, in GR-mediated repression of IL-6 in response to DEX in the 
presence and absence of TNFα.  
 
GRIP-1 is part of the p160 family of co-factors, which interacts with the conserved 
LXXLL sequence motif situated in the AF-1 region of steroid receptors (McKenna 
2002). This family of co-factors is generally accepted for their role as co-activators 
(McKenna et al., 1999). However recently, GRIP-1 has been reported to be involved in 
DEX-mediated repression of the AP-1 driven collegenase-3 gene (Rogatsky et al., 
2001) and a subsequent study also showed GRIP-1 acting as a co-repressor on a NFB-
driven promoter construct in response to DEX (Rogatsky et al., 2002). TNF induction 
of IL-6 expression has been reported to occur mainly via NFB (Vanden Berghe et al., 
1998), which recruits co-factors such as SRC-1 and CBP/p300 to the promoter region 
of the IL-6 gene (Vanden Berghe et al., 1998; Vanden Berghe et al., 1999; De Bosscher 
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et al., 2001). The present study shows that GRIP-1 was recruited to the IL-6 promoter 
in response to TNF not in the capacity of co-activator, but as co-repressor (Figure 
4.8). This is supported by the finding that overexpression of GRIP-1 attenuated TNFα-
induced IL-6 mRNA expression as shown in Figure 4.9. Co-factor interaction with 
other steroid receptors such as the PR, ER, and AR in the absence of ligand (in response 
to a non-steroid hormone stimulus) has been previously reported (An et al., 2006; 
Tremblay & Giguère, 2001; Dutertre & Smith, 2003; Smith et al., 1993; Deblois & 
Giguère, 2003; Zwijsen et al., 1998; Lavinsky et al., 1998). GnRH treatment of mouse 
pituitary T3-1 cells induced progesterone response element (PRE) reporter promoter 
activity, which was dependent on both PR and steroid receptor co-activator (SRC)-3 
expression (An et al., 2006). Both PR and SRC-3 were recruited to the PRE and 
gonadotropin -subunit promoter in response to GnRH (An et al., 2006). In contrast to 
results of the present study showing that GRIP-1 acts as a co-repressor, SRC-3 
knockdown studies showed that SRC-3 is required for maximal GnRH induction of the 
PRE (An et al., 2006). Furthermore, cylin-D1 and increased cAMP levels induced the 
interaction of SRC-1 with the ER in a ligand-independent manner (Kalkhoven et al., 
1996). Increased cAMP levels have also been shown to facilitate interaction between 
SRC-1 and chicken PR in a ligand-independent manner (Rowan et al., 2000) and SRC-
1 and AR protein-protein interaction was induced in response to IL-6 in the absence of 
androgens as determined by two-hybrid- and co-immunoprecipitation assays (Ueda et 
al., 2002). Ligand-independent repression by the TR, RAR, and PPAR has also been 
shown to be mediated by the co-factors nuclear receptor corepressor protein (NCoR) 
and the silencing mediator of retinoid and thyroid hormone receptors (SMRT) (Horlein 
et al., 1995; Chen & Evans 1995; Yu et al., 2005). Furthermore, phosphorylation of 
both PR and ER increases their association with co-factors namely SRC-1 (steroid 
receptor co-activator-1), GRIP-1, and CREB-binding factor (CBP) (Dutertre & Smith, 
2003; Rowan et al., 2000). Phosphorylation of the ER at Ser-104/106/118 has also been 
shown to regulate SRC-1, GRIP-1 and CBP interaction with unliganded ER (Dutertre & 
Smith, 2003). Using a mammalian two-hybrid system in HeLa cells, mutations of Ser-
104/106/118 decreased co-factor-ER interactions drastically. The authors confirmed the 
requirement of phosphorylation in vitro by the treatment of recombinant ER with 
phosphates, which decreased ER co-immunoprecipitation with the co-factors (Dutertre 
& Smith, 2003). Phosphorylation of the GR at Ser-226 might be required for the 
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interaction of GRIP-1 with the unliganded GR and certainly needs further investigation. 
This would be consistent with the findings of Avenant and co-workers (2010) that 
showed ligand-induced phosphorylation of transfected human GR at one or more serine 
residues (211, 226, or 203) is required for GRIP-1 interaction in transfected COS-1 
cells (Avenant et al., 2010).  
 
The results of the present study also suggest that TNFrecruits one or more other 
protein e.g NFB and/or c-Jun, which facilitates GRIP-1 recruitment to the IL-6 
promoter. This is because GRIP-1 recruitment to the IL-6 promoter was only observed 
in the presence of TNF with and without DEX and not with DEX alone (Figure 
4.6B). This phenomenon also argues against GR agonist contamination in the 
treatment medium. TNF is a potent activator of NFB and AP-1, both of which are 
required for maximal induction of IL-6 gene expression (Ng et al., 1994; Vanden 
Berghe et al., 1999b). The p65 subunit of NFB has been shown to interact with the 
liganded GR in in vitro co-immunoprecipitation assays (McKay & Cidlowski, 2000; 
Caldenhoven et al., 1995 Scheinman, et al., 1995; Ray & Prefontaine 1994) with the 
co-factor CBP increasing this interaction. Similarly, c-Jun has been shown to directly 
interact with the liganded GR (Brogan et al., 1999). It is certainly plausible that these 
transcription factors, which are also activated by TNF could interact with the 
unliganded GR in End1/E6E7 cells. Future studies certainly need to investigate what 
transcription factor acts as a bridging factor to recruit GRIP-1, which causes 
dampening of TNFinduced IL-6 gene expression mediated by unliganded GR.  
 
To conclude, from the present study, and other recent findings regarding the GR 
(Kotitschke, et al., 2009), it is clear that a paradigm shift concerning the mechanism of 
action of the GR is developing. The present study shows that the unliganded GR plays a 
role in attenuating expression of IL-6 mRNA in response to TNF in endocervical 
epithelial cells. Although this study is not the first to report activation of the unliganded 
GR (Kotitschke et al., 2009; Tanaka et al., 1996; Eickelberg et al., 1999), this is the 
only study thus far to show the involvement of unliganded GR in gene repression. 
TNFα significantly stimulates IL-6 mRNA expression, while GR knockdown and 
GRIP-1 overexpression experiments suggest that TNFα also limits maximal IL-6 
promoter activity by recruiting unliganded GR and GRIP-1 proteins, thereby effectively 
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diminishing over-production of IL-6 in the endocervical epithelial cells. While the 
epithelial cells lining the lower FRT are effective in protecting women against infection 
they do so without compromising reproductive functions such as menstruation, 
transport of sperm, fertilization, implantation, gestation and parturition (Wira et al., 
2005). Uncontrolled inflammation could have negative effects on the FRT, such as 
increased susceptibility to disease (Lin & Karin, 2007). The present study proposes a 
model whereby TNF significantly increases pro-inflammatory IL-6 gene expression 
while concurrently diminishing it by recruiting unliganded GR and GRIP-1 to the IL-6 
promoter. This mechanism could be described as an in-built restriction of inflammation 
in the FRT epithelium. Physiological relevance might also apply to other mucosal 
surfaces such as the respiratory- and intestinal mucosa. The prevention of excessive IL-
6 mRNA expression by the GR might also apply to other cytokine genes induced by 







CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Introduction 
The endocervical mucosa, which is composed of columnar epithelial cells, forms part 
of the lower FRT. It provides an effective physical barrier against microbial infection 
while at the same time playing a role in both innate and adaptive immunity (Wira et 
al., 2005). Additionally, the endocervix as well as the rest of the FRT should be 
adaptable to a range of physiological events involved in reproduction. The 
endocervical mucosa constitutively expresses immune mediators that are significantly 
upregulated on TNF and IL-1stimulation (Fichorova et al., 1999). However, 
overproduction of inflammatory regulators could influence the onset and progression 
of disease. The pro-inflammatory mediators IL-6 and IL-8 have both been implicated 
in replication and shedding of HIV (Alfano & Poli, 2005; Poli & Fauci, 1993; Lane et 
al., 2001; Narimatsu et al., 2005; Poli et al., 1990; Schnittman et al., 1991; Breen et 
al., 1990; Gumbi et al., 2008). Chronic inflammation of the endocervix also causes 




 lymphocytes, which are HIV host cells 
(Gumbi et al., 2008). Additionally, chronic inflammation has been implicated in 
promotion and/or exacerbation of cancer (Libra et al., 2009; Castle et al., 2001; Watts 
et al., 2005). Besides their pro-inflammatory role, IL-8 and IL-6 also promote 
angiogenesis and prevent apoptosis and these cytokines have thus been implicated in 
cervical cancer progression (Lin & Karin, 2007; Wei et al., 2001; Chauhan et al., 
1997; Wei et al., 2001; Klein et al., 1995; Rose-John et al., 2006; Nilsson et al., 
2005). Moreover, chronic inflammation of the cervix can lead to other diseases such 
as endometriosis and pelvic inflammatory disease (Lusk & Konecny, 2008; Richter et 
al., 1999). The inflammatory response of the FRT should protect against invading 
pathogens yet be sensitive enough to prevent overproduction of pro-inflammatory 
mediators that might negatively affect reproductive function.  
 
The present study used the End1/E6E7 immortalised endocervical epithelial cell line as 
a cell model for the endocervical mucosa. This cell line has been reported to exhibit 
similar immune mediator expression and morphology to primary endocervical epithelial 
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cells (Fichorova et al., 1997; Fichorova & Anderson, 1999). Little is known about the 
effects of the synthetic progestins MPA and NET-A, as compared to the endogenous 
hormone P4, in the endocervix, and whether or not they interfere with local 
endocervical epithelial immune function. In the first part of this study (Chapter 3) the 
effects of MPA, NET-A, and P4 on immune function gene regulation were investigated. 
In the second part of this study (Chapter 4), due to an interesting observation in Chapter 
3, the role of the GR in TNF regulation of IL-6 in the absence and presence of DEX 
was examined.  
 
Regulation of pro-inflammatory cytokine genes by the natural 
hormone P4 and the synthetic progestins MPA and NET-A 
MPA and NET-EN/NET-A are extensively used as contraceptives and in HRT and also 
at high dosages for the treatment of endometriosis and certain cancers (Wira et al., 
2005). Very few studies have investigated the effects of MPA and NET-A on the 
expression of genes involved in immune function in the endocervical muscosa. 
Furthermore, little is know about their mechanism of action at the cellular level. 
However, there is evidence to suggest that these compounds may play an important role 
in local immune responses. Increased susceptibility to viral and bacterial infections in 
the FRT of both humans and primates has been reported in response to progestin 
treatment (Morrison et al., 2004; MacLean, 2005; Marx et al., 1996; Trunova et al., 
2006), although some studies do not find a correlation between susceptibility to viral 
infection and progestin treatment (Kleinschmidt et al., 2007; Myer et al., 2007; 
Morrison et al., 2007). Furthermore, an increase in both HIV and HSV shedding has 
been reported in subjects treated with injectable contraceptives (Mostad et al., 1997; 
Mostad et al., 2000; Wang et al., 2004). MPA has also been associated with increased 
acquisition of cervical chlamydial and gonococcal infections, the most common 
bacterial sexually transmitted infections (STIs) (Morrison et al., 2004a).  
 
The extent to which changes in immune function in vivo are due to progestin treatment 
is not known. In addition, little is known about the mechanism of action of synthetic 
progestins at a molecular level, especially in the cervical mucosae. The present study 
focused on the effect of P4, MPA, and NET-A on expression of the IL-6, IL-8, and 
RANTES genes. These cytokines were chosen specifically as their expression levels 
110 
 
had previously been shown to be influenced by MPA. MPA inhibited expression of IL-
6 (Bamberger et al., 1999; Kurebayashi et al., 1999; Mantovani et al., 1997; Kriek MSc 
thesis 2005) and IL-8 (Koubovec et al., 2005; Kelly et al., 1994) in several cell lines. 
MPA has also been reported to cause both increased and decreased expression of 
RANTES in different cell systems (Deng et al., 2007; Zhao et al., 2002)  
 
Results presented in Chapter 3 show that MPA and NET-A both augment 
TNFinduced IL-8 and RANTES gene expression and differentially regulate IL-6 
gene expression (Figure 3.1). This is in contrast to P4, which only induced IL-6 
expression (Figure 3.1). In the absence of TNF the progestins P4, MPA, and NET-A 
increase the expression of IL-6 although to different extents (Figure 3.2). These results 
would appear to be inconsistent with results by others for MPA (Koubovec et al., 2004; 
Koubovec et al., 2005; Bamberger et al., 1999; Kelly et al., 1994; Zhao et al., 2002). 
However a likely cause for these discrepancies is the different cell lines in which these 
studies were conducted. Similarly, P4 has been reported to decrease IL-8 expression in 
uterine cervical fibroblasts derived from rabbits (Ito et al., 1994). Although generally 
considered to be anti-inflammatory, the present study reports that progestins including 
P4, appear to play a pro-inflammatory role in endocervical epithelial cells. These results 
suggest that MPA and NET-A could have important implications for endocervical 
immune function, as pro-inflammatory cytokines are associated with elevated levels of 
HIV-1 shedding in the female genital tract (Gumbi et al., 2008). It would be interesting 
to examine the effect of these compounds on viral infectability (prior and concomitant 
treatment with virus) in the End1/E6E7 cell line, in addition to measuring how 
cytokine/chemokine expression is affected in the presence of virus. In addition, both IL-
6 (Wei et al., 2001) and IL-8 (Rasmussen et al., 1997) have also been implicated in 
cervical cancer progression and pathogenesis which may be affected by progestin 
treatment.  
 
Having shown that P4, MPA, and NET-A differentially regulate TNF-induced IL-6 
gene expression, more in-depth investigations followed, examining the molecular 
mechanism involved in IL-6 gene expression by the progestins in the presence of 
TNF Progestins, like other steroid hormones, mediate a biological effect by 
interacting with steroid receptors. Repression of IL-6 and RANTES in response to 
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MPA, has previously shown to be mediated by the GR and PR, respectively 
(Bamberger et al., 1999; Koubovec et al., 2004; Zhao et al., 2002). Therefore the role 
of steroid receptors in IL-6 expression by the progestins was investigated. The 
endogenous steroid receptor expression profile of the End1/E6E7 cell line had not 
been reported, and consequently the expression of ER, GR, PR-B, MR, and AR in 
these cells was investigated by Western blotting. The results showed that the ER, 
GR, MR, and AR are expressed in the End1/E6E7 cells (Figure 3.3). However, only 
the ER and GR were found to be transcriptionally competent on a transiently 
transfected synthetic steroid response element (SRE) promoter reporter construct 
(Figures 4A & 4B). Non-functional expressed AR has been reported in genital skin 
fibroblast due to abnormal AR mRNA splicing leading to the deletion of 123 
nucleotides from the mRNA. Translation of the truncated mRNA resulted in an AR 
protein 5 kDa smaller than the wild type that is unable to induce a biological response 
due to ineffective ligand-binding (Ris-Stalpers et al., 1990). Moreover, androgen 
insensitivity experienced by cancer patients is normally due to non-functional AR 
being expressed (Brinkmann et al., 1995; Quigley et al., 1995). Therefore it is 
plausible that a similar non-functional AR is expressed in the End1/E6E7 cell line. 
Surprisingly, no PR-B was detected, although immunohistochemical analysis has 
shown the PR to be expressed in the human cervix (Remoue et al., 2003; Nair et al., 
2005; Konishi et al., 1991). However, the expression of the PR-B has been shown to 
be dependent on the menstrual cycle as its expression is diminished during the 
follicular phase (Konishi et al., 1991; Stjernholm-Vladic et al., 2004). Decreased 
circulating P4 results in decreased total PR expression (Konishi et al., 1991; 
Stjernholm-Vladic et al., 2004). Thus since the cells are grown in the absence of P4 
and also may have been established during the follicular phase, this could explain the 
absence of PR-B expression. However, that does not exclude the possibility that the 
PR-A isoform is expressed and that P4, MPA, and NET-A might also act via this 
receptor. 
 
GR antagonist- and/or GR siRNA experiments showed that P4, MPA and NET-A elicit 
at least part of their response via the GR (Figures 3.6, 3.8B and Figure B1). GR 
knockdown studies (Figure 3.8B) do however suggest that the induction of IL-6 by P4, 
MPA, and NET-A is mainly via the GR, since complete abrogation of IL-6 induction is 
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observed in the presence of GR siRNA (Figure 3.8B). In agreement, results whereby 
various steroid receptors were overexpressed, showed that only overexpressed GR 
increases NET-A induced IL-6 mRNA expression (Addendum Figure B2). 
Interestingly, in the absence of glucocorticoids, both RU486 and decreased GR 
expression augmented TNFinduced IL-6 expression and this phenomenon was 
further investigated in Chapter 4.  
 
Future studies certainly need to further investigate the role of other steroid receptors 
such as ER in this response, since NET-A metabolites can bind to the ER albeit with 
low affinity (Sasagawa et al., 2008). In fact, preliminary results show that NET-A-
induced IL-6 mRNA decreases in the presence of overexpressed ER, suggesting that 
NET-A could induce IL-6 gene repression via the ER Experiments using an ER-
specific antagonist and ER siRNA could indicate a role of the ER in mediating 
induction of IL-6 by NET-A. Since both MPA and NET-A are used in combination 
with estrogen in HRT (Sitruk-ware, 2004), it would be of interest to determine how the 
expression of IL-6, IL-8, and RANTES are affected by the progestins in the presence of 
estrogen.  
 
The effect of progestins on steroid receptor levels also certainly needs to be examined 
as increase in steroid receptor expression and turnover could have an effect on 
progestin-induced signalling. While the present study observed no differences in GR 
protein levels after 24 hrs treatments with the compounds (Figure 3.5), other steroid 
receptor such as PR-A and ER levels were not monitored and future studies need to 
investigate this.  
 
Another possible mechanism for the differential IL-6 regulation by the progestins could 
be the involvement of different MAPK signalling pathways. Further analysis of the 
differential activation of MAPKs by MPA and NET-A using MAPK inhibitors 
indicated that ERK and p38 are involved in induction of IL-6 gene expression by NET-
A, but not MPA (Figure 9). Interestingly, the p38 but not the ERK pathway is involved 
in P4 induction of IL-6 mRNA expression (Figure 3.10). The results with the MAPK 
inhibitors should ideally be confirmed using other strategies, since these inhibitors can 
act non-specifically (Kotitschke PhD thesis, 2009). Other strategies could include 1) 
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overexpression of dominant negative and wild type ERK, p38, and JNK expression 
plasmids, and 2) knockdown of individual MAPKs using siRNA technology.  
 
To summarise, although MPA and NET-A were created to be biologically similar to the 
endogenous hormone, P4, the findings presented in Chapter 3 suggest that the 
progestins act differently to each other and P4 depending on the cytokine gene. P4, 
MPA and NET-A significantly upregulate IL-8 and RANTES gene expression, unlike 
P4, while they differentially regulate IL-6 gene regulation. Interestingly, although P4, 
MPA, and NET-A differentially regulate IL-6 mRNA expression, all three compounds 
appear to act mainly via the GR. However, differential MAPK signalling pathways 
appear to be responsible for the observed differential IL-6 regulation by the progestins. 
A better understanding of the mechanism of differential gene regulation by the different 
progestins and the steroid receptors and signalling pathways involved could assist in the 
design of new progestins with fewer side effects.  
 
Ligand-independent activation of the GR modulates IL-6 expression in 
response to TNF
 
Ligand-independent activation of the GR has not been extensively studied although it 
has been widely reported for other steroid receptors (Cenni and Picard 1999; Weigel 
and Zhang 1998). Increased transcriptional activity of the unliganded GR in response 
to ursodeoxycholic acid, the beta-adrenergic receptor agonists salmeterol and 
salbutamol, and GnRH has been reported (Tanaka et al., 1996; Eickelberg et al., 
1999; Kotitschke et al., 2009). Chapter 4 focused on TNF activation of the GR in the 
absence of GR ligand. Figure 5.1 summarises the results of this chapter in the form of 
a model for the role of the GR in modulation of the IL-6 response in response to 
TNF. The results showed that the GR is required for the repression of IL-6 mRNA 
by DEX and interestingly that the GR also modulates the response to TNFin the 
absence of DEX(Figure 4.2C & Figure 5.1). It was also shown that TNF induced 
nuclear translocation of the GR in the absence of DEX, albeit to a lesser extent than in 
the presence of DEX (Figure 4.5B & Figure 5.1). Nuclear translocation has also been 
reported for the unliganded GR in response to ursodeoxycholic acid, beta-adrenergic 
receptor agonists, and GnRH (Tanaka et al., 1996; Eickelberg et al., 1999; Kotitschke 
et al., 2009). Consistent with activation of the GR by TNF TNF induced hyper-
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phosphorylation of the GR at Ser-226 and not Ser-211, unlike DEX, which induced 
hyper-phosphorylation of both serine residues (Figure 4.4) as depicted in Figure 5.1B 
versus Figure 5.1C. Selective phosphorylation of the GR in response to GnRH has 
previously been reported (Kotitschke et al., 2009), with GnRH inducing 
phosphorylation of Ser-226 and not Ser-211, similar to the results presented here for 
TNFα. Similarly, ligand-independent phosphorylation of other steroid receptors has 
also been reported (Ueda et al., 2002; Dutertre & Smith, 2003). Others have shown 
that the GR is also phosphorylated at Ser-203 (Weigel & Moore, 2007) and Ser-404 
(Galliher-Beckley & Cidlowski, 2009) in response to DEX and it would be interesting 
to determine how TNF affects phosphorylation at these sites by using phospho-
specific antibodies as phosphorylation at Ser-226 would appear to be required for 
ligand-independent activation. In addition, the signalling pathway(s) responsible for 
the selective phosphorylation by TNF still needs to be examined. TNFacting via 
its cognate receptor activates a wide variety of signalling pathways (Barbara et al., 
1996). Any of these pathways might be involved in the differential phosphorylation of 
the GR and this certainly needs further examination. However, as already showed in 
Figure 3.10., the MAPK inhibitors had no effect on TNF-induced IL-6 gene 
expression, which might exclude these signalling pathways although the 
phosphorylation status of the GR was not determined in the presence of the MAPK 
inhibitors. The precise mechanism of glucocorticoid-independent activation of the GR 
by TNF remains an intriguing question that requires further investigation. It would 
be particularly interesting to examine whether phosphorylation at Ser-226 is a cause 
or a consequence of a key event. 
 
Interestingly, TNF induced the recruitment of the GR to the IL-6 promoter to the 
same extent as that induced by DEX, providing further confirmation of ligand-
independent activation of the GR by TNF (Figure 4.6 & Figure 5.1). Interestingly, 
less nuclear translocation of the GR occurs in the presence of TNF alone than in the 
presence of DEX, although similar GR levels were recruited to the IL-6 promoter as 
shown in Figure 5.1B vs Figure 5.1C. This would suggest that the affinity of the GR 
for the IL-6 promoter is high and independent of excess GR present in the nucleus. 
Alternatively, it is possible that more GR is recruited in the presence of DEX, but that 
this GR is not all accessible to the antibody, due to the presence of other proteins in a 
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complex on the promoter. A similar situation has been described for the ER, the 
presence of which is masked by GRIP-1 on the TNF promoter (Cvoro et al., 2006).  
 
Figure 5.1: Schematic presentation of GR cross-talk with TNF signalling and resulting 
modulation of IL-6 gene expression in endocervical epithelial cells. (A) DEX stimulated 
IL-6 promoter, (B) TNF stimulated IL-6 promoter, (C) TNFand DEX stimulated IL-6 
promoter, (D) TNF stimulated IL-6 promoter in the absence of GR. Abbreviations: c-Jun; 
cellular Jun, c-Fos; cellular Fos, GR; glucocorticoid receptor, GRIP-1; GR–interacting protein 
type 1, NFB; nuclear factor kappa B, TNF; tumour necrosis factor-alpha, X; unknown co-
factor induced by TNF responsible for the increase in IL-6 promoter activity, Y unknown 




The involvement of the GR and co-factor GRIP-1 in DEX-dependent and DEX-
independent regulation of IL-6 gene expression was investigated by ChIP analysis. 
Figure 5.1 summarises the results of these experiments together with the results for 
nuclear translocation and GR phosphoryation, which schematically illustrates the 
ligand-independent activation of the GR and its subsequent modulation of IL-6 
expression in response to TNF(Figure 5.1)The co-factor GRIP-1 was found to be 
recruited to the IL-6 promoter in response to TNF(Figure 4.8) and on further 
analysis when GRIP-1 was overexpressed it was shown to be acting as a co-repressor 
(Figure 4.9). GRIP-1, which is generally considered to be a co-activator, has been 
reported to act as a co-repressor in response to DEX on both NFB and AP-1 driven 
reporters (Rogatsky et al., 2001; Rogatsky et al., 2002) and in response to E2 on the 
endogenous TNFpromoter in the U2OS cell line (Cvoro et al., 2006). Interestingly, 
only in the presence of TNF is GRIP-1 recruited to the IL-6 promoter (Figure 4.8), 
which suggests that TNF recruits a transcription factor such as NFB and AP-1 that 
assists in the recruitment of GRIP-1 as schematically presented in Figure 5.1. This 
certainly needs further investigation.  

It has been suggested that NFB is the most important transcription factor involved in 
IL-6 gene expression (Libermann & Baltimore, 1990; Shimizu et al., 1990; Zhang et 
al., 1990; De Bosscher et al., 1997; Vanden Berghe et al., 1999; Vanden Berghe et 
al., 2000), and a mutation in the NFB response element has been shown to abrogate 
TNF induction of the IL-6 promoter (De Bosscher et al., 2001). But while NFB is 
essential for IL-6 induction, activation of additional transcription factors such as AP-1 
is required for maximal IL-6 induction (Vanden Berghe et al., 1999). Repression of 
TNF-induced IL-6 expression by liganded GR has been reported to be mediated via 
direct interaction between GR and NFB (De Bosscher et al., 2001). TNFis also 
known to be able to activate C/EBP (Barbara et al., 1996), which with NFB and AP-
1 is recruited to the IL-6 promoter (Vanden Berghe et al., 2000). It could be 
hypothesised that ligand-independent GR modulation of IL-6 gene expression in 
response to TNF in the endocervical epithelial cells also occurs via direct interaction 
between GR and one or all of these transcription factors. The likely tethering of the 
GR to these transcription factors is thus proposed as illustrated in Figure 5.1. To test 
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this hypothesis one could perform ChIP on ChIP analysis, using p65 (NFB subunit) 
and GR specific antibodies for sequential immunoprecipitation steps. Additionally, by 
using primer sets designed to identify specific regulatory sites present in the IL-6 
promoter, the promoter region at which the interaction occurs could be identified or 
more precisely mapped by ChIP. However, this strategy might not be feasible as the 
cis-regulatory sites are situated in close proximity to each other (Figure 1.2). As 
alternative strategy, End1/E6E7 cells could be transfected with human IL-6 promoter-
reporter constructs with point mutations at the various cis-regulatory elements, 
thereby testing the requirement of the each response element for the ligand-
independent GR repression on TNFα-induced promoter activity. In addition, a similar 
approach could also be followed to determine the possible involvement of AP-1 as 
shown in Figure 5.1 as the GR is also known to physically interact with AP-1 (Jonat 
et al., 1990). These experiments will help identify the transcription factor via which 
the unliganded GR tethers and the particular cis-regulatory elements are involved. It 
would also be interesting to compare the molecular mechanism of ligand-independent 
GR repression of IL-6 to that of liganded GR. 
 
The recruitment of regulatory proteins to the IL-6 promoter in response to TNF must 
be carefully controlled to allow a significant increase in transcriptional activity and 
yet prevent over-stimulation of the promoter. As the results of the present study 
suggest GRIP-1 recruitment to the IL-6 promoter is in the capacity of co-repressor, it 
would be interesting to determine which co-activators are recruited in response to 
TNF(Figure 5.1C, Factor X) to result in the large TNF-induced upregulation. Co-
factors CREB binding protein (CBP), p300, and steroid receptor co-factor-1 (SRC-1) 
have been reported to interact with AP-1 and NFB (Gerritsen et al., 1997; Perkins et 
al., 1997; Na et al., 1998; Lee et al., 1998; McKay & Cidlowski, 2000; De Bosscher 
et al., 2000) and CBP/p300 has been reported to play an important role in increasing 
IL-6 promoter activity through the interaction with NFB (De Bosscher et al., 2000; 
Vanden Berghe et al., 1999). Recruitment of these co-activators to the IL-6 promoter 
might be blocked by ligand-activated GR and this possibility could be investigated by 
ChIP using co-activator specific antibodies eg. CBP, p300, and SRC-1. In contrast, 
CBP has been shown to increase the interaction between p65 and GR, thus 
augmenting ligand-dependent GR-mediated repression of the NFB-responsive 
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promoter reporter (McKay & Cidlowski, 2000). CBP may therefore play a similar role 
in endogenous IL-6 gene regulation in endocervical epithelial cells. Overexpression or 
knockdown of CBP may lend support to this hypothesis. 
 
Finally, the mechanism of action of unliganded GR studied here might not be unique 
to IL-6, and other cytokine genes such as IL-8 and RANTES might also be affected. 
This certainly needs to be considered for further investigations. Similarly, ligand-
independent activation in response to TNF might not be cell-specific and could also 
apply to other cells in the lower FRT such as the ectocervical and vaginal epithelial 
cells. Unliganded GR cross-talk with other early response pro-inflammatory cytokines 
such as IL-1β also needs to be investigated.  
 
The current study has established that the activity of progestins in the context of the 
endocervix is primarily pro-inflammatory. This may be a mechanism whereby 
progestins provide protection against certain infections. However, since HIV infection 
requires inflammatory cells to be recruited and activated by the immune-mediators 
investigated, this pro-inflammatory activity could be a drawback, and actually 
increase susceptibility to HIV infection. This is consistent with reports that HIV 
infection and viral load are increased in the presence of the cytokines investigated 
(Gumbi et al., 2008). Additionally, since progestins increase markers of inflammation, 
use of progestins as contraception could also lead to chronic inflammation of the 
endocervix, which could affect cancer progression. This possibility and certainly 
needs further investigation. 
 
In the second part of this study it was established that in endocervical epithelial cells, 
unliganded GR restricts the over production of IL-6 mRNA in response to TNF. The 
present study is the first study to report a role for the unliganded GR in a 
transrepression model and to suggest an auto-regulatory mechanism involving 
restriction of IL-6 expression by the unliganded GR. This finding suggest a 
mechanism whereby the FRT should be immune-sensitive in order to prevent 
infection by invading pathogens, while the immune response should not impair 
reproductive processes. Modulation of TNFα induction of IL-6 by unliganded GR 







A.1: Quantitative real time PCR (qPCR) optimisation 
Isolation of RNA is a crucial first step in the analysis of gene expression. It is important 
to obtain high quality, intact RNA as poor quality RNA can compromise experimental 
results obtained by qPCR, which is very time-consuming, labour-intensive, and 
expensive. Therefore, RNA quality was routinely assessed by two methods prior to 
reverse transcription. The first method was measuring the optical density (OD) with a 
spectrophotometer at 260 nm (specific for nucleic acids) and 280 nm (specific for 
proteins). The OD 260/280 ratio greater than 1.9 is generally considered acceptable and 
indicative of good quality RNA (Sambrook et al., 1989). However, the 260 nm OD 
reading, which is also used for concentration determination, can be compromised by the 
presence of genomic DNA. Therefore, the isolated RNA was secondly analysed on a 
denaturating formaldehyde agarose gel. The 28S RNA band should be approximately 
twice as intense as the 18S RNA band. Thus a 2:1 ratio is a good indication that the 
RNA is intact. A smear is indicative of degraded RNA, and genomic DNA generally 
remains in the well due to its high molecular weight. Figure A1.1 shows an example of 
such a gel, showing intact RNA uncontaminated by genomic DNA. 
 
 
Figure A1.1: Representative of a 0.5 g RNA agarose gel showing the quality of 
RNA. RNA was isolated from End1/E6E7 cells using TriReagent® (Sigma-Aldrich).  
 
 
Following RNA isolation and assessment of the RNA integrity, cDNA was synthesised 
as described in Chapter 2. However, initial qPCR experiments were found to be very 
irreproducible. On investigation it was found that the cDNA synthesis step and not the 
actual PCR step was at fault. Three different cDNA synthesis kits from three different 
manufacturers were therefore tested to solve this problem. These kits were compared in 
triplicate parallel reactions, from a single RNA sample. The relative GILZ mRNA 
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expression was measured for each sample, as shown in Figure A1.2. A high degree of 
variability was detected for kits B and C. Kit B, which had been used initially was 
found to exhibit large error in the efficiency of cDNA synthesis between parallel 
reactions Kit A exhibited the highest degree of reproducibility and it was therefore 
decided to use Kit A for subsequent experiments. 
 






























Figure A1.2: Comparison of different cDNA synthesis kits. cDNA synthesis from a single 
RNA sample was performed in triplicate, using three different cDNA synthesis kits 
designated A, B, and C. Relative GILZ mRNA expression was subsequently measured by 
qPCR in duplicate and normalised to relative GAPDH mRNA expression. The average 
crossing-point of the duplicate PCR samples amplified with GILZ primers was normalised to 
the average crossing point of duplicate PCR samples analysed with GAPDH primers to give 
the relative GILZ expression levels.  
*Kit P was initially used and the likely source of the irreproducibility experienced at the outset 
 
 
The relative expression of the genes of interest was calculated using the Pfaffl 
equation (Pfaffl, 2001), as shown below and expressed relative to the expression 
levels of the untreated control.  
 
 
Relative expression levels      =     (Ei)
CP (control - sample) 
               (Er)
CP (control - sample)
   
 
Ei is the amplification efficiency of the gene of interest, and Er the efficiency of the 
reference gene. The difference in crossing points (CP) between the vehicle control 
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and the treated samples is calculated for the gene of interest and the reference gene 
(Pfaffl MW, 2001).  
 
As the method of Pfaffl (2001) was used to calculate the relative gene expression of 
the various cytokines, the primer efficiencies of the primer sets used (i.e. IL-6, IL-8, 
RANTES, and GAPDH) were determined. This was calculated by creating serial 
dilutions of a single cDNA sample,  and performing triplicate qPCR reactions for each 
dilution. A dilution curve is generated by plotting the crossing points for each dilution 
(Y-axis) against the log of cDNA concentration (X-axis) as shown in Figure A.1.3.  
 
 
Figure A1.3. Example of dilution series data generated by Rotorgene software for IL-6 
amplification products. 
 
The slope of the curve as given by the Rotorgene software (annotated as M) is used to 
calculate the primer efficiency, by means of the following equation (Pfaffl, 2001).  
 
Efficiency (E) = 10
[-1/slope] 
 
The final primer efficiencies used of the cytokine genes together with the reference 
gene, GAPDH, was determined by pooling the primer efficiencies determined from 








Table A1.1. Primer efficiency determination the various cytokine genes investigated 
together with the reference gene GAPDH 
 Primer set 
IL-6 IL-8 RANTES GAPDH 
1 2.00 2.05 1.96 2.04 
2 2.43 2.07 2.12 1.55 
3 2.23 1.94 1.89 2.32 
Average 2.22 2.02 1.99 1.97 
 
 
However, before commencing on calculating the relative gene expression levels, it is 
important to perform a melting curve analysis at the end of each qPCR reaction. The 
position of the peak of the melting curve is unique for each PCR product and is used 
to distinguish between different amplification products and therefore essential to 




Figure A.1.4. Example of melting curve analysis generated by the Rotogene software for 
IL-6 amplification products.  
 
 
A.2. ChIP assay optimisation 
ChIP assays are used to investigate the association of proteins with specific DNA 
regions. This technique involves crosslinking of proteins with chromatin, fragmentation 
by sonication, and immunoprecipitation with an antibody specific for the protein of 
interest. The DNA sequence associated with the protein of interest is then identified and 
quantified by means of PCR. Sonication of the chromatin is a critical step in the ChIP 
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protocol as it not only aids in further lysing of crosslinked cells, but also determines the 
average size of the DNA fragments for immunoprecipitation. The optimal DNA 
fragment sizes should be between 300 bp and 800 bp (Ma et al., 2003) as very small 
fragments may be lost during the DNA purification step and large chromatin fragments 
might not allow for efficient immunoprecipitation. The sonication step therefore needs 
to be optimised for different cell lines, to yield appropriately sized chromatin 
fragments. Pilot experiments using different settings and times were performed. The 
size of the fragmented chromatin was evaluated by agarose gel electrophoresis after 
crosslinking reversal. In Figure A2.1 End1/E6E7 cells were sonicated using the 
Misonix Sonicator® set on power 3, for 10 cycles at 20 sec per cycle, with 40 sec 
intervals between pulses, producing chromatin fragments with a average size of 400 bp. 
Brief pulses of sonication were used because sonication generates heat. Proteins are 
heat sensitive and long sonication intervals could cause overheating and denature 
proteins. 
 
Figure A.2.1: Example of gel-electrophoresis analysis of chromatin 
after sonication. End1/E6E7 cells were treated with (A) EtOH or (B) 1 
mM DEX for 2 hrs after which cells were crosslinked, harvested and 
sonicated at Power 3 for 10 cycles at 20 sec per cycle, with 40 sec 
intervals between pulses using a Misonix Sonicator®. Subsequently 
crosslinking was reversed overnight and DNA was purified using 
QiaQuick® columns. Sonicated chromatin was analysed by 1% 
agarose gel electrophoresis. 
 
In addition, the qPCR product from the ChIP analysis was routinely analysed by 
melting curve analysis and agarose gel electrophoresis to confirm the amplification a 





Figure A.2.2: Verification of amplification of a single product of expected size. 
End1/E6E7 cells were treated with (1) EtOH or (2) 1 mM DEX for 3 hrs or pre-treated with 
(3) EtOH or (4) 1 M DEX for 1 hr and subsequently treated with 20 ng/LTNF for an 
additional 2 hrs, followed by ChIP. Results shown are those of input samples only. PCR 
products were analysed by (A) 2% agarose gel electrophoresis and (B) melting curve analysis. 












Figure B1: The role of the GR in IL-6 gene expression in response to P4 and the 
synthetic progestins MPA and NET-A in the endocervical cell line End1/E6E7. 
End1/E6E7 cells were treated with 20 ng/L TNFand 1 M P4, MPA, NET-A, or DEX in 
the absence or presence of 1 M RU486. Total RNA was isolated after 24 hrs and 500 ng 
mRNA was reverse-transcribed. Relative IL-6 mRNA expression was measured by 
quantitative real-time PCR and normalised to relative GAPDH gene expression, which served 
as internal control. Relative IL-6 gene expression of treated samples was calculated relative to 
vehicle control, which was set at 1. Graphs represent pooled results of at least three 
independent experiments. For statistical analysis two-way ANOVA was used with Bonferroni 


















































































































Overexpression of various steroid receptors
Figure B2: End1/E6E7 cells were transiently transfected with 500ng empty vector (pGL2-basic) (solid bars) 
or (A) GR (pCMV-HA-human GR), (B) PR-B (pSG5hPR-B), (C) AR (pSVARo), and (D) ER (pSG5-
hER) expression vectors (checked bars). Twenty-four hrs after transfection cells were treated with EtOH 
(0.1%) or 1 M steroid receptor specific agonists for 24 hrs. Total RNA was isolated after 24 hrs treatments 
and 500 ng total RNA was reverse-transcribed. Relative IL-6 mRNA expression was measured by quantitative 
real-time PCR and normalised to relative GAPDH mRNA expression, which served as internal control. 
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